Assessment report on *Piper methysticum* G. Forst., rhizoma

Based on Article 10a of Directive 2001/83/EC (well-established use)

Based on Article 16d(1), Article 16f and Article 16h of Directive 2001/83/EC (traditional use)

Draft

<table>
<thead>
<tr>
<th>Herbal substance(s) (binomial scientific name of the plant, including plant part)</th>
<th><em>Piper methysticum</em> G. Forst., rhizoma</th>
</tr>
</thead>
<tbody>
<tr>
<td>Herbal preparation(s)</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Pharmaceutical form(s)</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Rapporteur</td>
<td>C. Purdel</td>
</tr>
<tr>
<td>Peer-reviewer</td>
<td>O. Palomino</td>
</tr>
</tbody>
</table>

Note: This draft assessment report is published to support the public consultation of the draft public statement on *Piper methysticum*, rhizoma. It is a working document, not yet edited, and shall be further developed after the release for consultation of the public statement. Interested parties are welcome to submit comments to the HMPC secretariat, which will be taken into consideration but no ‘overview of comments received during the public consultation’ will be prepared on comments that will be received on this assessment report. The publication of this draft assessment report has been agreed to facilitate the understanding by Interested Parties of the assessment that has been carried out so far and led to the preparation of the draft public statement.
# Table of contents

Table of contents ................................................................................................................... 2

1. Introduction ....................................................................................................................... 4
   1.1. Description of the herbal substance(s), herbal preparation(s) or combinations thereof .. 4
   1.2. Search and assessment methodology ..................................................................... 7

2. Data on medicinal use ........................................................................................................ 7
   2.1. Information about products on the market .............................................................. 7
   2.1.1. Information about products on the market in the EU/EEA Member States ................. 7
   2.1.2. Information on products on the market outside the EU/EEA .................................. 11
   2.2. Information on documented medicinal use and historical data from literature ............ 11
   2.3. Overall conclusions on medicinal use .................................................................... 15

3. Non-Clinical Data ............................................................................................................. 16
   3.1. Overview of available pharmacological data regarding the herbal substance(s), herbal preparation(s) and relevant constituents thereof ........................................................... 16
   3.1.1. Primary pharmacodynamics .............................................................................. 16
   3.1.2. Secondary pharmacodynamics .......................................................................... 25
   3.1.3. Safety pharmacology ....................................................................................... 30
   3.1.4. Pharmacodynamic interactions .......................................................................... 34
   3.1.5. Conclusions .................................................................................................... 34
   3.2. Overview of available pharmacokinetic data regarding the herbal substance(s), herbal preparation(s) and relevant constituents thereof ........................................................... 35
   3.3. Overview of available toxicological data regarding the herbal substance(s)/herbal preparation(s) and constituents thereof ....................................................................... 38
   3.3.1. Single dose toxicity .......................................................................................... 38
   3.3.2. Repeat dose toxicity ......................................................................................... 38
   3.3.3. Genotoxicity ................................................................................................... 40
   3.3.4. Carcinogenicity ................................................................................................ 40
   3.3.5. Reproductive and developmental toxicity ............................................................ 41
   3.3.6. Local tolerance ................................................................................................ 41
   3.3.7. Other special studies ........................................................................................ 41
   3.3.8. Conclusions .................................................................................................... 42
   3.4. Overall conclusions on non-clinical data ................................................................ 42

4. Clinical Data ..................................................................................................................... 43
   4.1. Clinical pharmacology ......................................................................................... 43
   4.1.1. Overview of pharmacodynamic data regarding the herbal substance(s)/preparation(s) including data on relevant constituents ........................................................................ 43
   4.1.2. Overview of pharmacokinetic data regarding the herbal substance(s)/preparation(s) including data on relevant constituents ........................................................................ 45
   4.2. Clinical efficacy .................................................................................................. 47
   4.2.1. Dose response studies ...................................................................................... 47
   4.2.2. Clinical studies (case studies and clinical trials) ................................................... 47
   4.3. Clinical studies in special populations (e.g. elderly and children) .............................. 71
   4.4. Overall conclusions on clinical pharmacology and efficacy ...................................... 71

5. Clinical Safety/Pharmacovigilance ................................................................................... 72
   5.1. Overview of toxicological/safety data from clinical trials in humans ......................... 72
5.2. Patient exposure ................................................................................................ 77
5.3. Adverse events, serious adverse events and deaths........................................... 77
5.4. Laboratory findings ........................................................................................... 82
5.5. Safety in special populations and situations ....................................................... 83
  5.5.1. Use in children and adolescents ...................................................................... 83
  5.5.2. Contraindications ........................................................................................... 83
  5.5.3. Special warnings and precautions for use ....................................................... 83
  5.5.4. Drug interactions and other forms of interaction .............................................. 83
  5.5.5. Fertility, pregnancy and lactation .................................................................... 83
  5.5.6. Overdose ....................................................................................................... 83
  5.5.7. Effects on ability to drive or operate machinery or impairment of mental ability ...... 84
  5.5.8. Safety in other special situations .................................................................... 84
  5.6. Overall conclusions on clinical safety ................................................................. 84
6. Overall conclusions (benefit-risk assessment) ............................................................. 85
Annex .......................................................................................................................... 85
1. Introduction

1.1. Description of the herbal substance(s), herbal preparation(s) or combinations thereof

- Herbal substance(s)

Different definitions regarding the plant part used can be found in literature:

According to DAC, 1998\(^1\) the herbal substance consists of dried rhizomes, usually free from roots and sometimes scraped, of *Piper methysticum* G. Forst. (Piperaceae). It contains not less than 3.5% of kavalactones calculated as kavain \((C_{14}H_{14}O_3\); \(Mr=230.2\)) (DAC, 1998).

According to definition from BHP (1993) kava-kava is the peeled, dried rhizome of *Piper methysticum* Forst. a plan indigenous to, and cultivated, in the Solt Sea Islands from Hawaii to the East Indies, that contains about 5% of a resin composed of a number of closely related 5,6-dihydro-α-pyrone.

Description: The dried rhizome consists of irregular, transverse and longitudinal pieces, varying considerably in size and shape: 3–20 cm in length and 1–5 cm in diameter. The outer surface is light yellowish or greyish-brown, longitudinally wrinkled, with large, whitish, circular root scars. The fracture is coarsely fibrous, the inner surface is yellow-white, with thin bark, radiate xylem, and large pith (WHO, 2004).


The main active constituents (kavalactones) consist of a group of structurally related lipophilic lactone derivatives with an aryl-ethylene-alpha-pyrone skeleton. They are typically 4-methoxy-2-pyrones with phenyl or styryl substituents at the 6-position and represent 3–20% of the dried rhizome depending on age of the plant and specific cultivar.

At least 18 kavalactones have been isolated from kava rhizome, of which six compounds are present in the highest concentrations and account for approximately 96% of the total kavalactones: kavain (dextro-isomer), 5,6-dihydrokavain, yangonin, desmethoxyyangonin, methysticin, and dihydromethysticin. Kavalactones are not water soluble but soluble in ethanol 95% or acetone.

Other constituents of dried rhizome are starch (43%), fibres (20%), sugars (3,2%), proteins (3,6% including peptides such as glutathione) and 3.2% minerals (potassium, calcium, magnesium, sodium, aluminum, and iron), dihydrochalcones (Flavokavains A, B and C) and pipermethystine (an alkaloid).

A complete list of organic compounds (soluble in ethanol 95% or other organic solvent) isolated from kava was published by WHO, 2007 and includes two classes:

**Kavalactones:** 11-Hydroxy-12-methoxydihydrokavain; 7,8-Dihydro-5-hydroxykavain; 11,12-Dimethoxydihydrokavain; Methysticin; Dihydromethysticin; Kavain; 7,8-Dihydrokavain; 5,6-Dehydromethysticin; 5,6-Dehydrokavain; Yangonin; 5,6,7,8-Tetrahydroyangonin; 5,6-Dihydroyangonin; 7, 8-Dihydroyangonin; 10-Methoxyyangonin; 11-Methoxyyangonin; 11-Hydroxyyangonin; 5-Hydrokavain; 11-Methoxy-12-hydroxydehydrokavain

**Others:** Flavokavin A; Flavokavin B; Flavokavin C; Dihydrokavain-5-ol; Cuproic acid; Cinnamalketone Methyleneoxy-3,4-cinnamalketone; 4-Oxoxonanoic acid; Benzoic acid; Phenyl acetic acid; Dihydrocinnamic acid; Cinnamic acid; Pipermethystine; 1-(meta-methoxycinnamoyl)pyrrolidine and 1-Cinnamoylpyrrolidine.

\(^{1}\) no longer available
Small amounts (1mg/4 kg herbal substance) of cepharadione A (aporphine-type) were also isolated (Jaggy & Achenbach, 1992).

Variation of the composition

According to Whitton et al. (2003) who investigated the localization of the kavalactones within the different root structures, the greatest concentration of kavalactones is in the bark with relatively lower concentrations in the parenchyma and sclerenchyma tissues. In the cross-sections of the roots, the kavalactone concentration is higher in the younger root, this reflecting the lower amounts of parenchyma and sclerenchyma tissues compared with the bark.

Analysis of the Quality of Different Kava Varieties

It was reported that there are significant differences between the composition of kava plants from different islands. ‘Noble’ kava varieties from Vanatu contains substantially less flavokavin B than ‘non-noble’ kava but higher level of kavain (Lebot & Lévesque, 1996; Simeoni & Lebot, 2002; Lebot & Legendre, 2016).

Adulteration

a. With other parts of the plant: stem peelings may be included as raw material in kava commerce due to the high demand for the rhizome; Pipermethystine is present in stem peelings (traces to 0.85%); 3,4α-Epoxy-5β-pipermethysticin (0.93%) was isolated from stem peelings of one cultivar, but was absent from 10 other cultivars. 7,8-Dihydrokawain, 7,8-dihydromethysticin and 5,6,7,8-tetrahydroyangonin are present in stem peelings.

b. With other species: the main adulteration species are P. auritum and P. aduncum (Singh, 1992; IARC, 2015).

Contaminants

Just a few data are published regarding kava contamination with mycotoxins (Teschke & Lebot, 2011). A study on ochratoxin A contamination found concentrations of 3.0 ng/g in one sample of kava root (Trucksess et al., 2006). The level of contamination with aflatoxin B1 in four samples of ground kava was 0.5 ng/g (Weaver & Trucksess, 2010).

• Herbal preparation(s)

In the literature there are mentioned different types of preparations:

a. Traditionally non EU kava preparations (beverage)- these are prepared by maceration of finely ground roots in a water and coconut milk solution (Norton & Ruze, 1994).

b. Herbal extracts of kava: the solvents used are either ethanol (60% or above) or acetone (60% or above) in order to specifically extract the kavalactones. These are standardised extracts as the extract has been concentrated and standardised to contain a certain amount of a particular component (e.g. total kavalactones). In general, ethanolic extracts are standardized to 30 % kavalactones, while acetonic extracts to 70 % kavalactones (WHO, 2007).

The processing techniques and specifically the extraction solvent and the ratio between solvent/plant material may have considerable influence on the chemical composition of the extracts. For example, even that pipermethystine is soluble in acetone 100%, it was not detectable in some commercial acetonic kava extracts (Teschke & Lebot, 2011).

Whitton et al. (2003) analyzed the composition of different extracts and concluded that extraction with 96% ethanol also resulted in 100% kavalactone extracted from the rhizoma, while extraction with 25%
ethanol gave only 15% kavalactones and the water extract contained <3% of kavalactones present in the herbal substance. The same author revealed that the ratio between kavalactone:glutathione in the extracts also depends on the extraction solvent.

Kava lactone:glutathione ratio in extracts prepared according to commercial preparations of *P. methysticum* roots

<table>
<thead>
<tr>
<th>Sample</th>
<th>Solvent</th>
<th>Kava lactone glutathione</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kava standardised extract powder (30% kavalactones)</td>
<td>25% ethanol, 75% water</td>
<td>1:0</td>
</tr>
<tr>
<td>82% ethanol extraction of kava root</td>
<td>None (this was already a liquid preparation)</td>
<td>1:0.017</td>
</tr>
<tr>
<td>Tincture extraction (1 part root to 3 parts solvent)</td>
<td>25% ethanol, 75% water</td>
<td>1:1.15</td>
</tr>
<tr>
<td>Fluid extract extraction (1 part root to 1 part solvent)</td>
<td>25% ethanol, 75% water</td>
<td>1:2.2</td>
</tr>
</tbody>
</table>

* Data are the means from ten replicate samples of each type.

Wang *et al.* (2015) determined contents of kavalactones in and chemotype of kava beverages prepared from roots and rhizomes of 2 varieties from Hawaii (Isa- "non noble" and Mahakea- "noble") and extraction efficiency of five different solvents including hexane, acetone, methanol, ethanol and ethyl acetate. The contents of kavalactones in the extracts with acetone, ethanol, and methanol did not differ significantly. Ethanol had the highest extraction efficiency for the six major kavalactones whereas hexane gave the lowest extraction efficiency.

<table>
<thead>
<tr>
<th>Solvents</th>
<th>Mahakea variety</th>
<th>Isa variety</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Total kavalactone content</td>
<td>Total kavalactone content</td>
</tr>
<tr>
<td></td>
<td>Root</td>
<td>Rhizome</td>
</tr>
<tr>
<td>Acetone</td>
<td>0.0819±0.0005</td>
<td>0.0513±0.0002</td>
</tr>
<tr>
<td>Ethanol</td>
<td>0.0948±0.0003</td>
<td>0.0569±0.0002</td>
</tr>
<tr>
<td>Ethyl acetate</td>
<td>0.0754±0.0002</td>
<td>0.0513±0.0003</td>
</tr>
<tr>
<td>Methanol</td>
<td>0.0797±0.0003</td>
<td>0.0482±0.0001</td>
</tr>
<tr>
<td>Hexane</td>
<td>0.0338±0.0004</td>
<td>0.0286±0.0002</td>
</tr>
</tbody>
</table>

Meissner & Haberlein (2005) analysed the amount of flavokavins A, B and C in an ethanolic kava extract (DER 14.5:1, extraction solvent ethanol 96% v/v) using an HPLC method. Flavokavins contents were: 0.62 mg flavokavin A/100 mg ethanolic extract, 0.34 mg flavokavin B/100 mg ethanolic extract and 0.14 mg flavokavin C/100 mg ethanolic extract.

Xuan *et al.* (2008) compared the content and composition of different extracts obtained using different solvents. The amount of total lactones in the water extract (108.6 mg/g) was almost similar to that in chloroform extract (106.2 mg/g) and much higher than that found in the methanol, ethanol and hexane extracts (45.6, 22.5, and 26.3 mg/g, respectively).

**Table 2** Quantity of seven major kava lactones and glutathione in kava roots (mg/g extract)

<table>
<thead>
<tr>
<th>Chemicals</th>
<th>Water</th>
<th>Acetone</th>
<th>Chloroform</th>
<th>Methanol</th>
<th>Ethanol</th>
<th>Hexane</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methysticin</td>
<td>0.0</td>
<td>5.5</td>
<td>14.4</td>
<td>0.0</td>
<td>0.0</td>
<td>1.2</td>
</tr>
<tr>
<td>Dihydrodihydroxykavain</td>
<td>31.5</td>
<td>51.9</td>
<td>18.9</td>
<td>5.4</td>
<td>3.2</td>
<td>3.6</td>
</tr>
<tr>
<td>Kavain</td>
<td>36.9</td>
<td>41.5</td>
<td>14.7</td>
<td>6.9</td>
<td>3.3</td>
<td>4.7</td>
</tr>
<tr>
<td>7,8-Dihydrokavain</td>
<td>3.8</td>
<td>55.1</td>
<td>23.0</td>
<td>18.6</td>
<td>9.4</td>
<td>10.1</td>
</tr>
<tr>
<td>Dihydro-5,6-dehydrokavain (DDK)</td>
<td>22.9</td>
<td>27.1</td>
<td>4.7</td>
<td>4.7</td>
<td>2.1</td>
<td>1.9</td>
</tr>
<tr>
<td>Desmethoxyyagonin</td>
<td>6.7</td>
<td>21.0</td>
<td>7.6</td>
<td>4.3</td>
<td>2.1</td>
<td>2.7</td>
</tr>
<tr>
<td>Yagonin</td>
<td>6.8</td>
<td>84.1</td>
<td>22.9</td>
<td>5.7</td>
<td>2.4</td>
<td>2.1</td>
</tr>
<tr>
<td>Total lactones</td>
<td>108.6</td>
<td>286.2</td>
<td>106.2</td>
<td>45.6</td>
<td>22.5</td>
<td>26.3</td>
</tr>
<tr>
<td>Glutathione</td>
<td>26.3</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
</tr>
</tbody>
</table>

- Combinations of herbal substance(s) and/or herbal preparation(s) including a description of vitamin(s) and/or mineral(s) as ingredients of traditional combination herbal medicinal products assessed, where applicable.

Not applicable
1.2. **Search and assessment methodology**

Databases and other sources used to research available pharmaceutical, non-clinical and clinical data on kava-kava or its relevant constituents:

- Relevant articles and references retrieved from databases: PubMed and Toxline. Search term: [kava], [kava-kava], [Piperis methysticum] and [Piperis methysticum rhizoma] combined with ‘human’, ‘clinical trial’, ‘randomised controlled trial’ and ‘review’; Publication year: up to January 2016. In summary more than 1700 publications were listed.

- Textbooks, pharmacopoeias and monographs.

Additionally, the European Commission’s databases on cosmetic ingredients (CosIng) was searched in August 2015 for information on [piper methysticum root or root extract].

Data was also provided by the EMA on behalf of interested parties.

The EudraVigilance database and VigiLyze database of the World Health Organization’s were searched in May 2016 using the term [Piper methysticum].

The abstracts of the references found were screened manually and all articles identified that could have a possible impact on the assessment report and monograph were included. This assessment report is based on the summary of the most relevant scientific literature.

2. **Data on medicinal use**

2.1. **Information about products on the market**

2.1.1. **Information about products on the market in the EU/EEA Member States**

**Information on medicinal products marketed in the EU/EEA**

Table 1: Overview of data obtained from marketed medicinal products.

<table>
<thead>
<tr>
<th>Active substance</th>
<th>Indication</th>
<th>Pharmaceutical form</th>
<th>Regulatory Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dry extract from Piperi methystici rhizoma (12.5-20.0:1), extraction solvent: ethanol 96% (V/V)</td>
<td>States of nervous anxiety, tension and restlessness.</td>
<td>Tablet 180-288 mg corresponding to 120 mg kavalactones &gt;12 years: 1 tablet 1-2 times daily (corresponding to 120-240 mg kavalactones per day)</td>
<td>1997-1999, DE, WEU according to Article 10a of Directive 2001/83/EC</td>
</tr>
<tr>
<td>Dry extract from Piperi methystici rhizoma (12.5-20.0:1), extraction solvent: ethanol 96% (V/V)</td>
<td>States of nervous anxiety, tension and restlessness.</td>
<td>Tablet 180-288 mg corresponding to 120 mg kavalactones &gt;12 years: 1 tablet 1-2 times daily (corresponding to 120-240 mg kavalactones per day)</td>
<td>At least since 1976 up to 2002, DE, WEU according to Article 10a of Directive 2001/83/EC</td>
</tr>
<tr>
<td>Dry extract from Piperi methystici rhizoma (11.5-21.5:1), extraction solvent:</td>
<td>States of nervous anxiety, tension and restlessness.</td>
<td>Oral liquid 1 ml oral liquid contains 33-63 mg extract corresponding to 25 mg</td>
<td>At least since 1976 up to 2002, DE, WEU according to Article 10a of Directive</td>
</tr>
<tr>
<td>Active substance</td>
<td>Indication</td>
<td>Pharmaceutical form</td>
<td>Regulatory Status</td>
</tr>
<tr>
<td>--------------------------------------</td>
<td>-----------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>ethanol 96% (V/V)</td>
<td>kavalactones &gt;12 years: 60 drops (≈7mg) 2-3 times daily</td>
<td>2001/83/EC</td>
<td></td>
</tr>
<tr>
<td>Soft extract from Piperi methystici rhizoma (13-20:1), extraction solvent: ethanol 96% (V/V)</td>
<td>States of nervous anxiety, tension and restlessness.</td>
<td>Capsule, soft 152-288 mg corresponding to 120 mg kavalactones &gt;12 years: 1 or 2 capsules 1 time daily (corresponding to 120 to 240 mg kavalactones per day)</td>
<td>2000-2002 DE, WEU according to Article 16a of Directive 2001/83/EC</td>
</tr>
<tr>
<td>Kava-kava extractum siccum, extraction solvent acetone 75% (m/m) – information on DER is not available</td>
<td>Long term conditions of anxiety, fear, psychological tension and restlessness, stress, psychovegetative disorders in menopause, possible alternative to benzodiazepines in gerontology.</td>
<td>Hard capsules 1 capsule contains 50 mg of the extract equivalent to 35 mg of kavalactones Dosage: 1 capsule 3 times daily Not to be used for more than 3 months For adults only</td>
<td>From 1998 to 2003, CZ (registration was granted the old legislative frame)</td>
</tr>
<tr>
<td>Kava-kava extractum siccum, extraction solvent acetone 75% (m/m) – information on DER is not available</td>
<td>Long term conditions of anxiety, fear, psychological tension and restlessness, stress, psychovegetative disorders in menopause, possible alternative to benzodiazepines in gerontology.</td>
<td>Hard capsules 1 capsule contains 100 mg of the extract equivalent to 70 mg of kavalactones Dosage: 1 capsule 3 times daily Not to be used for more than 3 months For adults only</td>
<td>From 1998 to 2003, CZ (registration was granted the old legislative frame)</td>
</tr>
<tr>
<td>Kava-kava extractum siccum, extraction solvent ethanol 96% (V/V), information on DER is not available</td>
<td>Long term conditions of anxiety, fear, psychological tension and restlessness, stress, psychovegetative disorders in menopause, possible alternative to benzodiazepines in gerontology.</td>
<td>Film coated tablets 1 tablet contains 375 _ 428.57 mg of the extract equivalent to 120 mg of kavalactones Dosage: ½ to 2 tablets (equivalent to 120 – 240 mg kavalactones) in the evening after meal. Not to be used more than 3 months.</td>
<td>From 1996 to 2001, CZ (registration was granted the old legislative frame)</td>
</tr>
<tr>
<td>Kava-kava extractum spissum, extraction solvent ethanol 96% (V/V), information on DER is not available</td>
<td>Mild to moderate depressions, neuroses, anxiety, tensions, restlessness, mood disorders, vegetative or psychosomatic disorders (neurovegetative dystonia), stress</td>
<td>Hard capsules 1 capsule contains Kava-kava extractum spissum Dosage:1 capsule 1 to 3 times daily</td>
<td>From 1997 to 2003, CZ (registration was granted the old legislative frame)</td>
</tr>
<tr>
<td>Soft extract from Piperi methystici rhizoma (11.5-21.5:1), extraction</td>
<td>States of nervous anxiety, tension and restlessness.</td>
<td>Capsule 67-125 mg corresponding to 50 mg kavalactones</td>
<td>Old product, not authorised, DE</td>
</tr>
<tr>
<td>Active substance</td>
<td>Indication</td>
<td>Pharmaceutical form</td>
<td>Regulatory Status</td>
</tr>
<tr>
<td>------------------</td>
<td>------------</td>
<td>----------------------</td>
<td>------------------</td>
</tr>
<tr>
<td>solvent: ethanol 96% (V/V)</td>
<td>States of nervous anxiety, tension and restlessness.</td>
<td>&gt;12 years: 1 capsule 3-4 times daily (corresponding to 150-200 mg kavalactones per day)</td>
<td></td>
</tr>
<tr>
<td>Dry extract from Piperi methystici rhizoma (13-20:1), extraction solvent: ethanol 96% (V/V)</td>
<td>States of nervous anxiety, tension and restlessness.</td>
<td>Tablet 75.2-120.2 mg corresponding to 50 mg kavalactones &gt;12 years: 1 tablet 1-2 times daily (corresponding to 150-200 mg kava pyrones per day)</td>
<td>Old product, not authorised, DE</td>
</tr>
<tr>
<td>Soft extract from Piperi methystici rhizoma (12.5-20:1), extraction solvent: ethanol 96% (V/V)</td>
<td>States of nervous anxiety, tension and restlessness.</td>
<td>Capsule 76-144 mg corresponding to 60 mg kavalactones &gt;12 years: 1 capsule 4 times daily (corresponding to 240 mg kavalactones per day)</td>
<td>Old product, not authorised, DE</td>
</tr>
<tr>
<td>Soft extract from Piperi methystici rhizoma (13-20:1), extraction solvent: ethanol 96% (V/V)</td>
<td>States of nervous anxiety, tension and restlessness.</td>
<td>Capsule, soft 152-288 mg corresponding to 120 mg kavalactones &gt;12 years: 1 capsule 2 times daily (corresponding to 240 mg kavalactones per day)</td>
<td>Old product, not authorised, DE</td>
</tr>
<tr>
<td>Soft extract from Piperi methystici rhizoma (11.5-21.5:1), extraction solvent: ethanol 96% (V/V)</td>
<td>States of nervous anxiety, tension and restlessness.</td>
<td>Capsule 67-125 mg corresponding to 50 mg kavalactones &gt;12 years: 1 capsule 4 times daily (corresponding to 200 mg kavalactones per day)</td>
<td>Old product, not authorised, DE</td>
</tr>
<tr>
<td>Soft extract from Piperi methystici rhizoma (12.5-20:1), extraction solvent: ethanol 96% (V/V)</td>
<td>States of nervous anxiety, tension and restlessness.</td>
<td>Oral liquid 1 g oral liquid contains 26-42.5 mg soft extract corresponding to 17.7 mg kavalactones &gt;12 years: 4 ml (=?g) 3 times daily</td>
<td>Old product, not authorised, DE</td>
</tr>
<tr>
<td>Extract from Piperi methystici rhizoma (13-20:1), extraction solvent: ethanol 96% (V/V)</td>
<td>States of nervous anxiety, tension and restlessness.</td>
<td>Oral liquid 1 ml oral liquid contains 22-105 mg extract corresponding to 25 mg kavalactones &gt;12 years: 3.2 ml 3 times daily</td>
<td>Old product, not authorised, DE</td>
</tr>
<tr>
<td>Dry extract from Piperi methystici rhizoma (12.5-20:1), extraction solvent: ethanol 96% (V/V)</td>
<td>States of nervous anxiety, tension and restlessness.</td>
<td>Coated tablet 54-113 mg corresponding to 40 mg kavalactones &gt;12 years: 2 tablets 3 times daily</td>
<td>Old product, not authorised, DE</td>
</tr>
<tr>
<td>Active substance</td>
<td>Indication</td>
<td>Pharmaceutical form</td>
<td>Regulatory Status</td>
</tr>
<tr>
<td>-----------------</td>
<td>------------</td>
<td>----------------------</td>
<td>------------------</td>
</tr>
<tr>
<td>Soft extract from Piperi methystici rhizoma (13-20:1), extraction solvent: ethanol 96% (V/V)</td>
<td>States of nervous anxiety, tension and restlessness.</td>
<td>Oral liquid 1 g oral liquid contains 26-42.5 mg extract &gt;12 years: 20 drops (=? mg) 3 times daily (corresponding to 60 mg kavalactones per day)</td>
<td>Old product, not authorised, DE</td>
</tr>
</tbody>
</table>

Additional data regarding the legal actions from the EU member states

**Belgium:** *Piper methysticum* belongs to list 1 of the Royal Decree on 1997, with plants considered to be too toxic for being used in food supplements/drugs.

**Czech Republic:** WHO rapid alert was received in 2002 with information that kava-kava products were withdrawn from the German market after evaluation of kava case reports on hepatotoxicity by BfArM. Based on this document the benefit/risk of the products on the Czech market was re-evaluated. Benefit/risk was found negative and therefore it was decided that renewal of products authorised will not be approved and withdrawn from the market was recommended.

**UK:** Kava has been prohibited in unlicensed medicines since January 2003, by the Medicines for Human Use (Kava-kava Prohibition Order 2002). Following the Prohibition Order in 2002, UK Ministers made a commitment to review the ban after it had been in force for 2 years. In February 2006, following advice from an Expert Working Group (EWG) of Committee on Safety of Medicines (CSM), it was announced that the prohibition was justified and proportionate and should remain in place.

**Spain:** In 2001, following the decision of the PhVWP regarding medicinal products containing kava-kava, the AEMPS recommended the withdrawal of the only product that was registered.

**France:** In 2002, the French Agency for the Safety of Health Products (AFSSAPS) suspended all preparations containing kava for the duration of one year. Prohibition was completed in March 2003. Homeopathic remedies with dilutions of 1/500 or greater are exempt from the prohibition.

**Portugal:** In 2002, Portugal followed France and suspended all kava containing products for one year.

**Germany:** In 2002 the German Federal Institute for Drugs and Medical Devices (BfArM) revoked the market authorization for kava kava-containing products.

**Hungary:** In 2002, following BfArM action, all kava-containing products were withdrawn. This overview is not exhaustive. It is provided for information only and reflects the situation at the time when it was established.

**Information on relevant combination medicinal products marketed in the EU/EEA**

Not applicable

**Information on other products marketed in the EU/EEA (where relevant)**

Not applicable
2.1.2. Information on products on the market outside the EU/EEA

On 19 December 2001, the US Food and Drug Administration (FDA) issued a letter asking healthcare professionals to report any adverse events that might link kava with hepatotoxicity to the FDA’s MedWatch program. On 25 March 2002, FDA published a consumer advisory concerning the potential risk of severe liver injury and rare hepatic failure associated with the use of kava-containing dietary supplements and posted on the FDA website (FDA, 2002).

2.2. Information on documented medicinal use and historical data from literature

The kava plant (*Piper methysticum* Forst.) is a robust, fairly succulent, well-branching and erect, perennial shrub belonging to the family Piperaceae. The generic name *Piper* comes from the Latin for “pepper”, and the species name methysticum from the Greek meaning “intoxicant”, thus *Piper methysticum* when translated into English means “intoxicating pepper”. Other names used to refer to kava include: kava kava; kava; ava; awa; yati; yagona; and yangona (NTP, 2012)

The term ‘kava’ and the variant "kawa", is primarily used to refer to the kava plant and the drink prepared from the fresh or dried roots of that plant. The term ‘kava’, however, is also used to refer to other preparations such as acetone or ethanol extracts of the plant for use in medicinal products.

Traditional use

Kava has a very long tradition of use in the South Pacific as a tranquilizing ritual beverage. The cultural history of the use of kava has been reviewed by Singh (1992) that indicate the use for at least 1500 years.

The traditional kava beverage is prepared by soaking the pulverized root in a bowl of water and/or coconut milk solution and filtering the mix to produce a brew in a communal bowl. The kava is then drunk from a cup, sometimes a coconut shell. In parts of Vanuatu and Papua New Guinea today, and in other regions across the Pacific in the past, the root is pulverised through mastication, whereas the ‘Fijian method’ involves pounding the root rather than chewing it (Cairney et al., 2002).

Kava consumed in Vanuatu is reputed to be the "strongest" (highest kavalactones content) anywhere in the South Pacific (Singh, 1992).

Use in the European Union

It has been determined that modern pharmaceutical preparations of *P. methysticum* contain extracts. The extracts are prepared by extracting the dried herb with an ethanol-water mixture (for extracts containing about 30 % kavapyrones) or with an acetone-water mixture (for extracts containing about 70 % kavapyrones). The herb-to-extract ratio is about 12-20:1 in both preparations (Schulz et al.,?, 1999).

According to Potter's Herbal Cyclopaedia, kava-kava is used as stimulant, relaxant and antifatigue, tonic and diuretic. The dosage indicated corresponds to 120 mg extract (Williamson, 2003)

In 'Precis de Matiere Medicale', kava roots are described. Following therapeutic indications are mentioned: treatment of genito-urinary tract (cystitis, blennorrhagia) and the diuretic effect. The daily dosage for hydro-alcoholic extract corresponds to 0.5 to 1 g. (Leulier & Manceau, 1946).

In Madaus (1938), the following indications are mentioned: gonorrhoea, cystitis and prostate infections; it is also mentioned one preparation with sedative effects, bactericide and diuretic action.
The preparation and dosage included are: kava rhizoma: 0.1-0.3 g, multiple times daily; alcoholic extract: 0.1-1 g; 1 tablet, 3 times daily (1 tablet containing 0.125 g kava rhizoma).

In Fischer & Hartwich (1919) the indications proposed are bronchitis and catarrhal conditions. The preparation described is a liquid extract (1000 g powdered rhizoma percolated with a mixture of ethanol 91%: water (8:2)); no data regarding the posology is provided (Fischer, 1919).

In a later edition of Hagers Handbuch, the following preparations are included: extractum Rhizoma Kava-Kava siccum (extraction solvent: ethanol 94% v/v + 1% methylethylcetone; contains 31.6 to 35.4 kavalactones); Kava-Kava dry hydro-alcoholic extract (contains 30% kavalactones); Kava-Kava dry acetonic extract (contains 70% kavalactones), Kava-Kava dichlormethane extract (called "kava resin"), and kava powdered rhizome (used for water extraction: 10 g powder/100 ml water). The daily dosage proposed is 60 to 120 mg kavalactones and the indications are nervous anxiety, stress, and restlessness (Hänsel et al., 1994).

British Pharmaceutical Codex 1911 includes 2 preparations based on kava-kava: Solid Extractum Kavae used in gonorrhoea and catarrhal conditions of the genito-urinary organs (dose: 6-30 centigrams) and Extractum Kavae Liquidum (100 g kava rhizome macerated for 8 hours with ethanol 45%, then percolated and evaporated to a soft extract, then dissolved in ethanol 90% v/v), used in mixtures form with bladder sedatives and diuretics; dose: 2-4 ml.

BHP (1993) mentioned as specific indication in infection of genito-urinary tract (cystitis, urethritis) and indication in rheumatism and joint pains (topical application). It can be used in combination with Althaea root, Apium and Agropyron in bladder disease or with Menyanthes, Cimicifuga and Apium in rheumatism. Preparation and dosage (thrice daily): Dried root: 2-4 g or by decoction; Liquid extract B.P.C: 2-4 ml

Martindale, The Extra Pharmacopoeia (2009) indicates that kava rhizome has been used in the South Pacific “to produce an intoxicating beverage used for recreational purposes and during convalescence”. It is reported to have sedative, skeletal muscle relaxant, and anaesthetic properties. It is given in some anxiety- and stress-related disorders. It was formerly used as an antiseptic and diuretic in inflammatory conditions of the genito-urinary tract in the form of a liquid extract. Kavain has also been used for nervous disorders and as a tonic. No details regarding dosages are given (Martindale, 2009).

In the monograph published in 1990 of Piperis methystici rhizoma (Kava-Kava-Wurzelstock), the German Commission E recommended the use of kava kava for conditions of nervous anxiety, stress, and restlessness. The daily dosage recommended for comminuted rhizome and other galenical preparations for oral use corresponds to 60 to 120 mg kavalactones for short-term use, not more than 3 months (Blumenthal, 1998).

WHO monograph describes for kava the traditional medicinal use to induce relaxation, reduce weight and treat fungal infections and the use in short-term symptomatic treatment of mild states of anxiety or insomnia, due to nervousness, stress or tension supported by clinical data. The daily dose indicated is: crude drug and extracts equivalent to 60-210 mg kavalactones (WHO, 2002).

ES COP monograph indicates that kava can be used in anxiety, tension and restlessness arising from various causes of non-psychotic origin. The doses proposed in adults and elderly are: dried rhizome or extracts corresponding to 60-120 mg kavalactones, usually for 1 month at most 2 months (ES COP, 2003)

PDR for Herbal Medicine also included Kava-kava as drug used for nervous tension, stress and agitation. The dosage indicated are: 150-300 mg root extract, twice daily, with a daily dosage of kavalactones of 50 to 240 mg; 30 drops of tincture with water, three times daily or 1/2 cup of infusion twice daily (Gruenwald et al., 2004).
The same indication (treatment of anxiety) is mentioned in Bruneton (2003) for one extract (not characterized) where the daily dose corresponds to 35 up to 120 mg kavalactones.

Table 2: Overview of historical data

<table>
<thead>
<tr>
<th>Herbal preparation</th>
<th>Documented use / Traditional use</th>
<th>Pharmaceutical form</th>
<th>Reference</th>
</tr>
</thead>
</table>
| Comminuted herbal substance | a) Sedative effect  
b) Gonorrhea, cystitis and prostate infections | Oral use  
Single dosage 0.1-0.3 g  
Multiple single doses/day | Madaus, 1938 |
| Infection of genito-urinary tract | | Oral use  
2-4 g dried root or by decoction; 3 times/daily | BHP, 1993 |
| Nervous anxiety, stress, and restlessness | | Oral use  
Daily dose: equivalent to 60 to 120 mg of kavalactones  
Duration of use: not more than 3 months | Blumenthal et al., 1990 |
| Nervous anxiety, stress, and restlessness | Oral use: 10 g powder/100 ml water  
The daily dosage corresponds to 60 to 120 mg kavalactones | Hänsel et al., 1994 |
| Nervous tension, stress and agitation | Oral use  
1/2 cup of infusion twice daily  
(no further detail) | Gruenwald et al., 2004 |
| Anxiety, tension and restlessness arising from various causes of non-psychotic origin | Oral use  
Daily dose corresponds to 60 to 120 mg of kavalactones  
Duration of use: usually for 1 months at most 2 months | ESCOP, 2003 |
| Short-term symptomatic treatment of mild states of anxiety or insomnia, due to nervousness, stress or tension | Oral use  
Daily dose corresponds to 60 to 210 mg of kavalactones | WHO, 2002 |
| Extract (no further detail) | Anxiety, tension and restlessness arising from various causes of non-psychotic origin | Oral use  
Daily dose corresponds to 60 to 120 mg of kavalactones  
Duration of use:  
a) usually for 1 months at most 2 months | a) ESCOP, 2003  
b) Blumenthal et al., 1990 |
<table>
<thead>
<tr>
<th>Herbal preparation</th>
<th>Documented use / Traditional use</th>
<th>Pharmaceutical form</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Extract (no further detail)</td>
<td>Anxiety</td>
<td>Oral use</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Daily dose corresponds to 35 to 120 mg of kavalactones</td>
<td>Bruneton, 2003</td>
</tr>
</tbody>
</table>
| Liquid extract B.P.C (no further detail) | a) Gonorrhea, cystitis and prostate infections  
   b) Rheumatism (joint pains-topical application). | 2-4 ml                                                                             | BHP 1993                        |
| Alcoholic extract (no further detail) | a) Sedative effect  
   b) Gonorrhea, cystitis and prostate infections | Oral use                                                                            | Madaus, 1938                    |
| Hydro-alcoholic extract (no further detail) | Treatment of genitourinary tract (cystitis, blennorrhagia) and the diuretic effect. | Oral daily dosage: 0.5 to 1 g.                                                      | Leurier et al., 1946.           |
| Solid Extractum Kavae      | Gonorrhoea and catarhal conditions of the genitourinary organs                                   | Oral use: 6-30 centigrams                                                           | British Pharmaceutical Codex 1911 |
| Extractum Kavae Liquidum   | Gonorrhoea and catarhal conditions of the genitourinary organs                                   | Oral use: 2-4 ml                                                                    | British Pharmaceutical Codex 1911 |
| Ethanolic Kava extract siccum (extraction solvent: ethanol 94% v/v; extract contains 31.6 to 35.4 kavalactones) | Nervous anxiety, stress, and restlessness                                                     | Oral use                                                                            | Hänsel et al., 1994            |
| Kava-Kava dry hydro-alcoholic extract (30% kavalactones) | Nervous anxiety, stress, and restlessness                                                        | Oral use                                                                            | Hänsel et al., 1994            |
| Kava-Kava dry Acetonic extract | Nervous anxiety, stress, and restlessness                                                        | Oral use                                                                            | Hänsel et al., 1994            |
2.3. Overall conclusions on medicinal use

From market overview (section 2.1) just one indication was identified for the products authorised in Germany as well-established use: "States of nervous anxiety, tension and restlessness" and the respective preparations are:

- Extract from Piperi mystemii rhizoma (DER 12.5-20.0:1), extraction solvent: ethanol 96% (V/V)-authorized from1976 to 2002
- Extract from Piperi mystemii rhizoma (DER 11.5-21.5:1), extraction solvent: ethanol 96% (V/V)-authorized from1976 to 2002
- Soft extract from Piperi mystemii rhizoma (DER 13-20:1), extraction solvent: ethanol 96% (V/V)-authorized from 2000 to 2002

Even that the medicinal use of kava preparations is documented in several medicinal handbooks throughout a period of at least 30 years, the medicinal products are withdrawn from the EU market since 2002 based on safety concern. The clinical efficacy of kava preparations, based on Article 10a of Directive 2001/83/EC as amended (well-established use) is evaluated in section 4 "Clinical data", while the safety concerns are included in section 5.

Insufficient data are available regarding characterization of herbal preparations included in literature (no DER or extraction solvent used) and posology (single dose is missing, while daily dosage is expressed only as equivalent to kavalactones). Therefore in the table 4 are included only preparations where all necessary data are available

The use of in children and adolescents under 18 years of age is not recommended due to lack of adequate efficacy and safety data.

Table 3: Overview of evidence on period of medicinal use

<table>
<thead>
<tr>
<th>Herbal preparation</th>
<th>Indication</th>
<th>Posology, Strength</th>
<th>Period of medicinal use</th>
</tr>
</thead>
<tbody>
<tr>
<td>Comminuted herbal substance*</td>
<td>Infection of genito-urinary tract</td>
<td>2-4 g dried rhizoma or by decoction; 3 times/daily</td>
<td>BHP 1993</td>
</tr>
<tr>
<td>Herbal preparation Pharmaceutical form</td>
<td>Indication</td>
<td>Posology, Strength</td>
<td>Period of medicinal use</td>
</tr>
<tr>
<td>----------------------------------------</td>
<td>------------</td>
<td>--------------------</td>
<td>------------------------</td>
</tr>
<tr>
<td>Dry extract from Piperi methystici rhizome (12.5-20.0:1), extraction solvent: ethanol 96% (V/V) Tablets</td>
<td>States of nervous anxiety, tension and restlessness.</td>
<td>Single dose: 120 mg kavalactones  Daily dose: 120-240 mg kavalactones</td>
<td>1976-2002, DE, WEU</td>
</tr>
<tr>
<td>Dry extract from Piperi methystici rhizome (11.5-21.5:1), extraction solvent: ethanol 96% (V/V) Liquid dosage form</td>
<td>States of nervous anxiety, tension and restlessness.</td>
<td>1 ml oral liquid contains 33-63 mg extract corresponding to 25 mg kavalactones &gt;12 years: 60 drops 2-3 times daily</td>
<td>1976-2002, DE, WEU</td>
</tr>
</tbody>
</table>

* only hysterical use

3. Non-Clinical Data

3.1. Overview of available pharmacological data regarding the herbal substance(s), herbal preparation(s) and relevant constituents thereof

The extracts used in the trials are specified in the comments as far as possible. Unfortunately, in many publications correct specifications of solvent and drug-extract ratio (DER) are missing. No distinction between chemovarieties is done in the published literature and often is mentioned simply as "Kava-Kava preparation". In these cases no details can be given, if the extract could not be identified otherwise.

3.1.1. Primary pharmacodynamics

Neurological and sedative effects, and anticonvulsive, muscle relaxing, and spasmolytic activity of kava extracts or isolated kavalactones have been examined in several in vitro and in vivo studies, mainly in rats and mice.

Interaction with neurotransmitter receptors

Kava extracts and kavalactones are extensively analyzed toward their activity on central nervous system (CNS) receptors (especially y-aminobutyric acid (GABA) receptors) and neurotransmitters (the inhibition of monoamine uptake or the modulation of 5-HT receptors activity) as well as toward the
modulation of voltage dependent Na\(^+\) and Ca\(^{2+}\) channels. An overview of biochemical mechanisms and possible molecular targets is given in some reviews (Bilia, 2002; Rowe et al., 2011).

**In vitro experiments**

Interaction with GABA and benzodiazepine receptors

**Ethanolic extract**

A hydroethanolic extract of kava (tested at concentration of 100 to 500 µM kavalactones; no further detail) concentration-dependently enhanced the binding of \([3H]\)muscimol to GABA\(_A\) binding sites in membrane fractions from different regions of the rat brain: hippocampus (HIP), amygdala (AMY), medulla oblongata (MED), frontal cortex (FC) and cerebellum (CER). The kava extract enhanced the binding of \([3H]\) muscimol in a concentration-dependent manner with maximal potentiation of 358% over control in HIP followed by AMY and MED (main target brain centers). Minimal stimulation was observed in CER followed by FC. In contrast, apart from CER, the potency of kavalactones was similar in the brain areas investigated with EC50 values ranging between 200 and 300 µM kavalactones. The observed effects of kavalactones were attributed to an increase in the number of binding sites (Bmax), rather than to a change in affinity. At a kavalactones concentration of 500 µM the order of enhancement in Bmax was HIP = AMY > MED > FC > CER (p<0.001 vs. control in each region) (Jussofie et al., 1994).

**Methanolic extract**

Different methanolic leaf and root extracts (no further detail) were tested on binding affinities to CNS receptors including GABA\(_A\) (GABA and benzodiazepine binding site), dopamine D2, opioid, serotonin (5-HT\(_6\) and 5-HT\(_7\)) and histamine (Dinh et al., 2001). The most potent binding inhibition was observed for leaf extracts to GABA\(_A\) receptors with IC\(_{50}\) values of approximately 3mg/ml, whereas root extracts were less active with IC\(_{50}\) values ranging from 5mg/ml (Nene) to 87mg/ml (Mahakea).

**Table 2** Effects of *Piper methysticum* Forst. extracts on binding of specific radioligands to selected CNS receptors

<table>
<thead>
<tr>
<th>IC(_{50}) (µg/ml)*</th>
<th>Benzdiazepine</th>
<th>Dopamine</th>
<th>GABA(_A)</th>
<th>Opioid</th>
<th>Histamine</th>
<th>Serotonin</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>D(_2)</td>
<td>µ</td>
<td>δ</td>
<td>H(_1)</td>
<td>H(_3)</td>
<td>5-HT(_6)</td>
</tr>
<tr>
<td>Mahaloe root extract</td>
<td>860 ± 60</td>
<td>850 ± 22</td>
<td>87 ± 17</td>
<td>592 ± 34</td>
<td>185 ± 61</td>
<td>850 ± 37</td>
</tr>
<tr>
<td>Mahaloe leaf extract</td>
<td>510 ± 35</td>
<td>68 ± 4</td>
<td>4 ± 1</td>
<td>19 ± 5</td>
<td>240 ± 30</td>
<td>36 ± 7</td>
</tr>
<tr>
<td>WC root extract</td>
<td>556 ± 88</td>
<td>101 ± 32</td>
<td>83 ± 15</td>
<td>256 ± 69</td>
<td>168 ± 16</td>
<td>603 ± 64</td>
</tr>
<tr>
<td>WC leaf extract</td>
<td>710 ± 36</td>
<td>36 ± 18</td>
<td>1 ± 0.5</td>
<td>74 ± 11</td>
<td>161 ± 39</td>
<td>206 ± 33</td>
</tr>
<tr>
<td>Purple Moi root extract</td>
<td>900 ± 97</td>
<td>374 ± 61</td>
<td>23 ± 4</td>
<td>980 ± 79</td>
<td>340 ± 32</td>
<td>&gt;1000</td>
</tr>
<tr>
<td>Purple Moi leaf extract</td>
<td>860 ± 89</td>
<td>43 ± 16</td>
<td>6 ± 2</td>
<td>263 ± 42</td>
<td>71 ± 23</td>
<td>404 ± 91</td>
</tr>
<tr>
<td>Nene root extract</td>
<td>830 ± 89</td>
<td>380 ± 82</td>
<td>5 ± 2</td>
<td>424 ± 16</td>
<td>390 ± 33</td>
<td>&gt;1000</td>
</tr>
<tr>
<td>Nene leaf extract</td>
<td>490 ± 68</td>
<td>37 ± 8</td>
<td>3 ± 1</td>
<td>228 ± 22</td>
<td>134 ± 28</td>
<td>337 ± 23</td>
</tr>
</tbody>
</table>

* Values represent means of triplicates from one to three experiments ± Standard Error of the Mean.

**Isolated constituents**

Isolated compounds (kavain, dihydrokavain, methysticin, yangonin and tetrahydroyangonin) were tested at concentration ranging from 100 µM to 1 mM for their ability to compete with \([3H]\) diazepam binding to GABA\(_A\) and benzodiazepine receptors in rat forebrain membranes. Only weak activity on GABA\(_A\) binding sites was observed while no binding to GABA\(_A\) was evident (Davies et al., 1992).

The influence of kavalactones (yangonin, (+)-kavain, (+)-dihydrokavain, (+)-methysticin, and (+)-dihydromethysticin) on the GABA\(_A\) receptor was demonstrated using radioreceptor assays. The kavapyrones have been investigated at assay concentrations between 10 nM and100 µM. All kavalactones enhanced the specific binding of \([3H]\)bicuculline methochloride (\([3H]\)BMC). (+)-Kavain, (+)-methysticin and (+)-dihydromethysticin showed maximal enhancements of 18% to 28% at a concentration of 0.1 µM, whereas a 100-fold concentration of (+)-dihydrokavain revealed a similar
modulatory activity of 22 %. In the presence of 1 µM yangonin an increase of about 21 % of the specific [3H]BMC binding was observed. A structure comparison of desmethoxyyangonin and yangonin indicated that the aromatic methoxy group was of particular importance for the modulatory activity. In contrast, the substitution pattern of the aromatic ring did not influence the modulatory activity of the enolides in a decisive manner. A structure comparison of desmethoxyyangonin and (+)-kavain revealed that an angular lactone ring was an important structure requirement. Desmethoxyyangonin did not alter the binding behavior of the GABA_A-receptor. No inhibition of specific binding of [3H]flunitrazepam was observed, indicating that the influence on the GABA_A receptor was not based on interaction with the benzodiazepine receptor (Boonen et al., 1998a).

Inhibition of monoamine uptake

Ethanolic extract and isolated compounds

In vitro effects of a kava "spissum extract" (containing 67.6% kavalactones; 13.9% kavain, 15.9 % dihydrokavain, 9.3% yangonin, 3.8% desmethoxyyangonin, 13.1% dihydromethysticin and 11.5% methysticin; no further detail regarding extraction solvent) and synthetic kavalactones on human platelet MAO-B was investigated and compared to amitriptyline, imipramine and brofaromine. The kava extract, tested at concentrations in the range of 0.25 µM up to 225 µM was found to be a reversible inhibitor of MAO-B in intact platelets (IC_{50} 24 µM) and disrupted platelet homogenates (IC_{50} 1.2 µM). Structural differences of kavalactones resulted in a different potency of MAO-B inhibition. The order of potency was desmethoxyyangonin > (±)-methysticin > yangonin > (±)-dihydromethysticin > (±)-dihydromethysticin > (±)-kavain. The two most potent kavapyrones, desmethoxyyangonin and (±)-methysticin, displayed a competitive inhibition pattern with mean Ki 0.28 µM and 1.4 µM, respectively. The authors suggest that the inhibition of MAO-B might be an important mechanism for kavalactone psychotropic activity (Uebelhack et al., 1998).

Isolated compounds

The natural compounds (+) methysticine and (+)-kavain, and the synthetic racemate (±)-kavain, were tested at concentrations ranging from 10 to 400 µM for their ability to block in vitro the uptake of monoamines in synaptosomes prepared from the cerebral cortex and hippocampus of rats. (±)-Kavain and (+)-kavain were found to potently inhibit the uptake of [3H]-noradrenaline, by 70-80% of the control at 400 µM. Uptake of [3H]-noradrenaline was inhibited in the following order of potency: (±)-kavain = (+)-kavain > (+)-methysticine, whereas none of the kavalactones efficiently blocked the uptake of [3H]-serotonin. The results indicate a pyrone-specific non-stereo-selective inhibition of the [3H]-noradrenaline uptake which might be responsible for or, at least, contribute to the psychotropic properties of kavalactones (Seitz et al., 1997)

Modulation of 5-HT receptor activity

Isolated compounds

(+)kavain and (+)dihydromethysticin at 20, 50 and 100 µM concentration-dependently reduced field potential changes induced on guinea-pig hippocampal slices by ipsapirone (a 5HT-1A receptor agonist), suggesting that these kavalactones modulate 5HT_A activity (Walden et al., 1997)

Recently, isolated kavalactones (7,8-Dihydrokavain, methysticin, 7,8-dihydromethysticin and yangonin) but also some synthetic compounds were tested at concentrations of 0.1, 0.5, 1.0, 5.0, and 10.0 µM for cannabinoid (CB) receptor affinity and inhibitory activity of two major metabolic enzymes of the endocannabinoid system, fatty acid amine hydrolase and monoacylglycerol lipase. Among the molecules tested, only yangonin exhibited affinity for the human recombinant CB_1 receptor with a K(i)=0.72 µM and selectivity vs. the CB_2 receptor (K(i)>10 µM). The authors comcluded that CB 1
receptor affinity of yangonin suggests that the endocannabinoid system might contribute to the anxiolytic kava effect (Ligresti et al., 2012).

In vivo

In vivo studies conducted on rats and mice evidenced sedative, tranquilizing and muscle relaxing effects of both the herbal preparations and isolated constituents.

Herbal preparations

Dichloromethane (called "kava resin") and aqueous extracts of kava (no further detail) were tested for their effect on amphetamine-induced hypermotility in mice and on conditioned avoidance response behavior in rats in a shelf-jump apparatus. Both kava extracts reduced amphetamine-induced hypermotility. Aqueous kava extract injected i.p. at doses of 30 mg/kg to 500 mg/kg had no effect on conditioned avoidance responses. At or below 100 mg/kg i.p. dichloromethane extract also failed to modify the number of conditioned avoidance responses obtained. However, 125 mg/kg of dichloromethane extract significantly reduced the number of conditioned avoidance responses by 18%. Increasing the dose to 150 mg/kg caused marked ataxia and sedation (Duffield et al., 1989b).

The central nervous activity of dichlormethane and aqueous extracts of kava (no further detail) was examined in Balb–c mice. The aqueous extract was injected i.p. at doses of 250, 125 and 62.5 mg/kg while the dichloromethane extract was injected in the same manner at dosages of 120, 150, 180 and 250 mg/kg (n = 3). Control mice (same number per group) were similarly injected with saline (0.9 % NaCl). A significant decrease of spontaneous motility was found in dosages as low as 62.5 mg/kg of the aqueous extract (p < 0.05). All other doses showed a highly significant reduction (p < 0.001). The maximum effect was obtained after 30 min and was maintained at this level for at least 2 hours. Concerning the dichloromethane extract, the spontaneous activity of the mice was significantly decreased (by 46 %) 5 – 10 min after the 120 mg/kg injection, with progressively greater reductions at dosages of 150 and 180 mg/kg (p < 0.001). At 180 mg/kg, most animals showed a loss of the righting reflex (ESCOP, 2003).

In cats with chronically implanted electrodes, a kava extract in arachis oil (50–100 mg/kg kavalactones i.p; no further detail) and isolated compound D,L-kavain (10–50 mg/kg i.p.) were investigated. Blood pressure, the EEG of cortical and subcortical areas, the electromyogram, EEG arousal reactions, and subcortical evoked potentials elicited by central stimulation were recorded before and after administration. Only the extract exerted marked effects on the EEG; it induced high amplitude delta waves, spindle-like formations, and a continuos alpha- or beta-synchronization in the amygdalar recordings (p < 0.001). As to the evoked potentials, the hippocampal response, following stimulation of the amygdalar nucleus, showed an increase in amplitude in the animals given D,L-kavain (50 mg/kg; p < 0.05) and in those given the extract equivalent to 100 mg kavalactones/kg (p < 0.01). In addition, after injection of the extract, further projections arising from the amygdala as well as the connection from the caudate nucleus to the amygdala proved to be activated (Holm et al., 1991).

Baum et al. (1989) investigated using in vivo microdialysis the effect of kava extract (containing D,L-19.5-23.8% kavain, 9.6-33.4% dihydrokavain, 19.5-22.3% methysticin, 5.5-11.7%, dihydromethysticin, 16.6-32.7% yangonin and 5.5-5.7% desmethoxyyangonin) and several kavalactones (D,L-kavain, dihydokavain, methysticin, dihydromethysticin, yangonin and desmethoxyyangonin) on neurotransmitter levels in the nucleus accumbens of rats. Three different doses of the kava extract were administered (20 mg/kg, 120 mg/kg and 220 mg/kg). The D,L-kavain was administered in doses of 30 mg/kg, 60 mg/kg and 120 mg/kg and the other kavalactones were injected in a dose of 120 mg/kg. A small dose of kava extract (20 mg/kg body weight i.p.) caused changes in rat behaviour and concentrations of dopamine in the nucleus accumbens. Higher doses (120 mg/kg i.p.) increased the levels of dopamine. With respect to the individual compounds, D,L-
kavain induced in low doses a decrease in dopamine levels and in higher amounts either an increase or no change in dopamine concentrations. Yangonin resulted in a decrease of dopamine levels to below the detection limit and desmethoxyyangonin in an increase of dopamine levels. Dihydrokavain, methysticin and dihydromethysticin did not produce any significant changes of dopamine levels. D,L-kavain caused a decrease in 5-HT concentrations. Some of the other kavalactones affected 5-HT levels as well. The results suggest that the relaxing and slightly euphoric actions may be caused by the activation of the mesolimbic dopaminergic neurones. Changes of the activity of 5-HT neurones could explain the sleep-inducing action.

Anxiolytic properties for kava extract and isolated kavalactones (kavain, dihydrokavain, methysticin, dihydromethysticin, yangonin and desmethoxyyangonin) have been documented in an experimental model of anxiety, the chick social separation-stress procedure. In a series of experiments, kava extracts (containing 12.8 to 100.0% total kavalactones -Experiment 1) and fractions containing 1–6 kavalactones of varying concentrations (0.1–67.5%; Experiment 2–3) were screened for activity and compared against a 5.0 mg/kg dose of chlor Diazepoxide (Experiment 3). Dependent measures were ventral recumbency latency (sedation), distress vocalizations, and a measure of stress-induced analgesia (in Experiment 1 and 2 only). Kava extracts samples attenuated distress vocalizations in a concentration-dependent manner. The kava fraction that contained the highest concentration of dihydrokavain attenuated distress vocalizations in a manner equivalent to that of chlor Diazepoxide. The extract samples and fractions that possessed anxiolytic properties did not possess the sedative properties found in chlor Diazepoxide. These findings suggest that at least 15% dihydrokavain may be necessary and sufficient for the anxiolytic activity of kava extract (Feltenstein et al., 2003).

Garrett et al. (2003) investigated the anxiolytic and sedative effects of kava ethanolic extract (20 mg powdered root extracted with 200 ml of 95% ethanol) in well established quantitative murine behavioral assays and compared with diazepam-induced behavioral changes. Diazepam was administered at doses from 0.0316 to 5 mg/kg and kava extract was administered at doses from 32 to 316 mg/kg intraperitoneally to BALB/cByJ inbred mice. Behavioral changes were measured in the mirrored chamber avoidance assay and elevated plus-maze assay. Reduced latency to enter and increased time spent in a normally avoided environment operationally defined anxiolysis. Kava extract produced statistically significant dose-dependent anxiolytic-like behavioral changes in both assays of anxiolysis. ED$_{50}$ values for kava-induced increases in time spent inside the mirrored chamber and on the open arms of the plus maze were 125 mg/kg and 88 mg/kg, respectively. Kava extract also caused a profound decrease in locomotor activity (ED$_{50}$ of 172 mg/kg). Flumazenil, a competitive benzodiazepine receptor antagonist, blocked both the anxiolytic and sedative effects of diazepam, but had no effect on kava’s behavioral actions.

In mice, kava extract (containing 7% kavalactones; no further detail) at doses of at least 50 mg/kg (by intraperitoneal injection) reduced spontaneous motility to a greater extent than did control. The effect was enhanced by the addition of (+)-kavain (ratio of kava extract to (+)-kavain, 1:0.12), although this compound had no sedative effect when administered alone. In another experimental model, kava extract 100 mg/kg and (+)-kavain 12 mg/kg, each administered alone, had no sedative effect, whereas a combination of the two substances significantly reduced amphetamine (5 mg/kg subcutaneously)-induced hypermotility (Barnes, 2007).

Sedative effects have also been demonstrated for an ethanolic extract of kava (containing 50% kavalactones; extraction solvent ethanol 96%) at a single dose of 100 mg/kg administered by gastric tube in the amphetamine-induced hypermotility test (reduction with 47%) and barbiturate-induced sleeping time, respectively (sleep duration was prolonged by 45.5%) (Capasso & Sorrentino, 2005).
**Isolated constituents**

Kavaine, methysticin, dihydromethysticin and yangonin showed a strong centrally caused muscle-relaxing activity on the skeletal muscle tone of unanaesthetized rabbits after intravenous administration. Yangonin proved to be the most potent compound almost completely depressed the electromyographically impulses at 5–10 mg/kg; the other kavalactones required doses 2–3 times larger to show the same effect. From simultaneous obtained cortical EEGs, high voltage synchronised waves developed with relaxing doses of kavalactones. The authors concluded that the sedative effect of kava is probably a result of both depression of muscle tone and depression of the cortical activation system and limbic area by kavalactones (Kertzschmar et al., 1971).

The effects of a single oral dose of 100 mg (+)-dihydromethysticin/kg body weight on striatal and cortical tissue concentrations of dopamine, serotonin, 3,4-dihydroxyphenylacetic acid and 5-hydroxyindoleacetic acid, as well as the dopamine and serotonin turnover were tested in rats. Additionally, other rats were fed with a (±)-kavain containing food (0.48 g/kg, leading to an intake of ca. 10.8 mg kavain/day) over a period of 78 days in order to evaluate the influence of a chronic treatment with kavalactones on the neurotransmitters. The results clearly demonstrate that neither (+)-dihydromethysticin in a high single dose, nor (±)-kavain chronically administered, altered the dopaminergic or serotonergic tissue levels in rats significantly (Boonen, 1998b).

Table 4: Overview of the main non-clinical data- studies

<table>
<thead>
<tr>
<th>Herbal preparation tested</th>
<th>Posology</th>
<th>Experimental model</th>
<th>Reference</th>
<th>Main non-clinical conclusions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hydroethanolic extract of kava (no further detail)</td>
<td>200-500 µM kavalactones</td>
<td>In vitro</td>
<td>Jussofie et al., 1994</td>
<td>Enhanced the binding of [3H]muscimol to GABAA binding sites in membrane fractions from different regions of the rat brain (EC50 between 200 and 300 µM kavalactones).</td>
</tr>
<tr>
<td>“Spissum extract” (containing 67.6% kavalactones; 13.9% kavain, 15.9 % dihydrokavain, 9.3% yangonin, 3.8% desmethoxyyangonin, 13.1% dihydromethysticin and 11.5% methysticin; no further detail regarding extraction solvent)</td>
<td>0.25 µM up to 225 µM</td>
<td>In vitro</td>
<td>Uebelhack et al., 1998</td>
<td>The extract was found to be a reversible inhibitor of MAO-B in intact platelets (IC50 = 24 µM) and disrupted platelet homogenates (IC50 = 1.2 µM).</td>
</tr>
<tr>
<td>Herbal preparation tested</td>
<td>Posology</td>
<td>Experimental model</td>
<td>Reference</td>
<td>Main non-clinical conclusions</td>
</tr>
<tr>
<td>------------------------------------------------------------------------------------------</td>
<td>---------------------</td>
<td>--------------------</td>
<td>-------------------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Ethanolic extract of kava (containing 50% kavalactones; extraction solvent ethanol 96%)</td>
<td>p.o 100 mg/kg</td>
<td><em>In vivo</em> Rats</td>
<td>Capasso, 2005</td>
<td>Sedative effects have been demonstrated in the amphetamine-induced hypermotility test (reduction with 47%) and barbiturate-induced sleeping time (sleep duration was prolonged by 45.5%)</td>
</tr>
<tr>
<td>Kava extract (containing 7% kavalactones; no further detail) with or without kavain</td>
<td>i.p 50 or 100 mg/kg</td>
<td><em>Mice</em> In vivo</td>
<td>Barnes, 2007</td>
<td>At 50 mg/kg kava extract reduced spontaneous motility; the effect was enhanced by the addition of (+)-kavain; at 100 mg/kg in combination with kavain significantly reduced amphetamine induced hypermotility</td>
</tr>
<tr>
<td>Ethanolic extract of kava (20 mg powdered root extracted with 200 ml of 95% ethanol)</td>
<td>32 to 316 mg/kg</td>
<td><em>In vivo</em> BALB/cByJ mice</td>
<td>Garrett <em>et al.</em>, 2003</td>
<td>Kava extract produced statistically significant dose-dependent anxiolytic-like behavioral changes in both assays of anxiolysis ($ED_{50}$ =125 mg/kg and 88 mg/kg, respectively). Kava extract also caused a profound decrease in locomotor activity ($ED_{50}$ =172 mg/kg).</td>
</tr>
<tr>
<td>Herbal preparation tested</td>
<td>Posology</td>
<td>Experimental model</td>
<td>Reference</td>
<td>Main non-clinical conclusions</td>
</tr>
<tr>
<td>---------------------------</td>
<td>----------</td>
<td>--------------------</td>
<td>-----------</td>
<td>-----------------------------</td>
</tr>
<tr>
<td>Kava extract (containing D,L-19.5-23.8% kavain, 9.6-33.4% dihydrokavain, 19.5-22.3% methysticin, 5.5-11.7%, dihydromethysticin, 16.6-32.7% yangonin and 5.5-5.7% desmethoxyyangonin) and isolated compounds</td>
<td>i.p. Kava extract: 20 mg/kg, 120 mg/kg and 220 mg/kg D,L-kavain: 30 mg/kg, 60 mg/kg and 120 mg/kg the other kavalactones: 120 mg/kg.</td>
<td>In vivo Rats</td>
<td>Baum et al., 1989</td>
<td>Kava extract at 20 mg/kg caused changes in rat behaviour; higher doses (120 mg/kg) increased the levels of dopamine. D,L-kavain induced in low doses a decrease in dopamine levels and in 5-HT concentrations. Desmethoxyyangonin increased dopamine levels.</td>
</tr>
<tr>
<td>Kava extract (no further detail) and isolated compound (D,L-kavain)</td>
<td>i.p. kava extract: 50–100 mg/kg kavalactones D,L-kavain: 10–50 mg/kg</td>
<td>In vivo Cats</td>
<td>Holm et al., 1991</td>
<td>Only the extract exerted marked effects on the EEG. The hippocampal response showed an increase in amplitude in the animals given D,L-kavain (50 mg/kg; p &lt; 0.05) and in those given the extract equivalent to 100 mg kavalactones/kg (p &lt; 0.01).</td>
</tr>
<tr>
<td>Dichlormethane and aqueous extracts of kava (no further detail)</td>
<td>i.p. Aqueous extract: 250, 125 and 62.5 mg/kg Dichlormethane extract: 120, 150, 180 and 250 mg/kg</td>
<td>In vivo Balb–c mice</td>
<td>ESCOP, 2003</td>
<td>A significant decrease of spontaneous motility was found in all dosages of both extracts</td>
</tr>
<tr>
<td>Dichloromethane and aqueous extracts of kava (no further detail)</td>
<td>i.p. 30 mg/kg to 500 mg/kg aqueous extract</td>
<td>In vivo Rats and mice</td>
<td>Duffield, 1989</td>
<td>Both extracts reduced amphetamine-induced hypermotility in</td>
</tr>
<tr>
<td>Herbal preparation tested</td>
<td>Posology</td>
<td>Experimental model</td>
<td>Reference</td>
<td>Main non-clinical conclusions</td>
</tr>
<tr>
<td>---------------------------</td>
<td>----------</td>
<td>--------------------</td>
<td>-----------</td>
<td>------------------------------</td>
</tr>
<tr>
<td></td>
<td>100 to 150 mg/kg dichloromethane extract</td>
<td></td>
<td></td>
<td>mice. Aqueous kava extract at doses of 30 mg/kg to 500 mg/kg had no effect on conditioned avoidance responses in rats. At or below 100 mg/kg dichloromethane extract had no effect, but at 125 mg/kg significantly reduced the number of conditioned avoidance responses by 18%. Increasing the dose to 150 mg/kg caused marked ataxia and sedation.</td>
</tr>
</tbody>
</table>

**Isolated compounds**

| Kavain, dihydrokavain, methysticin, yangonin and tetrahydroyangonin | 100 µM to 1 mM | In vitro | Davies et al., 1992 | Only weak activity on GABA<sub>A</sub> binding sites was observed while no binding to GABA<sub>B</sub> was evident |
| Yangonin, (+)-kavain, (+)-dihydrokavain, (+)-methysticin, and (+)-dihydromethysticin | 10 nM up to 100 µM and | In vitro | Boonen et al., 1998a | All kavalactones enhanced the specific binding of [3H]bicuculline methochloride but no inhibition of specific binding of [3H]flunitrazepam was observed. |
| (+) methysticine and (+)-kavain, and the synthetic racemate (±)-kavain, | 10 to 400 µM | In vitro | Seitz et al., 1997 | (±)-Kavain and (+)-kavain were found to potently inhibit the uptake of [3H]-noradrenaline, by 70-80% of the control at 400 µM. Uptake of [3H]- |
### 3.1.2. Secondary pharmacodynamics

1. Anticonvulsive activity

**In vitro**

Methysticin anticonvulsant and neuroprotective properties were tested on different in vitro seizure models using extracellular recordings in rat temporal cortex slices containing the hippocampus and the entorhinal cortex. Elevating [K⁺] induced seizure-like events with tonic and clonic electrographic

<table>
<thead>
<tr>
<th>Herbal preparation tested</th>
<th>Posology</th>
<th>Experimental model</th>
<th>Reference</th>
<th>Main non-clinical conclusions</th>
</tr>
</thead>
<tbody>
<tr>
<td>(+)-kavain and (+)-dihydromethysticin</td>
<td>20, 50 and 100 µM</td>
<td>In vitro</td>
<td>Walden et al., 1997</td>
<td>Concentration-dependently reduced field potential changes induced on guinea-pig hippocampal slices by ipsapirone.</td>
</tr>
<tr>
<td>7,8-Dihydrokavain, methysticin, 7,8-dihydromethysticin and yangonin</td>
<td>0.1, 0.5, 1.0, 5.0, and 10.0 µM</td>
<td>In vitro</td>
<td>Ligresti et al., 2012</td>
<td>Yangonin exhibited affinity for the human recombinant CB₁ receptor with a K(i)=0.72 µM and selectivity vs. the CB₂ receptor (K(i)&gt;10 µM)</td>
</tr>
<tr>
<td>Kavaine, methysticin, dihydromethysticin and yangonin</td>
<td>i.v Yangonin 5–10 mg/kg The other compounds: 10–30 mg/kg</td>
<td>in vivo rabbits</td>
<td>Kertzschmar et al., 1971</td>
<td>All compounds showed a strong centrally caused muscle-relaxing activity; Yangonin proved to be the most potent compound</td>
</tr>
<tr>
<td>Dihydromethysticin (+)Kavain</td>
<td>p.o 100 mg/kg, as a single dose 10.8 mg/day, 78 days</td>
<td>In vivo rats</td>
<td>Boonen &amp; Hberlein, 1998b</td>
<td>No influence on neurotransmitters</td>
</tr>
</tbody>
</table>
phases in area CA1. Lowering [Ca\(^{2+}\)] caused recurrent seizure like episodes with large negative field potential shifts. Lowering Mg\(^{2+}\) induced short recurrent discharges in area CA3 and CA1 while ictaliform events lasting for many seconds were induced in the subiculum, entorhinal and temporal neocortex. In the hippocampus the activity stayed stable over a number of hours. In contrast, the ictaliform events in the subiculum, entorhinal and temporal cortex changed their characteristics after one to two hours to late recurrent discharges. In a concentration-range from 10 to 100 microM methysticin reversibly blocked all these types of epileptiform activity. Decreases in [Ca\(^{2+}\)] and associated slow field potentials evoked by repetitive stimulation of the stratum radiatum or the alveus remained almost unaffected by methysticin. A paired pulse stimulus paradigm used to test for effects of methysticin on synaptically evoked transient field potentials in normal medium revealed interference with mechanisms involved in frequency potentiation. While responses to alvear stimulation were largely unaffected, the responses to a paired pulse stimulus to stratum radiatum were depressed over the whole range of tested stimulus intervals. According to the authors, the findings suggest that methysticin has effects on different patterns of epileptiform activity possibly by interfering with processes responsible for frequency potentiation (Schmitz et al., 1995).

The anticonvulsive action of synthetic (+)–kavaine on veratridine-stimulated increase in intrasynaptosomal Na\(^+\)concentration ([Na\(^+\)]\textsubscript{i}) of cerebrocortical synaptosomes of rats was investigated. Veratridine (5 µmol/l) enhanced basal [Na\(^+\)]\textsubscript{i} 6.6-fold from 11.3 to 74.1 mmol/l Na\(^+\). Incubation of synaptosomes for 100 sec with (+)–kavaine was sufficient to dose-dependently reduce the stimulated increase of [Na\(^+\)]\textsubscript{i} with an IC\(_{50}\) value of 86.0 µmol/l, and almost complete inhibition of Na\(^+\) channels was attained with 400 µmol/l (+)–kavaine. The reference compounds, procaine (400 µmol/l) and tetrodotoxin (TTX, 10 µmol/l) reduced veratridine-elevated [Na\(^+\)]\textsubscript{i} to 30.4 % and 7.9 % of control. Post-application of 400 µmol/l (+)–kavaine immediately diminished veratridine-elevated [Na\(^+\)]\textsubscript{i} to nearly basal levels with a half life of 69.7 sec. To study the influence of (+)–kavaine on non stimulated synaptosomes, an increase in [Na\(^+\)]\textsubscript{i} was induced by 200 µmol/l ouabain, which enhanced [Na\(^+\)]\textsubscript{i} hyperbolically with an initial rate of 18.4 mmol Na\(^+\)/1 min. Preincubation of synaptosomes with 400 µmol/l (+)–kavaine or 10 µmol/l TTX prevented Na\(^+\)-influx to the same extend for both compounds, approx. 57 % of the control. The authors came to the conclusion that the data presented indicates a fast and specific inhibition of voltage-dependent Na\(^+\) channels by (+)–kavaine (Gleitz et al., 1995).

The same authors investigated the interaction of (+)–kavaine with epitopes of voltage-dependent Na\(^+\) channels and the actions of (+)-kavaine on 4–aminopyridine-stimulated synaptosomes as a model of firing neurons from cerebral cortex. \(^{[3H]}\)saxitoxin and \(^{[3H]}\)batrachotoxin were used for radioligand-binding assays performed with synaptosomal membranes.(±)-kavaine failed to compete with \(^{[3H]}\)saxitoxin up to 400 µmol/l but dose-dependently suppressed binding of \(^{[3H]}\)batrachotoxin with an IC\(_{50}\) value of 88 µmol/l (Ki = 72 µmol/l) although displacement of \(^{[3H]}\)batrachotoxin was restricted to 33 % of the control at 400 µmol/l (+)–kavaine. In stimulated synaptosomes, 5 mmol/l 4–aminopyridine provoked an increase in [Na\(^+\)]\textsubscript{i} and [Ca\(^{2+}\)]\textsubscript{i} to 38 and 29 % of control, respectively. Consistent with the increase in [Na\(^+\)]\textsubscript{i} and [Ca\(^{2+}\)]\textsubscript{i}, 4–aminopyridine provoked glutamate release, which was dose-dependently diminished to 60 % of the control by 400 µmol/l (+)–kavaine. KCl depolarization provoked an increase in [Ca\(^{2+}\)]\textsubscript{i} and glutamate release almost identical to the response elicited by 4–aminopyridine but 400 µmol/l (+)–kavaine suppressed only the rate of glutamate release by 9 % of the control. The authors concluded that the data suggests an interaction of (+)–kavaine with voltage-dependent Na\(^+\) and Ca\(^{2+}\) channels (Gleitz et al., 1996).

In a radiological binding assay using rat cerebrocortical synaptosomes, (+)kavain, (+) kavain, (+) dihydrrokavain, (+) dihydrrokavain and dihydromethysticin significantly decreased the apparent total number of binding sites (Bmax) for \(^{[3H]}\)-batrachotoxinin-A 20a-benzoate (control: 0.5 pmol/mg protein, kavalactones: 0.2—0.27pmol/mg protein) with little change in the equilibrium constants for
[\textsuperscript{3}H]-batrachotoxin-A 20\textalpha-benzoate (control: 28.2 nM, kavalactones: 24—31 nM). The results indicated that kavalactones non-competitively inhibit [\textsuperscript{3}H]-batrachotoxinin-A 20\textalpha-benzoate binding to receptor site 2 of voltage-gated Na\textsuperscript{+} channels (Friese et al., 1998).

**In vivo**

Several studies investigated the capability of kava extracts and kavalactones to antagonize chemically or otherwise induced convulsions.

Klohs et al. (1959) investigated the anticonvulsive action of the ground root of kava, a chloroform extract (5 kg roots/30 L chloroform) and of isolated compounds (kavain, dihydrokavain, methysticin, dihydromethysticin, yangonin) as determined by their ability to antagonize clonic strychnine convulsions and death in mice. The crude extract, methysticin and dihydromethysticin were particularly effective in affording protection against the lethal effects of strychnine, while yangonin was practically ineffective. An indication of synergistic action was found by testing a mixture of kavaine (19.5 %), dihydrokavaine (33.4 %), methysticin (19.5 %), dihydromethysticin (5.5 %), yangonin (16.6 %) and "compound A" (5.5 %; chemical structure unknown). These compounds were combined in the ratio in which they were isolated from the crude extract. The mixture showed an ED\textsubscript{50} of 100 mg/kg, indicating a potency at least as good as that of dihydromethysticin.

<table>
<thead>
<tr>
<th>Strychnine</th>
<th>Roller cage</th>
<th>Sleeping time</th>
</tr>
</thead>
<tbody>
<tr>
<td>ED\textsubscript{50} w. 95% cl. in mg/kg</td>
<td>dose, mg/kg</td>
<td>result</td>
</tr>
<tr>
<td>Dihydrokavain</td>
<td>340 (270—430)</td>
<td>300 no effect</td>
</tr>
<tr>
<td>Yangonin</td>
<td>no protection at 1,000</td>
<td>300 no effect</td>
</tr>
<tr>
<td>Kavain</td>
<td>215 (160—290)</td>
<td>300 no effect</td>
</tr>
<tr>
<td>Compound A</td>
<td>no protection at 200</td>
<td>300 no effect</td>
</tr>
<tr>
<td>Methysticin</td>
<td>160 (110—232)</td>
<td>300 no effect</td>
</tr>
<tr>
<td>Dihydromethysticin</td>
<td>115 (97—132)</td>
<td>390 no effect</td>
</tr>
<tr>
<td>Chloroform extract</td>
<td>140 (121—162)</td>
<td>300 12/18 fall-out</td>
</tr>
<tr>
<td>Ground root</td>
<td>1,700 (1,400—2,100)</td>
<td>10,000 12/18 fall-out</td>
</tr>
<tr>
<td>Meprobamate</td>
<td>no protection at 700</td>
<td>ED\textsubscript{50} = 165 (122—201)</td>
</tr>
</tbody>
</table>

Another study investigated the qualitative and quantitative effect of dihydromethysticin and dihydrokavain administered intraperitoneal on electroconvulsion and compared the results to the effects of anticonvulsive substances (phenobarbital, primidone, diphenylhydantoin, ospolote; chlorpromazine). The lowest effective dosage of dihydromethysticin was 25 mg/kg and produced a convulsive threshold elevation of 33.1%. The lowest effective dosage of dihydrokavain was found to be 60 mg/kg, which is 2.4 times higher. With this dosage the convulsive threshold was elevated by only 18.8 % (p <0.01). After the application of 40 mg/kg dihydromethysticin the elevation was 100 %. The same effect was demonstrated by 150 % dihydrokavain. No dosage, not even dosages lower than 25 and 60 mg/kg, or doses above 60 and 150 mg/kg, lowered the threshold, thereby contrasting the effect of chlorpromazine. The effect of dihydromethysticin and dihydrokavaine was comparable to that of the known anticonvulsive substances. However, the threshold doses of those substances were 5 – 10 mg/kg lower than those of the two kavalactones (Hänsel, 1968).

The same authors also investigated of the effect of dihydromethysticin and dihydrokavain on chemically induced convulsions in mice (by pentetrazol, bemegride, picrotoxin and strychnine). Dihydromethysticin and dihydrokavaine were administered intraperitoneal 30 min before injection of the respective convulsant. Pre-treatment with 30 mg/kg of dihydromethysticin inhibited of spasms induced by dosages of up to 2.5 mg strychnine; the SD\textsubscript{50} for tonic spasms was significantly raised by
about 50%. No effect was shown against 3 mg/kg strychnine. The clonic threshold as well as intensity and duration of spasms induced by picrotoxin, bemevide and pentetrazol were not influenced by dihydromethysticin. There was no clear effect by dihydromethysticin on the tonic phase induced by picrotoxin. In contrast, the same dosage of dihydromethysticin increased tonic extension spasms induced by bemevide and pentetrazol; the SD50 was lowered by 19.6 and 14.2%, respectively. Dihydromethysticin did not reduce lethality of tonic spasms induced by picrotoxin, bemevide and pentetrazol. The effect was dose-dependent: 45 and 30 mg/kg, respectively, had exclusively anticonvulsive against tonic picrotoxin and strychnine induced spasms. Dosages of 60 mg/kg and higher have a similar effect against the tonic phase of all four convulsants, after application of 90 mg/kg no maximal extension spasm was inducible. The influence on the clonic phase was different, there was no dose-dependent influence of dihydromethysticin on the convulsants (Hänsel, 1996).

Another study demonstrated the anticonvulsive action of the other kavalactones, such as methysticin, kavain, yagononin, and desmethoxyyangonin. The anticonvulsive effect was tested using maximal electroshock and pentylenetetrazol-induced convulsions (115 mg/kg s.c. or 50 mg/kg i.v.). Further comparative studies with phenobarbital, diphenylhydantoin, mephenesin, and procaine were made. With regard to the duration of action and the influence on the seizure pattern, the anticonvulsant activity of methysticin, dihydromethysticin, kavaine, and dihydrokavaine against maximal electroshock as well as against the pentylenetetrazol convulsions resembled that of local anaesthetic compounds and differs from the action of phenobarbital and diphenylhydantoin. The anticonvulsant activity of the pyrones was characterized by an inhibition of the maximum tonic extensor seizure response elicited by maximal electroshock and by pentylenetetrazol as well as by an intensification of the clonic seizure response to pentylenetetrazol. 150 mg/kg of kavain and dihydrokavaine, 70 mg/kg of methysticin and dihydromethysticin, and 750 mg/kg of yangonin p.o. produced a maximum protection of 60 – 80%. At lower dosages the kavalactones, like procaine, had a weak facilitating effect on the tonic extensor phase of pentylenetetrazol-induced convulsions. The anticonvulsive action of yangonin and desmethoxyyangonin against maximal electroshock resembled that of the other pyrones. In convulsions induced by pentylenetetrazol, yangonin also inhibited the tonic extensor phase but there was no intensification of the clonic seizure phase in high doses of yangonin, rather a small inhibition. When administered i.p. and p.o., the anticonvulsant activity decreased in the following sequence: methysticin > dihydromethysticin kavaine > dihydrokavaine >> desmethoxyyangonin > yangonin (Kretzschmar & Meyer, 1965).

2. Spasmolytic activity

Isolated compounds

Dihydromethysticin inhibited hystamine, acetylcholine, 5-HT and barium chloride- induced spasms in isolated guinea-pig ileum with ED50 values (2.6-7.2 x 10^-6g/ml) of the same order as those of papaverine (Hänsel, 1968).

Synthetic (±)-kavain (1 µM – 1 mM) dose-dependently reduced contractions of guinea-pig ileum evoked by carbachol (10 µM), by BAY K 8644 (0.3 µM), or by substance P (0.05 µM). (±)-kavaine also inhibited the contractile responses induced by raising the extracellular K+ concentrations from 4 to 20 mM and by blocking the K+ channel by barium chloride (1 mM) or 4-aminopyridine (0.3 mM). After pre-incubation with 1 µM nifedipine, carbachol (1 µM) evoked 18.2 ± 14.3% of contraction at control (i.e. prior preincubation with nifedipine). This remaining response was completely abolished by high concentrations of (±)-kavaine (400 µM). After treatment of the longitudinal ileum strips with pertussis toxin (PTX), carbachol (1 µM) evoked 27.0 ± 6.2% of the control response in untreated ileum. These contractions were also blocked by (±)-kavaine in a concentration of 400 µM. However, (±)-kavaine had no effect on the caffeine induced (20 mM) contractions of ileum strips, which were permeabilized with digitonin or β-escin. Moreover, it failed to affect Ca-evoked contractions of skinned muscles.
These results suggest that the (+)-kavaine may act in a non-specific musculotropic way on the smooth muscle membrane (Seitz et al., 1997).

Synthetic (+)-kavain and (+)-methysticin at concentration of 1-400 µM exerted a rapid and reversible inhibition of voltage-dependence of Na(+)-channels in rat CA1 hippocampal neurons (Magura et al., 1997).

3. Neuroprotective effect

Backhauß (1992) investigated the neuroprotective effects of an acetone-water kava extract (70% kavalactones) and isolated kavalactones (kavain, dihydrokavain, methysticin, dihydromethysticin and yangonin) in rodent models focal cerebral ischemia in mice and rats. Ischemia was induced by microbipolar coagulation of the left middle cerebral artery (MCA). The effects of the kava extract and its constituents were compared with those produced by the typical anticonvulsant, memantine. The kava extract, methysticin and dihydromethysticin produced effects similar to those of the reference substance memantine. The kava extract (150 mg/kg, 1 h before ischemia) diminished the infarct area (p<0.05) in mouse brains and the infarct volume (p< 0.05) in rat brains. Methysticin, dihydromethysticin (both 10 and 30 mg/kg, 15 min before ischemia) and memantine (20 mg/kg, 30 min before ischemia) significantly reduced the infarct area in mouse brains. The authors concluded that the neuroprotective activity of kava extract was probably mediated by its constituents methysticin and dihydromethysticin.

Recent studies on isolated kavalactones (methysticin, kavain, and yangonin) have revealed other neuroprotective mechanisms of action, such as the activation of Nrf2 (NF-E2-related factor 2) that can explain the kavalactone-mediated protection against amyloid-induced neurotoxicity in neuronal and glial cell lines or the stimulation of ERK1/2 phosphorylation in PC12 cells that is responsible for the subsequent activation of Nrf2 (Tzeng & Lee, 2015).

4. Analgesic activity

Antinociceptive activity of dihydrokavain and dihydromethysticin was investigated in mice against heat induced pain and compared with other analgesic compounds. Dihydrokavain and dihydromethysticin were suspended in arachis oil (1 %) and injected intraperitoneally in doses of 80, 100 and 180 mg/kg. The reference substances morphine (2.5 mg/kg), aminopyrine (100 mg/kg), acetylsalicylic acid (200 mg/kg) were injected s.c. The minimal effective dose of dihydrokavain was 100 mg/kg (p < 0.001), the effect was maximal 25 min after application and the duration of diminished excitability 1 hour. 120 mg/kg were even more effective: 15 min after application a significant result was obtained, the maximum effect was reached after 35 min, and the duration was 2.5 hours. Dihydromethysticin was a little less effective: 100 mg/kg did not produce a clear effect on reaction time but 140 mg/kg induced a significantly prolonged reaction time. Maximum efficacy was reached after 1 hour, the effect lasted for 2 hours. 140 mg/kg dihydromethysticin were less effective than 120 mg/kg dihydrokavain. The dose-effect-relationship of dihydrokavaine and dihydromethysticin was calculated to be 1.3:1. In comparison to the substances with known analgesic effects it was demonstrated that 120 mg/kg dihydrokavain had about the same analgesic effect as 100 mg/kg aminopyrine and was superior in duration of effect. The data on the combined administration of dihydrokavain with the antipyretic drugs aminopyrine or acetylsalicylic acid indicated that there is an additive synergism in the analgesic potency of these mixtures (Hänsel, 1968).

Antinociceptive activity in vivo (mice) has been investigated also in other two distinct tests (the tail immersion method and the abdominal constriction procedure using acetic acid) for dichlormethane extract "kava resin" (150 mg/kg; no further detail) , aqueous extract (250 mg/kg; no further detail) and for the individual kavalactones, such as dihydrokavain, dihydromethysticin, kavain and methysticin at doses of 150, 275, 300 and 360 mg/kg), yangonin and desmethoxyyangonin(at doses up to 1 g/kg)
and compared with controls. For the tail immersion test all drugs were injected intraperitoneal while for the acetic acid-induced writhing test only aqueous extract was administered intraperitoneally. In the tail immersion test the dichlormethane extract (150 mg/kg) had a marked antinociceptive action, which was evident at the first test time of 10 min after injection and lasted for about 80 min (p < 0.005), while the aqueous extract had a less pronounced antinociceptive effect (p < 0.05). Kavain, dihydromethysticin, methysticin and dihydromethysticin have potent analgesic properties. The peak analgesic effect was similar, but the duration of action markedly differed. The action of dihydromethysticin was very rapid but short lived (20 – 30 min), that of kavain a little more prolonged (up to 2 hours), while the actions of methysticin and dihydromethysticin were considerably more persistent (3.5 – 4 hours). Yangonin and desmethoxyyangonin had no analgesic action at all in doses of up to 1 g/kg. Both aqueous and dichlormethane extracts were effective in inhibiting the number of writhes induced by acetic acid injection. Oral administration of 200 mg/kg dichlormethane extract effectively reduced writhing (p < 0.001). Aqueous extract is inactive orally, but dramatically reduced writhing when is administered intraperitoneally in a dose of 250 mg/kg 55 min before acetic acid (Jamieson & Duffield, 1990).

5. Other activities

*In vitro* pre-treatment of human platelets with (+)–kavain 5 min before the addition of arachidonic acid dose-dependently suppressed the aggregation (IC$_{50}$ 78 µmol/l), diminished the release of ATP (IC$_{50}$ 78 ± 45 µmol/l) as well as the formation of PGE2 (IC$_{50}$ 115 µmol/l) and suppressed the generation of TXB2 (detected as a representative of TXA2) dose-dependently with an IC$_{50}$ of 71 µmol/l. According to the authors, the similarity of the IC$_{50}$ values suggest an inhibition of cyclooxygenase by (+)–kavain as primary target, thus suppressing the generation of TXA2 which induces aggregation of platelets and exocytosis of ATP by its binding on TXA2-receptors (Gleitz *et al.*, 1997).

The effect of isolated compounds (kavain, dihydromethysticin, methysticin yangonin) on COX-1 and COX-2 isoenzymes was determined by measuring the rate of oxygen uptake in a cyclo-oxygenase inhibitory assay. Three non-steroidal anti-inflammatory drugs (NSAIDs) were included as positive controls. Naproxen was the most effective in each case, resulting in approx. 32% inhibition of COX-1 and approx. 28% inhibition of COX-2. All kava compounds tested at 100 or 50 µg/ml demonstrated better or similar COX-1 inhibition activities as compared to ibuprofen, aspirin and naproxen. Dihydrokavain showed the highest COX-1 inhibitory activity (approx. 58%) and yangonin showed the highest COX-2 inhibitory activity (approx. 34%) at 100 µg/ml. The minimum kavalactone inhibition for each COX enzyme was 25% approx (Wu *et al.*, 2002).

The fungistatic principles of the kava rhizomes are the 4-methoxy-α-pyrones, like dihydrokavain. Experiments with dihydrokavain showed that it inhibits Aspergillus niger completely in a concentration of 0.5 mg/ml; bacteria did not seem to be inhibited (Hänsel, 1968).

3.1.3. Safety pharmacology

Tolerance

The development of tolerance to the aqueous extract of kava (no further detail) and to the lipid soluble extract (kava resin; no further detail) was tested in mice. Tolerance developed very rapidly, in the aqueous extract given parenterally. A minimally effective daily dose (50 mg/kg) of the aqueous extract for 3 days was sufficient to produce tolerance to a test dose of 150 mg/kg, which is close to the ED$_{50}$.

As tolerance was evident at the first test period it can be assumed to be physiological tolerance. Kava resin decreased spontaneous motility and caused a loss of muscle control. A minimally effective daily dose of kava resin (100 mg/kg) did not produce tolerance to the above effects of a weekly test dose of kava resin (166 mg/kg) within 7 weeks. In a further experiment the dose was raised to 150 mg/kg
twice daily and this schedule caused partial tolerance to occur within 3 weeks, but very little further tolerance developed over the ensuing 2-week period. To try to induce learned (behaviourally acquired) tolerance a dose of 166 mg/kg kava resin was injected daily and animals were tested each day while under the influence of the drug. However, even under these conditions, there was no tolerance evident within 3 weeks, when the experiment was terminated. It appears difficult to induce the development of physiological or learned tolerance to kava resin in mice (Duffield & Jamieson, 1991).

**Cytotoxicity and hepatotoxicity**

Direct hepatotoxicity of kavalactones and kava-extracts has been assessed in numerous *in vitro* studies yielding different and partly inconsistent results. Tang *et al.*, (2010) studied the *in vitro* toxicity of kavain, methysticin and yangonin in HepG2 cells using lactate dehydrogenase (LDH) release and ethidium bromide assays. Toxic effects were observed for methysticin and kavain at 100 and 200 µM, respectively. For yangonin, pronounced decrease of cell viability to 40% at 25 µM in the ethidium bromide assay was detected. Furthermore, the mode of cell death was elucidated using acridine orange/ethidium bromide dual staining. Early and late apoptotic cells were detected after a treatment with 200 µM methysticin and 25 µM yangonin but not with 200 µM kavain. Glutathione levels were not decreased by kavalactone treatment so glutathione depletion may not be the cause of the observed toxicity.

These findings differ from other *in vitro* studies, which analyzed the effect of individual kavalactones and kava ethanolic extract on ATP levels in primary human hepatocytes. At 100 µM concentrations, kava ethanolic extract, methysticin, and desmethoxyyangonin decreased ATP approximately up to 50%. Methysticin and dihydromethysticin were found to be the most toxic and, surprisingly, yangonin was the least toxic kavalactone (Zou *et al.*, 2004).

Nerurkar *et al.* (2004) investigated *in vitro* the toxicity of desmethoxyyangonin, dihydromethysticin and pipermethystine in HepG2 cells. In preliminary experiments the kavalactones failed to show any toxic potential in HepG2 at concentrations less than 0.5 µM for up to 2 weeks. Based on these observations, the authors tested dihydromethysticin and desmethoxyyangonin and pipermethystine at 1, 25, 50, 100, and 200 µM concentrations for 48 h. At 200 µM pipermethystine caused cell death within the first 6 h, while 50 and 100 µM pipermethystine caused significant (65 and 90%, p < 0.001) cell death within 24 h, as measured by the release of LDH into the medium. Higher concentrations of the dihydromethysticin and desmethoxyyangonin (200 µM) caused only 30% cell death after 48 h (p < 0.01), while lower concentrations of dihydromethysticin and desmethoxyyangonin (100 and 50 µM) did not show any toxicity at 24 h and up to 8 days of treatment.

Zhou *et al.* (2010) demonstrate that flavokavain B is a potent hepatocellular toxin, inducing cell death in HepG2 (LD50 = 15.3 ± 0.2 µM) and human hepatocyte cell line L-02 (LD50 = 32 µM). Hepatocellular toxicity of flavokavain B is mediated by induction of oxidative stress, depletion of reduced glutathione (GSH), inhibition of IKK activity leading to NF-κB transcriptional blockade, and constitutive TNF-α-independent activation of mitogen-activated protein kinase (MAPK) signaling pathways. Furthermore, pretreating hepatocytes with exogenous GSH normalizes NF-κB and MAPK signaling and rescues hepatocytes from flavokavain-induced toxicity.

Lüde *et al.* (2008) compared the hepatocellular toxicity of three different kava extracts (a methanolic and an acetic root and a methanolic leaf extract), and investigated their toxicity on HepG2 cells and isolated rat liver mitochondria. Methanolic and acetic root extracts contained approximately 80% kavalactones and 0.011% pipermethysticine whereas the methanolic leaf extract had 24% kavalactones and 1.34% pipermethysticine. All three extracts showed cytotoxicity starting at a concentration of 50 µg/ml (lactate dehydrogenase leakage) or 1 µg/ml (MTT test). The mitochondrial membrane potential was decreased (root extracts starting at 50 µg/ml) and the respiratory chain
inhibited and uncoupled (root extracts) or only uncoupled (leaf extract) at 150 µg/ml, and mitochondrial beta-oxidation was inhibited by all extracts starting at 100 µg/ml. The ratio oxidized to reduced glutathione was increased in HepG2 cells, whereas the cellular ATP content was maintained. Induction of apoptosis was demonstrated by all extracts at a concentration of 150 µg/ml. These results indicate that the kava extracts are toxic to mitochondria, leading to inhibition of the respiratory chain, increased ROS production, a decrease in the mitochondrial membrane potential and eventually to apoptosis of exposed cells.

Not only the in vitro findings but also in vivo toxicity testing leads to different results concerning kavalactones or kava extracts toxicity. Both aqueous and organic extracts as well as isolated kavalactones have been investigated.

Sorrentino et al. (2006) assessed the hepato-toxicity of an ethanolic kava extract (ethanolic extractum spissum, containing kavain 12.4%, dihydrokavain 8.8%, methysticin 11.8%, dihydromethysticin 6.0%, yangonin 5.0%, desmethyoxy-yangonin 3.4%) in rats. Wistar rats of both sexes were fed 7.3 or 73 mg/kg body weight of ethanolic kava extract for 3 and 6 months. The animals were examined for changes in body weight, hematological and liver parameters, and macroscopical and microscopical histological changes in the major organs. No signs of toxicity could be found. In addition, no behavioural or physiological changes were observed on discontinuation of kava-extract feeding after 3 months.

Singh et al. (2003) investigated the effects of an aqueous kava extract (extracted with water at room temperature; no further detail) on liver function in rats (daily dosages of 200 or 500 mg kavalactones/kg) for 2 up to 4 weeks and compared with control groups. The serum levels of ALT (alanine aminotransferase), AST (aspartate aminotransferase), ALP (alkaline phosphatase) and LDH (lactate dehydrogenase) were almost twice as much in the control groups after 2 weeks compared with 4 weeks. After 2 weeks, all enzymes were lower with both doses of kava extract. The changes were significant (p<0.05) at 500 mg/kg for ALT and AST and at 200 mg/kg for ALP. The reduction in ALT was also significant (p<0.05) after 4 weeks with 500 mg/kg.

Clayton et al. (2007) examined the effects of an organic kava extract (containing yangonin 42.76%, 7,8-dihydrokavain 34.69%, kavain 8.87%, 7,8-dihydromethysticin 4.03%, methysticin 3.23% and 5,6-dehydrokawain 2.42%) administered in corn oil by gavage F344 in rats at concentration of 0.125, 0.25, 0.5, 1.0, and 2.0 g/kg/day, 5 days per week for 14 weeks. Time- and dose-dependency of hepatotoxicity was revealed. Increased gamma-glutamyl-transpeptidase (GGT) activities were observed in the 2.0 g/kg males and 1.0 and 2.0 g/kg females, as well as increased serum cholesterol levels in males and females at 0.5 g/kg and higher. Increases in incidence and severity of hepatocellular hypertrophy were noted in males at 1.0 g/kg and females at 0.5 g/kg and higher, as well as increased liver weights. Immunohistochemical analyses of the expression of cytochrome-P450 (CYP) enzymes in liver of the control and 1.0- and 2.0-g/kg-treated groups indicated decreased expression of CYP2D1 (human CYP2D6 homolog) in 2.0 g/kg females and increased expression of CYP1A2, 2B1, and 3A1 in 1.0 and 2.0 g/kg groups of both sexes. The no-observed adverse effect level (NOAEL) corresponds to 0.25 g/kg in both genders, based on increases in GGT, cholesterol, liver weight, and hypertrophy and decreases in body weight.

Another study conducted in rats investigated the effect of an acetonic extract (DER 11–20:1, extraction solvent: acetone 75%, m/m) and an ethanolic extract (DER 13–20:1, extraction solvent: ethanol 96%, m/m) at three different oral doses 31.25, 62.5 and 133 mg/kg diet, for 3 months. The tested doses did not produce any liver injury based on serum markers of liver damage (sorbitol dehydrogenase activities, bile acid concentrations, and β-glucuronidase activities) and serum lipid peroxide readings. Moreover, for these same parameters, kava feeding did not enhance the effects of the hepatotoxin galactosamine (500 mg/kg ip); the dose of 133 mg/kg (for both kava preparations)
plus 62.5 mg/kg dose of ethanolic extract even showed modest protection against liver injury. Liver histology analysis showed no signs of kava causing or enhancing liver injury (Di Silvestro, 2007).

Isolated compounds

Fu et al. (2008) investigated the effect of kavain on liver ultrastructure and function by infusing 10 µg/mL kavain solution for 2 h in isolated rat livers. After standard fixation and tissue preparation, the samples were examined by scanning electron microscopy (SEM), transmission electron microscopy (TEM), and light microscopy (LM). LM, SEM, and TEM examinations indicated kavain-treated rat livers displayed severe vascular and endothelial damage manifesting as vasoconstriction, gaps and loss of endothelial and subendothelial liver tissue integrity compared to control livers.

Zhang et al. (2012) investigated the hepatotoxicity of kavain and methysticin at concentration of 43.3 µM in perfused livers of rats, which were either pretreated or not with the macrophage intoxicant gadolinium chloride. An extensive damage was observed in kavalactone-perfused livers whereas the damage was significantly lower with a gadolinium chloride pretreatment. The authors suggested that the activation of liver macrophages may be a key factor for observed hepatotoxicity of kavalactones.

The hepatotoxic potential of flavokavain B was investigated in vivo in mice that received daily oral doses of 25 mg/kg flavokavain B or vehicle (0.5% methyl-cellulose) for 1 week. Histological analysis revealed massive liver damage with hepatocellular swelling and vesiculated cytoplasm indicating inflammatory infiltration. Inflammatory infiltration was also evident predominantly in the periportal area. Consistent with histologically observed liver damage, serum AST and AKP levels were also increased in mice treated with flavokavain B (Zhou et al., 2010).

Assessor comment: the amounts of flavokavain B (which is a minor constituent) of found in kava extracts vary considerably from 0.54-7.06 mg in ethanolic extracts (equated to 120 mg kavalactones). The tested dose in vivo (25 mg/kg) is 250 times higher than the usual daily uptake of patients.

Narayanapillai et al. (2014) evaluated the toxicity of kava ethanolic extract (standardized to 150 mg/mL total kavalactones) as a single entity(long-term study) or in combination with acetaminophen (APAP) in C57BL/6 mice(short-term study). In the long-term study, mice in the kava group were given 500 mg/kg/day ethanolic extract via gavage, 6 days a week, for 14 weeks, while control group was treated with PEG-400. At the tested dose kava extract did not affect mouse growth. There were also no statistically or biologically significant differences between control and kava- treated mice with respect to ALT and AST. The short-term combination studies were designed to evaluate the potential synergism of kava and its chemicals to APAP-induced hepatotoxicity. C57BL/6 mice were treated with PEG-400 (control group), kava ethanolic extract (500 mg/kg), dihydromethysticin (37.5 mg/kg) or Flavokavains A(8, 16, 32 mg/kg) and Flavokavains B (11.5, 23, 46 mg/kg), daily via oral gavage for 2 days. On the third day, mice in the respective groups were coadministered with APAP (800 mg/kg). Kava pretreatment potentiated APAP-induced hepatotoxicity, resulted in an increase in serum ALT and AST(3-fold increase relative to APAP alone), and increased severity of liver lesions. Histopathological analyses of the liver tissues revealed no lesions in control and kava treated mice confirming the lack of hepatotoxicity by kava treatment alone. Flavokavains A and B together at all three doses tested did not induce any changes on serum ALT and AST but combined with APAP, dose-dependently potentiated the increase in ALT and AST (2-3 times) induced by APAP; dihydromethysticin had no such effect.

Pipermethystine

Pipermethystine (at 50 µm or higher) caused cytotoxicity and apoptosis under in vitro conditions using HePG2 cells assays (Nerurkar, 2004), but in vivo studies in rats treated with high doses of 10 mg/kg/day pipermethystine failed to reveal any experimental liver injury (Lim et al., 2007).
Assessor comments: the level of pipermethystine in kava-rhizoma extracts is lower than the detection limit, therefore the evidence for pipermethystine as culprit of human kava hepatotoxicity is not realistic.

### 3.1.4. Pharmacodynamic interactions

**Prolongation of barbiturate-induced sleeping time**

Klohs et al., (1959) demonstrated the ability of kava chloroform extract ((5 kg roots/30 L chloroform) and kava isolated components to potentiate sodium pentobarbital-induced sleeping time in mice. Dihydromethysticin appeared to be the most potent agent; at a dosage of 60 mg/kg sleeping time was prolonged by 413 %. The chloroform extract at doses of 60, 160 and 250 mg/kg prolonged sleeping time by 134, 250 and 440%, respectively. Methysticin, kavain, dihydrokavaine and yangonin were administered in dosages of 160 mg/kg, but only prolonged sleeping time by 150 (yangonin, dihydrokavaine) to 250 % (methysticin; kavain: 235 %). In additional experiments, varying doses of dihydromethysticin further demonstrated its potency. 10 mg/kg caused a prolongation by 152 ± 30 %, 20 mg/kg prolonged sleeping time by 240 ± 27%, 40 mg/kg: 457 ± 43 %, 60 mg/kg: 896 %, 160 mg/kg: 1800 %

Another study on male mice demonstrated that premedication with dihydrokavain or dihydromethysticin prolonged and deepened sodium hexobarbital anaesthesia. The lowest effective dose of dihydromethysticin, 20 mg/kg, doubled hexobarbital induced sleeping time. The lowest effective dose of dihydrokavain was 60 mg/kg. Dihydromethysticin proved to be at least twice as effective as dihydrokavain over the entire dose range. However, none of the drugs reached the efficacy of chlorpromazine (Hänsel, 1968).

An ethanolic extract of kava (extraction solvent ethanol 96%) at a single dose of 100 mg/kg (corresponding to 50 mg kavalactones) administered by gastric tube in mice prolonged barbiturate-induced sleeping time, by 45.5% (Capasso & Sorrentino, 2005).

**Interaction with ethanol**

A intraperitoneally dose of 200 mg/kg of dichloromethane kava extract (no further detail) caused a highly significant (p < 0.001) increase in the sleeping time of mice injected with 3.5 g/kg or 4 g/kg of ethanol. Increasing the kava extract dosage to 300 mg/kg further prolonged the hypnosis, but proved lethal to three of the six mice treated with 4 g/kg ethanol, indicating that toxicity as well as hypnosis was increased. A dosage of 1 g/kg ethanol did not alter the kava induced sleeping times of mice when injected with either 350 or 450 mg/kg of the extract but 2 g/kg ethanol greatly prolonged the mean sleeping time produced by 350 mg/kg kava extract (Bilia, 2002).

### 3.1.5. Conclusions

Several in vitro and in vivo studies were conducted on kava extracts, isolated kavalactones or synthetic kavalactones in order to investigate neurological and sedative effects, anticonvulsive, muscle relaxing and spasmyloytic activity.

Because in vitro studies were performed with different extracts (aqueous, methanolic, dichlormethane or ethanolic) not always well characterised, the relevance of the results is questionable. The same comment regarding the heterogeous type of extracts tested is applicable for the in vivo studies, where the results are not consistent.

Regarding safety pharmacology, direct hepatotoxicity of isolated kavalactones and kava extracts has been assessed in numerous in vitro studies yielding different and partly inconsistent results. However,
it is important to note that the demonstration of in vitro cytotoxicity is not the best predictor of the potential of a compound to cause in vivo hepatotoxicity. Also in vivo toxicity leads to different results concerning its intrinsic potential; some studies on rats revealed an increased serum level of transaminases and hepatocellular hypertrophy while other studies were negative. There are some in vivo studies on hepatotoxic potential of flavokavain B, but the tested doses are 250 times higher than the usual daily uptake, therefore further studies are needed.

These results should be correlated with NTP carcinogenicity studies (see 3.3.4. Carcinogenicity)

3.2. Overview of available pharmacokinetic data regarding the herbal substance(s), herbal preparation(s) and relevant constituents thereof

Herbal preparations

In vitro

Bioavailability of kavalactones in ethanolic and aqueous extracts was studied in vitro using Caco-2 cell monolayers (Matthias et al., 2007). The extracts showed only minor differences in ratio of kavalactones but there was a difference in total amount (204 mg/mL in ethanolic and 103 mg/mL in aqueous extracts). Good bioavailability permeability (Papp) calculated from uptake data from 10 to 90 min was for all > 40 x 10⁻⁶ cm/s. Complete intestinal absorption is considered for Papp > 1 x 10⁻⁶ cm/s. Yangonin was potentially retained in Caco-2 cells as recovery on the apical side was only 40%. Permeability of purified kavain was significantly lower compared to kavain uptake from extracts. Bioavailability was not affected by the extraction method.

In vivo

When "crude kava resin" (120 mg/kg, containing 44 mg of kavain, 23 mg of dihydrokavain, 18 mg of yangonin and 16 mg desmethoxyyangonin; no further detail) was given intraperitoneally to male Balb/c mice, the maximum concentrations of kavain and yangonin in brain markedly increased (2 and 20 times, respectively) relative to the value measured from their individual injection while the concentrations of 7,8-dihydrokavain and desmethoxyyangonin were similar to those measured after they were injected separately (Keledjian et al., 1988).

After oral administration of a kava extract (no further detail) to mice at 100 mg/kg, maximum plasma concentration of individual kavalactones (kavain, dihydrokavain, methysticin, and dihydromethysticin, but not yangonin) ranging between 300-900 ng/ml, were attained within 5 minutes; the elimination
half-life was approx. 30 minutes. When mice and rats were treated orally with 100 mg/kg of kava extract formulation (suspended in 0.2 % agar), bioavailability clearly increased, with maximum plasma levels of kavalactones in mice reaching 1.7-2.5 µg/ml (except yangonin, 0.3 µg/ml) 0.5 hours after administration; in rats, however, two absorption peaks of lactones were observed, at 15 min. and approx. 2 hours. Surprisingly, kavalactones levels in the brain showed peak concentrations (1.1-2 µg/g of brain) at the same time as in plasma. Elimination half-life in mouse plasma and brain were approx. 1 hour and even longer in the rat (Biber, 1992).

The same researchers investigated in mice the bioavailability of the kavalactones after oral administration (in 0.2 % agar) of either 100 mg/kg extract WS 1490, or 100 mg/kg of the same extract as a formulation (WHO, 2007). In addition pure (+)-kavain was administered to mice at a dose of 14.4 mg/kg, which was the corresponding dose of kavain in the extract. Dogs received an oral dose of 10 mg/kg WS 1490 as the formulation as well as the pure lactones. In both species bioavailability increased in the order pure compound, extract and extract formulation. The authors concluded that clinical data from one preparation or formulation cannot simply be transferred to other formulations without corresponding biopharmaceutical characterisation.

Guo et al. (2009) investigated the changes in gene expression of drug metabolizing enzymes in the livers of Fischer 344 male rats administered kava extract in corn oil (no further detail) by gavage at doses of 0.125, 0.25, 0.5, 1.0, or 2.0 g/ kg/ day, 5 days per week for 14 weeks. Analysis of 22, 226 genes revealed that there were 14, 41, 110, 386, and 916 genes significantly changed in the 0.125, 0.25, 0.5, 1.0, and 2.0 g/kg treatment groups, respectively. There were 16 drug metabolizing genes altered in all three high-dose treatment groups, among which seven genes belong to cytochrome P450 isozymes. While gene expression of CYP1A1, 1A2, 2C6, 3A1, and 3A3 increased; CYP 2C23 and 2C40 decreased, all in a dose-dependent manner.

Isolated compounds

**Oral route**

Kavain is rapidly absorbed from the gastrointestinal tract, distributed to tissues, and eliminated.

In male F344 rats given kavain at a single oral dose of 100 mg/kg, the maximum blood concentration of kavain was measured at 0.88 hours, after which plasma concentrations declined with a mean terminal half-life of 1.3 hours. The mean oral bioavailability of kavain in F344 rats was about 50% (Mathews et al., 2005).

In male F344 rats given kavain orally for 7 days, kavain was primarily excreted in the urine, with about 77% recovered during the 72 hours after the last dose. Faecal excretion accounted for about 14% of the administered dose. Only 0.4% of the kavain was retained in the tissues, and kavain did not accumulate preferentially in any particular tissue. In addition, there were no differences in the pharmacokinetics of kavain when administered as a single dose or as repeated doses (Mathews et al., 2005).

The absorption of 6 kavalactones (kavain, dihydrokavain, methysticin, dihydromethysticin, yangonin, and desmethoxyyangonin) administered orally in a peanut oil solution was investigated in mice. Kavain and dihydrokavain were rapidly absorbed from the gastrointestinal tract (with a peak at 10 minutes), followed by methysticin and dihydromethysticin (30–45 minutes). Yangonin and desmethoxyyangonin were poorly absorbed, and rapid elimination occurred (Singh, 1992; Robinson et al., 2009).

**Parenteral route**

In male F344 rats given an intravenous injection of kavain at a dose of 7 mg/kg bw, kavain was rapidly eliminated from the systemic circulation, with a terminal half-life of 0.63 hours. Systemic clearance
and volume of distribution were 89 mL/minutes per kg and 2.70 L/kg, respectively, indicating that a significant amount of kavain was rapidly distributed out of the plasma into tissues and quickly cleared from the body (Mathews et al., 2005).

Keledjian et al. (1988) observed a peak concentration at 5 minutes in brain for kavain and 7,8-dihydrokavain; the compounds were rapidly eliminated after intraperitoneal administration (100 mg/kg bw) of individual kava constituents in male Balb/c mice. The maximum concentrations of kavain and 7,8-dihydrokavain were 64.7 and 29.3 ng/mg wet brain tissue, respectively, and were rapidly eliminated. In contrast, desmethoxyyangonin and yangonin had poorly defined maxima corresponding to concentrations of 10.4 and 1.2 ng/mg wet brain tissue, lower than those of kavain or 7,8-dihydrokavain but were more slowly eliminated from brain tissue.

Metabolism and excretion

**In vitro**

Fu et al. (2009 and 2012a) studied the rat microsomal metabolism of kavain, desmethoxyyangonin and methysticin (each at concentration of 10 µg/ml). P-hydroxykavain, m,p-dihydroxykavain, and p-hydroxyyangonin were identified as primary metabolites. Moreover, cytochrome P450 isoforms responsible for kavalactone metabolism were examined. CYP3A1/3A23 was found to be responsible for kavalactone metabolism in female rats, CYP3A2 in male rats while the roles of CYP1A2, -2C6, -2C9, -2E1 and -3A4 are limited. For desmethoxyyangonin CYP2C6 and CYP2C11 were involved in males and CYP2C12 in females. CYP3A1/3A23 may also be involved in females.

The disposition profiles of three kavalactones (kavain, methysticin and desmethoxyyangonin) and their respective metabolites were also examined in the perfusate and bile of the isolated perfused rat liver (Fu et al., 2012b). The rat livers were exposed to kavain, methysticin and desmethoxyyangonin for 120 min. Metabolism was found to be of first-order nature with similar half-lives of decay (1.2 – 3 h). p-hydroxykavain and m,p-dihydroxykavain were found as metabolites. Biliary excretion of kavalactones was negligible.

**In vivo**

Rasmussen et al. (1979) and later NTP (2012) investigated the metabolism of five kavalactones (kavain, dihydrokavain, methysticin, yangonin, and dihydroyangonin) in male albino rats. The individual kavalactones were administered orally (400 mg/kg bw) or intraperitoneally (100 mg/kg bw), the metabolites and the recovered parent substrate in the urine were then identified:

**Dihydrokavain** - approximately half of an oral dose of dihydrokavain (400 mg/kg) was recovered as metabolites in the urine in 48 hours. Nearly a 2:1 ratio between hydroxylated and ring-opened products was seen. There were three mono- and three di-hydroxlated derivatives, of which p-hydroxydihydrokavain was the most abundant. The remaining third consisted of metabolites formed by scission of the 5,6-dihydro-a -pyrone ring and included hippuric acid. Small amounts of unchanged dihydrokavain were found in the feces. No metabolites were identified in feces or 0-22 hour bile samples.

**Kavain** - although lower amounts of urinary metabolites were excreted following kavain administration, both hydroxylated and ring-opened products were formed. Metabolites identified included p-hydroxybenzoic acid; 4-hydroxy-6-phenyl-5-hexen-2-one; hippuric acid; 4-hydroxy-6-hydroxyphenyl-5-hexen-2-one; p-hydroxydihydrokavain; hydroxykavain; p-hydroxykavain; and p-hydroxy-5,6-dehydrokavain. Two metabolites were unidentified. Large amounts of unchanged compound were identified in the feces.
Methysticin - methysticin gave rise to only small amounts of two urinary metabolites formed by demethylenation of the methylenedioxyphenyl moiety (m,p-dihydroxykawain and m,p-dihydroxydihydrokawain). Unchanged methysticin was identified in feces.

7,8-Dihydroxyyangonin - the major urinary metabolite of 7,8-dihydroxyyangonin was p-hydroxy-5,6-dehydro-7,8-dihydrokawain, two minor metabolites were hydroxylated derivatives of this compound. No ring-opened products were detected.

Yangonin - relatively small amounts of yangonin metabolites were detected in the urine. The three metabolites identified were formed via O-demethylation; the major metabolite was p-hydroxy-5,6-dehydrokawain. No ring-opened products were detected

Enzyme interactions

Yamazaki et al. (2008) investigated the effects of administration of kava preparations on gene expression of hepatic CYP1A isoforms in rats. A high dose (380 mg kavalactones/kg/day) of two different types of kava products (Kava A: standardized kava root extract (kavalactones: 80% or greater) and Kava B: unfiltered juice of whole lateral root of kava, freshly freeze-dried) for 8 days significantly increased liver weights. CYP1A2 mRNA expression was moderately increased (2.8–7.3 fold). More importantly, the high dose of kava markedly enhanced CYP1A1 mRNA expression (75–220 fold) as well as ethoxyresorufin O-deethylase activities and CYP1A1 immunoreactivities.

3.3. Overview of available toxicological data regarding the herbal substance(s)/herbal preparation(s) and constituents thereof

3.3.1. Single dose toxicity

Herbal preparation

The LD50 values of an acetone-water extract of kava (DER 11-20:1, 70% kavalactones) were in mice: 380 mg/kg (intraperitoneal) and 1800 mg/kg (oral); in rats: 370 mg/kg (intraperitoneal) and 1600 mg/kg (oral) Acute reactions were dose-dependent and manifested by reduced spontaneous motility, ataxia, sedation, lying on their sides with reduced reflex excitability, unconsciousness and death from respiratory paralysis (Duke, 2002)

Isolated compounds

For isolated compounds following values of oral, intraperitoneal and intravenous LD50 were found to be: kavain(1130 mg/kg, 420 mg/kg and 69 mg/kg); dihydrokavain(890 mg/kg, 490 mg/kg and 53 mg/kg); methysticin(> 800 mg/kg, 530 mg/kg and 49 mg/kg); dihydromethysticin (1050 mg/kg, 420 mg/kg and 67 mg/kg); demethoxyyangonin (> 800 mg/kg, >800 mg/kg and 55 mg/kg) and yangonin (> 1500 mg/kg, >1500 mg/kg and 41 mg/kg)(Duke, 2002).

3.3.2. Repeat dose toxicity

Herbal preparation

Following studies were conducted and reported by NTP (2012):

2-week studies (rats and mice)

In one study rats were treated with kava extract (containing 27% kavalactones with 3% methysticin, 6,3%kavain, 7% dihydrokavain, 4% yangonin, 3% dihydromethysticin) in corn oil by gavage at doses of 0, 0.125, 0.25, 0.5, 1.0, or 2.0 g/kg, 5 days per week for 16 days. One female rat administered 2.0 g/kg kava extract died on day 3 of the study. Mean body weights of all dosed groups of rats were
similar to those of the vehicle controls. Clinical findings included abnormal breathing, ataxia, and lethargy in the 2.0 g/kg groups of males and females and ataxia and lethargy in the 1.0 g/kg group of females. Liver weights were significantly increased in 1.0 and 2.0 g/kg males and in 0.5 g/kg or greater females compared to the vehicle controls. Minimal hepatocellular hypertrophy occurred in all 2.0 g/kg males and in all females administered 0.25 g/kg or greater.

In another study mice were treated with kava kava extract (containing 27% kavalactones with 3% methysticin, 6,3% kavain, 7% dihydrokavain, 4% yangonin, 3% dihydromethysticin) in corn oil by gavage at doses of 0, 0.125, 0.25, 0.5, 1.0, or 2.0 g/kg, 5 days per week for 17 days. In the 2.0 g/kg group of males, one died on day 2 and one died on day 3. Mean body weights of all dosed groups of mice were similar to those of the vehicle controls. Clinical findings included abnormal breathing, ataxia, and lethargy in males and females in the 1.0 and 2.0 g/kg groups. Liver weights of 2.0 g/kg males and females were significantly increased. The incidence of hepatocellular hypertrophy in 2.0 g/kg female mice was significantly greater than that in the vehicle control group.

3-month studies (rats and mice)

Rats were treated with kava extract (containing 27% kavalactones with 3% methysticin, 6,3% kavain, 7% dihydrokavain, 4% yangonin, 3% dihydromethysticin) in corn oil by gavage at doses of 0, 0.125, 0.25, 0.5, 1.0, or 2.0 g/kg, 5 days per week for 14 weeks. Deaths attributed to kava kava extract administration included three males and four females in the 2.0 g/kg groups and one female in the 1.0 g/kg group. One 0.25 g/kg male and one vehicle control female also died before the end of the study. The mean body weights of males in the 1.0 and 2.0 g/kg groups and females in the 2.0 g/kg group were significantly less than those of the vehicle controls. Ataxia and lethargy were observed in males and females in the 1.0 g/kg groups during week 1 and in the 2.0 g/kg groups throughout the study. Increased γ-glutamyltransferase activity in 1.0 g/kg females and 2.0 g/kg males and females may represent enzyme induction. However, the hepatocellular hypertrophy observed in the 2.0 g/kg females may have contributed to the increased γ-glutamyltransferase activity. The liver weights of 0.25 g/kg or greater males and 0.5 g/kg or greater females were significantly increased compared to the vehicle controls. The kidney weights of 0.5 g/kg or greater males and females were significantly increased compared to the vehicle controls. The incidence of hepatocellular hypertrophy in 2.0 g/kg females was significantly greater than that in the vehicle controls.

In another study mice were treated with kava extract (containing 27% kavalactones with 3% methysticin, 6,3% kavain, 7% dihydrokavain, 4% yangonin, 3% dihydromethysticin) in corn oil by gavage at doses of 0, 0.125, 0.25, 0.5, 1.0, or 2.0 g/kg, 5 days per week for 14 weeks. Four male and three female 2.0 g/kg mice died during week 1; these deaths were attributed to kava kava extract administration. One additional 2.0 g/kg female died during week 6 due to a gavage accident. The mean body weights of dosed males and females were similar to those of the vehicle controls. Ataxia and lethargy occurred in males and females in the 1.0 and 2.0 g/kg groups during week 1. The liver weights of 2.0 g/kg males and 1.0 and 2.0 g/kg females were significantly increased compared to those of the vehicle control groups. The incidences of centrilobular hypertrophy in the liver of 0.5 g/kg or greater males and 1.0 and 2.0 g/kg females were significantly greater than those in the vehicle controls.

Isolated compounds

The toxicity of the demethoxyyangonin was evaluated in male ICR mice and male Wistar rats. Mice received oral demethoxyyangonin doses of 30, 100, or 300 mg/kg twice a day for 14 days or 100 mg/kg twice a day for 9 weeks; rats were treated with 30, 100, or 300 mg/kg daily for 3 months. In all groups, histological and hematological findings were negative. In rats, demethoxyyangonin lowered cholesterol in the first two months but increased cholesterol after three months (Hsu et al., 1994).
3.3.3. Genotoxicity

Herbal preparation

Kava extract (containing 27% kavalactones with 3% methysticin, 6.3% kavain, 7% dihydrokavain, 4% yangonin, 3% dihydromethysticin) was not mutagenic in Salmonella typhimurium (strains TA97, TA98, TA1535 or TA100) or Escherichia coli strain WP2 uvrA pKM101 with or without metabolic activation (rat liver S9) at concentration up to 10 000 µg/plate. In one trial out of three of which two of the results were negative, kava extract tested equivocal in TA97 with metabolic activation (NTP, 2012).

Two types of lipid soluble extracts of kava (containing 150 mg kavalactones/g extract) at concentrations up to 200 and 400 µg/ml, respectively and 6 isolated compounds (dihydromethysticin, desmethoxyyangonin, methysticin, dihydrokawain, yangonin, D-Kavain and DL-Kavain) were evaluated in L5178Y mouse lymphoma cells. The maximum dose levels tested for each kavalactones were 300 µg/ml dihydromethysticin; 150 µg/ml methysticin; 200 µg/ml dihydrokavain; 160 µg/ml DL-kavain and 160µg/ml D-kavain. Neither the kava extracts nor the kavalactones induced a mutagenic response in the L5178Y mouse lymphoma mutation assay with the addition of human liver S9 activation. (Whittaker et al., 2008)

The only report of positive mutagenic activity with n-butanol fraction of kava leaves (two positive results, but six negative results) involved the \textit{umu} point mutation assay. Further investigations using bioassay-directed isolation and analysis indicated that 2 C-glycoside flavonoid compounds accounted for the positive mutagenic results. Two isolated compounds were identified as 2''-O-rhamnosylvitexin and schaftoside (Jhoo et al., 2007). These data are considered by IARC not useful, because the results were not analysed statistically. In the same time the results cannot be extrapolated for kava rhizoma.

\textit{In vivo}, in male or female mice given kava extract (containing 27% kavalactones with 3% methysticin, 6.3% kavain, 7% dihydrokavain, 4% yangonin, 3% dihydromethysticin) at a dose of up to 2.0 g/kg/day by gavage for 3 months, there was no increase in the frequency of micronucleated normochromatic or polychromatic erythrocytes in blood (NTP, 2012).

3.3.4. Carcinogenicity

Herbal preparation

In one study in B6C3F1 mice kava extract (containing 27% kavalactones with 3% methysticin, 6.3% kavain, 7% dihydrokavain, 4% yangonin, 3% dihydromethysticin) was given orally, by gavage, at a dose of 0 (corn oil vehicle, 10 mL/kg), 0.25, 0.5, or 1.0 g/kg/day, 5 days per week, for 105 weeks. In males, the mean body weight of the dosed groups was similar to that in the control group. In females, the mean body weight of the group at 1.0 g/kg was 11% less than that in the control group after week 21. The mean survival time of male and female mice in the dosed groups was similar to that of the controls. In males, the incidence of hepatoblastoma was significantly higher in the groups receiving the intermediate and highest dose, and had a significant positive trend. The incidence of hepatocellular carcinoma and hepatoblastoma (combined) was significantly higher in the group receiving the intermediate dose. The incidence of eosinophilic hepatocyte foci, a preneoplastic hepatocyte lesion, was significantly higher in the groups receiving the intermediate or highest dose. In females, the incidence of hepatocellular carcinoma was significantly higher in the group receiving the lowest dose. The incidence of hepatocellular adenoma or carcinoma (combined) was significantly higher in the groups receiving the lowest and intermediate doses. The incidence of hepatocellular carcinoma and hepatoblastoma (combined) was significantly higher in the group receiving the lowest dose. The incidence of eosinophilic hepatocyte foci was significantly higher in the group receiving the highest
dose. The incidence of squamous cell hyperplasia of the forestomach was significantly higher in the groups receiving the lowest or intermediate doses (Behl et al., 2011; NTP, 2012).

In male and female F344/N rats kava extract (containing 27% kavalandones with 3% methysticin, 6.3% kavain, 7% dihydrokavain, 4% yangonin, 3% dihydromethysticin) was given orally, by gavage, at a dose of 0 (corn oil vehicle, 5 mL/kg), 0.1, 0.3, or 1.0 g/kg/day, 5 days per week, for 104 (male rats) or 105 (female rats) weeks. The mean body weight of the groups at 1.0 g/kg bw was 10% less than that of the control group after week 65 in males and after week 41 in females. The mean survival time for rats in the dosed groups was similar to that of controls for both sexes. In males, the incidence of testis interstitial (Leydig) cell adenoma was significantly higher in the groups at the intermediate or highest dose, and had a significant positive trend. The incidence of this tumour in controls was low (76%) compared with that in historical controls (corn oil vehicle controls: range, 76–94%; all routes: range, 54–98%). The incidence of renal pelvis transitional cell hyperplasia was significantly higher in the group receiving the highest dose. In females, the incidence of renal pelvis transitional cell hyperplasia was significantly higher in the groups at the highest or intermediate dose. There was no significant increase in the incidence of any neoplasm in females (Behl et al., 2011; NTP, 2012).

NTP concluded that "there is sufficient evidence in experimental animals for the carcinogenicity of kava extract, but is inadequate evidence in humans, therefore is classified as possible carcinogenic to humans (Group 2 B)". The reported carcinogenicity in animals is most probably mediated through nongenotoxic mechanisms.

There are no studies conducted on other type of preparations. NB: The extract used by NTP in the repeated dose, genotoxicity and carcinogenicity studies is characterised only by its kavalandones pattern but not also by other parameters, such as DER or extraction solvent. Because the phytochemical comparability with other preparations is not demonstrated, the results are attributed only to this preparation.

### 3.3.5. Reproductive and developmental toxicity

There are no studies on herbal preparations.

NTP, on its website (http://ntp-server.niehs.nih.gov; accessed on January 2016) in its toxicity profile for kava-kava, refers to an old study conducted or rats and rabbits treated orally with a mixture of 40 percent kavain, 40 percent dihydrokavain, and 20 percent yangonin. The mixture was administered orally at doses of 100 or 500 mg/kg on days 6-15 of gestation. The mixture was not teratogenic or embryotoxic in Wistar rats. The mean fetal weight in treated animals was lower than in the controls, although it still fell within physiological limits. The possibility of an effect of the compounds on fetal weight could not be excluded. The mixture was also negative for teratogenic activity in New Zealand strain rabbits when administered orally at doses of 20 or 200 mg/kg on days 6-18 after mating. There was a significant dose-related reduction of fetal weight in treated rabbits (NTP, 1998 http://ntp.niehs.nih.gov)

### 3.3.6. Local tolerance

No data available.

### 3.3.7. Other special studies

No data available.
3.3.8. Conclusions

Extensive toxicological data are published by NTP regarding one kava preparation. Repeated dose studies on rats and mice revealed increased weights of liver and kidney and hepatocellular hypertrophy. The same preparation was used in the carcinogenicity studies conducted on two species (mice and rats), treated by gavage. In mice the preparation caused a significant increase in the incidence of hepatoblastoma in males and hepatocellular adenoma or carcinoma (combined) and hepatocellular carcinoma in females at doses of 0.25 and 0.5 mg/kg. In male rats the same extract at doses of at 0.5 and 1.0 mg/kg caused a significant increase in the incidence of testis interstitial cell adenoma. In conclusion, there is sufficient evidence in experimental animals for the carcinogenicity of this kava extract, but is inadequate evidence in humans, therefore this preparation is classified by NTP as possible carcinogenic to humans (Group 2B).

The same extract was not mutagenic in vitro on Salmonella typhimurium (strains TA97, TA98, TA1535 or TA100) or Escherichia coli strain WP2 uvrA pKM101 with or without metabolic activation, neither in vivo in the micronucleus test.

The extract used by NTP in the repeated dose, genotoxicity and carcinogenicity studies is characterised only by its kavalactones pattern but not by other parameters, such as DER or extraction solvent. Because the phytochemical comparability with other preparations is not demonstrated, the results are attributed only to this preparation.

There are no adequate reproductive and developmental toxicity studies on kava preparations. The only study is related with a mixture of isolated compounds, therefore its relevance is limited.

3.4. Overall conclusions on non-clinical data

Results from in vitro and in vivo studies with extracts and isolated constituents are not consistent and are endorsed with limited relevance, because they are conducted with heterogeneous extracts, not always well characterised.

Non-clinical information on the safety, especially in vivo studies suggests that kava preparations may have hepatotoxic potential. This assumption should be correlated with the repeated dose studies and carcinogenicity studies that provided sufficient evidence in experimental animals for the carcinogenicity of one kava preparation (containing 27% kavalactones with 3% methysticin, 6.3% kavain, 7% dihydrokavain, 4% yangonin, 3% dihydromethysticin). In mice, the preparation caused a significant increase in the incidence of hepatoblastoma in males and hepatocellular adenoma or carcinoma (combined) and hepatocellular carcinoma in females at doses of 0.25 and 0.5 mg/kg. In male rats the same extract caused a significant increase in the incidence of testis interstitial cell adenoma at doses of 0.5 and 1.0 mg/kg.

Based on the previous results, NTP included this preparation into group 2B, meaning sufficient evidence in experimental animals and possible carcinogenic to humans. This constitutes a strong cause for safety concern.

The same extract gave negative results in several standard bacterial assays for mutation in the absence or presence of metabolic activation, therefore the reported carcinogenicity of kava extract is most likely mediated through a non-genotoxic mechanism.

There are no adequate reproductive and developmental toxicity studies on kava preparations. The only study is related with a mixture of isolated compounds, therefore its relevance is limited.
4. Clinical Data

The extracts used in the trials are specified in the comments as far as possible. Unfortunately, in some publications correct specifications of solvent and drug-extract ratio (DER) are missing. In these cases no details can be given, if the extract could not be identified otherwise.

4.1. Clinical pharmacology

4.1.1. Overview of pharmacodynamic data regarding the herbal substance(s)/preparation(s) including data on relevant constituents

a) Herbal substance

No data.

b) Herbal preparations

Cognitive performance

Acetone-water extract

The effects of oxazepam and an acetone-water kava extract (WS 1490, containing 70% kavalactones), were investigated for reaction time and event-related potentials (ERPs) in a visual search paradigm on 12 healthy young males (age: 24 – 37) using a double-blind design. Three types of medication were administered: placebo, 3 x 200 kava extract mg/day for 5 days, and oxazepam 1 x 15 mg on the day before testing, 75 mg on the morning of the experimental day. Participants took one capsule three times daily for five days prior to the experimental session. Significant effects were obtained with oxazepam in a number of psychometric tests as well as search time and quality. Several ERP components of different latency, topography and functional significance were affected by the medication. Oxazepam led to a reduction of the amplitude of the parietal N1, frontal N2, posterior contralateral N2, and occipital P3 components. Kava extract was associated with a greater posterior N1, posterior contralateral N2, and occipital P3. The authors value those findings as evidence of a positive effect of kava extract on the allocation of attention and processing capacity (Heinze et al., 1994).

Twelve healthy volunteers were tested in a double blind, cross-over study to assess the effect of oxazepam and an acetone-water kava extract (WS 1490), on behaviour and event-related potentials (ERPs) in a recognition memory task. The subject’s task was to identify within a list of visually presented words those that were shown for the first time and those that were being repeated. The repeated words were associated with an increased positivity beginning approximately 250 ms post stimulus. Oxazepam led to a reduction of a negative component in the 250 – 500 ms range for both old and new words and to a reduction of the old/new difference in the ERP associated with a significantly worse recognition rate. Kava on the other hand showed a slightly increased recognition rate and a larger ERP difference between old and new words. The authors summarise that hypotheses about the mechanisms of action of the two drugs can be derived from the ERP patterns, suggesting a deficiency in the generation of an internal code for the word stimuli in the case of oxazepam and an influence on later stages possibly related to conscious recollection in the case of kava (Münte et al., 1993).

Aqueous extract

The effects of kava -kava on alertness and speed of access to information from long-term memory were investigated in a single-blind study using letter-match task; two groups, each consisting of 9
caucasian (5 male) undergraduates, completed two identical experimental sessions 2-6 days apart. The no-kava group consumed no kava prior to either session. The low-dose kava group drank a 250-ml of aqueous preparation of kava (30 g of kava root powder soaked in water, then filtered) 30 min prior to testing on the second occasion. An additional group of 9 caucasian (5 male) consumed a 500-ml aqueous preparation of kava (made up to a strength of 1 g/kg body weight) 1 h prior to the test. Kava aqueous preparation was found to have no discernible effect on cognitive performance (Russell et al., 1987).

Vigilance

Acetone-water extract

A single blind pilot study with healthy volunteers (2 male, 4 female, age: 24 – 47) was carried out in order to determine the neurophysiologic efficacy (quantitative EEG, evoked potentials) and the effects of the kava acetone-water extract WS 1490 on emotional and general variables concerning personality, on the subjective state as well as on various cognitive parameters. The volunteers received 300 mg or 600 mg/day WS 1490 for one week. The quantitative EEG showed an increase in the β-/α-index typical for the pharmaco-EEG profile of anxiolytics. The increase in the β2-activity was most pronounced in the β2-range. Kava extract showed no sedative-hypnotic effects after administration of 600 mg. The results of the evoked potential studies indicate that information processing may be improved in the cortical areas studied, i.e., vigilance is increased. These findings correlate with the results of the psychometric tests, which indicate increased activity and an improvement in emotional stability (Johnson et al., 1991).

Ethanolic extract

In a double-blind, 3-fold crossover study 12 healthy volunteers received single doses of either an ethanolic extract (containing 120 mg kavapyrones) or 10 mg diazepam or placebo. All tests were done immediately before as well as 2 and 6 hours after administration of the preparations. The washout period between cross-over was seven days. After administration of kava extract and diazepam the EEG showed an increase in the relative intensity of slow waves, which was recorded in the occipital area for both preparations, and in the frontal area only for kava extract. Maximum effects were often recorded 2 hours after administration of diazepam. However, the kava preparation, showed the most distinct effects after 6 hours. A benzodiazepine-specific increase in beta-activity was not recorded for the kava preparation. During the observation period the placebo group showed a time-dependent decrease of the relative intensity in the zone of the alpha-waves. The marked beta-activity in the diazepam group is the result of frequent significant differences between the two test preparations. In psychophysiological tests the critical flicker frequency was more distinctly reduced by kava extract and diazepam than by placebo. As opposed to these results, the volunteers showed significantly better results in the mental performance test-PAULI test (p < 0.001), the simple reaction time test and the complex multiple-choice reaction test 2 hours after administration of kava-extract (p < 0.01). For diazepam and placebo an improvement of performance could not be statistically proven (Gessner et al., 1994).

Isolated compound (kavain)

In a double-blind, placebo-controlled study the encephalotropic and psychotropic effects of d,l kavain (synthetic), as compared with clobazam, were investigated, utilising EEG brain mapping as well as psychometric and psychophysiological analyses. 15 healthy volunteers received randomised single oral doses of placebo, 200, 400 or 600 mg d,l kavain as well as 30 mg clobazam as reference compound at weekly intervals. EEG recordings, psychometric tests, evaluations of pulse, blood pressure and side effects were carried out at the hours 0, 1, 2, 4, 6, and 8. Brain maps of drug induced pharmaco-EEG changes (pharmaco-EEG maps) demonstrated that kavain exerted a significant action...
on the human brain function as compared with placebo characterised by a dose-dependent increase of delta, theta and alpha 1 activity, while alpha 2, beta activity and the centroid of the total activity decreased. These findings are indicative of a sedative action, which was, however, in type quite different from that of the 1,5-benzodiazepine. The latter produced a decrease of delta, theta, alpha 1 and alpha 2 and an increase of beta activity while the total centroid was accelerated. Interestingly, 200 mg kavain also induced vigilance promoting effects with a decrease of delta and beta activity and an increase of alpha activity and total power. Psychometric tests also demonstrated clear differences between the two compounds on behaviour. Compared with placebo kavain at all three dosages significantly improvement in intellectual performance (PAULI test), attention, concentration, reaction time and motor speed (rigidity test), while opposite findings were observed after 30 mg clobazam. In regard to thymopsychic variables such as drive, wakefulness, affectivity, mood, well-being, 200 mg kavain produced an improvement when compared to placebo while 600 mg kavain produced sedation, as did 30 mg clobazam. Psychophysiological tests resulted in only minimal results. Topographically, most encephalotrophic effects after administration of kavain were found in the frontal area, after administration of clobazam in the central and parietal areas (Saletu et al., 1989)

Sleeping pattern

In a single-blind study was examined the influence of the acetone-water kava extract (WS 1490) on sleep quality in healthy volunteers versus placebo. Two groups with 6 volunteers each received either 150 mf or 300 mg kava extract or placebo. A polygraphic sleep-EEG was recorded on nights and the quality of sleep and the subjective state were recorded daily in a questionnaire. After 150 mg or 300 mg kava extract the amount of sleep spindles and the percentage of deep sleep increased, REM-sleep did not change, sleep stage 1 and sleep latency tended to decrease. The subjective sleeping time increased. The authors conclude that the kava extract WS 1490 might have an effect similar to chemical tranquillizers concerning spindle denseness in the sleep-EEG. Furthermore, kava extract positively influences sleep in general, mainly by increasing slow wave sleep (while REM sleep remains unchanged) and decreasing sleep latency (Emser et al., 1991)

Sedative effects

Two multiple crossover studies were performed with 12 healthy female volunteers (mean age 53.7 years) to screen for acute sedative effects of eight different plant extracts, including kava extract LI 158 (DER 12-5:1; extraction solvent not known) by quantitative EEG analysis. An increase in power of both the theta and slow alpha bands was noted 2 hours after administration of a single oral dose of 600 mg kava extract. The increase in theta power was still present 3 hours after administration, while fronto-centrally a decrease in power was evident in the high frequency beta 3 band. Although the quantitative EEG can indicate drug-induced CNS changes, is not easy to conclude whether such changes are valid predictors of sedation or anxiolysis (Schultz et al., 1999).

4.1.2. Overview of pharmacokinetic data regarding the herbal substance(s)/preparation(s) including data on relevant constituents

Few studies have been published on the kinetics of kava preparations or isolated compounds in humans.

Herbal preparations

Following ingestion of 1 L of kava beverage (prepared by the traditional method of aqueous extraction 450 g pulverised kava rhizome was immersed in 3 L water at room temperature) by healthy male subjects seven major, and several minor kavalactones were identified in human urine. Kavain, dihydrokavain, desmethoxyyangonin, tetrahydroyangonin, dihydromethysticin, 11-
methoxytetrahydroyangonin, yangonin, methysticin and dehydromethysticin were detected unchanged in human urine; metabolic transformations observed included reduction of the 3,4-double bond and/or demethylation of the 4-methoxyl group of the kavalactone ring. The C12 hydroxyanalogue of yangonin (12-hydroxy-12-desmethoxyyangonin) was also detected, and it may have been formed by demethylation of yangonin and/or C12 hydroxylation of desmethoxyyangonin. In contrast to metabolism in rats, no dihydroxylated metabolites of the kavalactones or products from ring opening of the 2-pyrene ring system, were identified in human urine (Duffield et al., 1989a)

Zou et al. (2005) identified a pyrone ring-opened product, 6-phenyl-3-hexen-2-one, a proposed metabolite of kava, as its mercapturic acid adduct, in urinary samples from two kava drinkers. This metabolite was possibly formed from enzymatic demethylation of 7,8-dihydromethysticin, followed by ring opening of the α-pyrene ring, and rearrangement.

11,12- Dihydroxy-7,8-dihydrokavain-o-quinone and 11,12-dihydroxykavain-o-quinone, two electrophilic metabolites, were identified as glutathione conjugates when kava extract was incubated with human liver microsomes, but not in the urine of a human volunteer. Instead, the glucuronic acid and sulfate conjugates of these two urinary metabolites were detected in a human volunteer who ingested a single dose of a dietary supplement containing kava extract (about 90 mg of kavalactones) (Johnson et al., 2003)

Isolated compounds

After a single oral dose of 200 mg D,L-kavain in humans, approx. 80% is absorbed, of which up to 98% is metabolized, mainly to more hydrophilic p-hydroxykavain, on first pass through the liver. Maximum plasma levels of p-hydroxykavain sulfate conjugate (50 ng/ml) and kavain (18 ng/ml) are obtained within 1.7-1.8 hours. The elimination half-life of p-hydroxykavain sulfate is about 29 hours, while elimination of kavain shows a biphasic pattern with half-lives of 50 min for the first phase and approx. 9 hours for the second (Hansel & Woelk, 1995).

Ten urinary metabolites were identified when synthetic D,L-kavain was given to five healthy volunteers as an oral dose of 200 mg. The major metabolite was a hydroxy-dihydrokavain. Hydroxylation of the phenyl ring, reduction of the 7,8 double bond, hydroxylation of the lactone ring with subsequent dehydration, and opening of the lactone ring appeared to be the main metabolic pathways. The metabolites were mainly excreted in the form of their conjugates (Köppel & Tenczer, 1991).

Tarbah et al. (2003) studied kinetics after administration of a single oral dose of 800 mg kavain in a self-medication study. The main metabolite of kavain is p-hydroxykavain, which was found in serum and urine in its free (~ 10% in serum) and conjugated forms (glucuronide and sulfate). Further metabolism takes place to p-hydroxy-7,8-dihydrokavain, which was only detected in urine in form of its conjugates. Opening of the lactone ring, demethylation, decarboxylation and oxidation leads to 6-phenyl-5-hexene-2,4-dione which was detected in urine after 24 h. Kavain is furthermore dehydrated to form 5,6-dehydrokavain. The latter molecule is hydroxylated and demethylated to desmethylhydroxy-5,6-dehydrokavain. Serum concentrations within 1-4 h after oral uptake ranged between 40 and 10 ng/mL for kavain, 300 and 125 ng/mL for p-hydroxykavain, and 90 and 40 ng/mL for o-desmethyl-hydroxy-5,6-dehydrokavain. The major metabolite p-hydroxykavain appears in serum in free and conjugated forms with a lag time of 0.25 h and peaks after 0.75 h. The half-lives of free and conjugated forms range between 0.7 and 1.9 h indicating that kavain metabolites can be found up to 10 h in serum samples.

Enzyme interactions

Several studies have shown that kavalactones are potent inhibitors but also inducers of CYP 450 isoforms (Mathews et al., 2002; Unger et al., 2002; Zou et al., 2002).
Mathews et al. (2002) tested one kava extract (KavaPure Kava PE 40%, no further detail), as well as individual kavalactones that were isolated from kava, for their potential to inhibit various CYP enzymes in vitro using human liver microsomes. Kava extract normalized to a concentration of 100 µM showed statistically significant CYP2C9 (92% compared with control), 2C19 (86%), 3A4 (78%), 2D6 (73%), 4A9/11 (65%) and 1A2 (56%) inhibition (p<0.001 for all CYPs). Lower kava concentrations (10 µM) were still significantly inhibitory towards the various CYPs, but the enzymes where inhibited to a lesser extent: CYP2C9 (53%, p<0.001), 2C19 (30%, p<0.01), 3A4 (42%, p<0.001), 2D6 (22%, p<0.01) and 1A2 (36%, p<0.01). To further investigate the inhibitory effects of the individual kavalactones, 10 µM concentration of each component was used. Kavain did not inhibit any of the enzymes, but there was significant inhibition of CYP2C9 by desmethoxyyangonin (42%, p<0.001), methysticin (58%, p<0.001) and dihydromethysticin (69%, p<0.001); of 2C19 by dihydromethysticin (76%, p<0.001); of 3A4 by desmethoxyyangonin (40%, p<0.001), methysticin (27%, p<0.01) and dihydromethysticin (54%, p<0.001); and of 2D6 by methysticin (44%, p<0.001).

Unger et al. (2002) tested several fractions with different polarity from a crude ethyl acetate extract of kava kava root powder (1 mg/ml) for CYP3A4 inhibitory effects. A significant inhibition (~80%) of CYP3A4 was observed with the methanolic fractions (50/75/100% methanol) and the acetone (~78%) and ethyl acetate (~70%) fractions. Further fractionation and analysis with liquid chromatography/electrospray ionisation–mass spectrometry identified the kavalactones kavain, dihydrokavain, methysticin, dihydromethysticin and dihydroyangonin as the main inhibitory principles. However no information on kavalactone inhibitory concentrations (such as IC50 values) was reported, therefore it is difficult to evaluate the results critically.

Zou et al. (2002) investigated the influence of the isolated kavalactones kavain, dihydrokavain, methysticin, dihydromethysticin, yangonin and desmethoxyyangonin on recombinant human CYP isoforms and calculated IC50 values from the mean of four determinations for the most potent inhibitory active compounds. Desmethoxyyangonin inhibited CYP1A2 (IC50=1.7 µM), CYP2C9 (IC50=50.12 µM), CYP2C19 (IC50=0.51 µM) and CYP3A4 (IC50=20.02 µM); dihydromethysticin inhibited CYP1A2 (IC50=14.8 µM), CYP2C9 (IC50=13.35 µM), CYP2C19 (IC50=0.43 µM), CYP2D6 (IC50=37.03 µM) and CYP3A4 (IC50=2.49 µM); kavain inhibited CYP1A2 (IC50=44.66 µM), CYP2C9 (IC50=128.30 µM), CYP2C19 (IC50=4.86 µM) and CYP3A4 (IC50=34.48 µM) and dihydrokavain inhibited CYP2C9 (IC50=130.95 µM), CYP2C19 (IC50=10.05 µM) and CYP3A4 (IC50=78.59 µM). Yangonin could not be evaluated for its CYP inhibitory effect using the fluorimetric assay employed due to its high native fluorescence. Kavain, methysticin, dihydromethysticin and desmethoxyyangonin were even more potent inhibitors of the isoform CYP2C19 than the positive control (tranylcypromine, IC50 =5.46 µM) used in the assay.

Ma et al. (2004) reported that isolated desmethoxyyangonin and dihydromethysticin of markedly induced the expression of CYP3A23 in rat hepatocytes. The maximum induction was ~8 fold and occurred at either 50 µM (dihydromethysticin) or 100 µM (desmethoxyyangonin). In contrast, no induction was detected with kavain even at 100 µM.

4.2. Clinical efficacy

4.2.1. Dose response studies

No data available.

4.2.2. Clinical studies (case studies and clinical trials)

a) Herbal substance
No data.

**b) Herbal preparations**

**Cognitive performance**

**Acetone-water extract**

The effects of oxazepam and an acetone-water kava extract (WS 1490, containing 70% kavalactones), were investigated for reaction time and event-related potentials (ERPs) in a visual search paradigm on 12 healthy young males (age: 24–37) using a double-blind design. Three types of medication were administered: placebo, 3 x 200 kava extract mg/day for 5 days, and oxazepam 1 x 15 mg on the day before testing, 75 mg on the morning of the experimental day. Participants took one capsule three times daily for five days prior to the experimental session. Significant effects were obtained with oxazepam in a number of psychometric tests as well as search time and quality. Several ERP components of different latency, topography and functional significance were affected by the medication. Oxazepam led to a reduction of the amplitude of the parietal N1, frontal N2, posterior contralateral N2, and occipital P3 components. Kava extract was associated with a greater posterior N1, posterior contralateral N2, and occipital P3. The authors value those findings as evidence of a positive effect of kava extract on the allocation of attention and processing capacity (Heinze et al., 1994)

Twelve healthy volunteers were tested in a double blind, cross-over study to assess the effect of oxazepam (15 mg on the day before testing and 75 mg on the morning of experimental day), of an acetone-water kava extract (WS 1490; 3 x 200 mg per day for 5 days) or placebo, on behaviour and event-related potentials (ERPs) in a recognition memory task. The subject's task was to identify within a list of visually presented words those that were shown for the first time and those that were being repeated. The repeated words were associated with an increased positivity beginning approximately 250 ms post stimulus. Oxazepam led to a reduction of a negative component in the 250 – 500 ms range for both old and new words and to a reduction of the old/new difference in the ERP associated with a significantly worse recognition rate. Kava on the other hand showed a slightly increased recognition rate and a larger ERP difference between old and new words. The authors summarise that hypotheses about the mechanisms of action of the two drugs can be derived from the ERP patterns, suggesting a deficiency in the generation of an internal code for the word stimuli in the case of oxazepam and an influence on later stages possibly related to conscious recollection in the case of kava (Münte et al., 1993)

**Aqueous extract**

The effects of kava -kava on alertness and speed of access to information from long-term memory were investigated in a single-blind study using letter-match task; two groups, each consisting of 9 caucasian(5 male) undergraduates, completed two identical experimental sessions 2-6 days apart. The no-kava group consumed no kava prior to either session. The low-dose kava group drank a 250-ml of aqueous preparation of kava (30 g of kava root powder soaked in water, then filtered) 30 min prior to testing on the second occasion. An additional group of 9 caucasian(5 male) consumed a 500-ml aqueous preparation of kava (made up to a strength of 1 g/kg body weight) 1 h prior to the test. Kava aqueous preparation was found to have no discernible effect on cognitive performance (Russell et al., 1987)

**Other extracts**

A preliminary study involving 20 healthy individuals assessed the effects of a single dose of 300 mg kava extract (containing 30% kavalactones; no further detail) on cognitive performance and mood in a randomised, double-blind, placebo controlled trial. Cognitive performance was examined with the
Sperling partial report and the Sternberg item recognition task, which were used as an index for visual attention and short-term memory processing. The intake of Kava extract led to an increase in state cheerfulness, while the phytopharmacon did not influence state seriousness and bad mood. The mood-elevating effects of Kava were most prominent in trait cheerful subjects, indicating that trait cheerfulness moderated the drug-induced increase in cheerful mood. Furthermore, Kava improved the accuracy and the speed of performing the partial report and the item recognition task, indicative of a beneficial effect of the phytopharmacon on visual attention and short-term memory retrieval, respectively (Thomson et al., 2004)

**Vigilance**

**Acetone-water extract**

A single blind pilot study with healthy volunteers (2 male, 4 female, age: 24 – 47) was carried out in order to determine the neurophysiologic efficacy (quantitative EEG, evoked potentials) and the effects of the kava acetone-water extract WS 1490 on emotional and general variables concerning personality, on the subjective state as well as on various cognitive parameters. The volunteers received 300 mg or 600 mg/day WS 1490 extract for one week. The quantitative EEG showed an increase in the β-/α-index typical for the pharmaco-EEG profile of anxiolytics. The increase in the β-activity was most pronounced in the β2-range. Kava extract showed no sedative-hypnotic effects after administration of 600 mg. The results of the evoked potential studies indicate that information processing may be improved in the cortical areas studied, i.e., vigilance is increased. These findings correlate with the results of the psychometric tests, which indicate increased activity and an improvement in emotional stability (Johnson et al., 1991).

**Ethanolic extract**

In a double-blind, 3-fold crossover study 12 healthy volunteers received single doses of either an ethanolic extract (containing 120 mg kavapyrones) or 10 mg diazepam or placebo. All tests were done immediately before as well as 2 and 6 hours after administration of the preparations. The washout period between cross-over was seven days. After administration of kava extract and diazepam the EEG showed an increase in the relative intensity of slow waves, which was recorded in the occipital area for both preparations, and in the frontal area only for kava extract. Maximum effects were often recorded 2 hours after administration of diazepam. However, the kava preparation, showed the most distinct effects after 6 hours. A benzodiazepine-specific increase in beta-activity was not recorded for the kava preparation. During the observation period the placebo group showed a time-dependent decrease of the relative intensity in the zone of the alpha-waves. The marked beta-activity in the diazepam group is the result of frequent significant differences between the two test preparations. In psychophysiological tests the critical flicker frequency was more distinctly reduced by kava extract and diazepam than by placebo. As opposed to these results, the volunteers showed significantly better results in the mental performance test-PAULI test (p < 0.001), the simple reaction time test and the complex multiple-choice reaction test 2 hours after administration of kava-extract (p < 0.01). For diazepam and placebo an improvement of performance could not be statistically proven (Gessner et al., 1994).

**Isolated compound (kavain)**

In a double-blind, placebo-controlled study the encephalotropic and psychotropic effects of d,l-kavain (synthetic), as compared with clobazam, were investigated, utilising EEG brain mapping as well as psychometric and psychophysiological analyses. 15 healthy volunteers received randomised single oral doses of placebo, 200, 400 or 600 mg d,l kavain as well as 30 mg clobazam as reference compound at weekly intervals. EEG recordings, psychometric tests, evaluations of pulse, blood pressure and side effects were carried out at the hours 0, 1, 2, 4, 6, and 8. Brain maps of drug induced pharmaco-EEG
changes (pharmaco-EEG maps) demonstrated that kavain exerted a significant action on the human brain function as compared with placebo characterised by a dose-dependent increase of delta, theta and alpha 1 activity, while alpha 2, beta activity and the centroid of the total activity decreased. These findings are indicative of a sedative action, which was, however, in type quite different from that of the 1,5-benzodiazepine. The latter produced a decrease of delta, theta, alpha 1 and alpha 2 and an increase of beta activity while the total centroid was accelerated. Interestingly, 200 mg kavain also induced vigilance promoting effects with a decrease of delta and beta activity and an increase of alpha activity and total power. Psychometric tests also demonstrated clear differences between the two compounds on behaviour. Compared with placebo kavain at all three dosages significantly improved in intellectual performance (PAULI test), attention, concentration, reaction time and motor speed (rigidity test), while opposite findings were observed after 30 mg clobazam. In regard to thymopsychic variables such as drive, wakefulness, affectivity, mood, well-being, 200 mg kavain produced an improvement when compared to placebo while 600 mg kavain produced sedation, as did 30 mg clobazam. Psychophysiological tests resulted in only minimal results. Topographically, most encephalotropic effects after administration of kavain were found in the frontal area, after administration of clobazam in the central and parietal areas (Saletu et al., 1989).

Sleeping pattern

In a single-blind study was examined the influence of the acetone-water kava extract WS 1490 on sleep quality in healthy volunteers versus placebo. Two groups with 6 volunteers each received either 150 mf or 300 mg kava extract or placebo. A polygraphic sleep-EEG was recorded on nights and the quality of sleep and the subjective state were recorded daily in a questionnaire. After 150 mg or 300 mg kava extract the amount of sleep spindles and the percentage of deep sleep increased, REM-sleep did not change, sleep stage 1 and sleep latency tended to decrease. The subjective sleeping time increased. The authors conclude that the kava extract WS 1490 might have an effect similar to chemical tranquillizers concerning spindle denseness in the sleep-EEG. Furthermore, kava extract positively influences sleep in general, mainly by increasing slow wave sleep (while REM sleep remains unchanged) and decreasing sleep latency (Emser et al., 1991).

Sedative effects

Two multiple crossover studies were performed with 12 healthy female volunteers (mean age 53.7 years) to screen for acute sedative effects by quantitative EEG analysis after a single oral dose of 600 mg of a kava extract(DER 12-5:1; solvent of extraction- not known). An increase in power of both the theta and slow alpha bands was noted 2 hours after administration. The increase in theta power was still present 3 hours after administration, while fronto-centrally a decrease in power was evident in the high frequency beta 3 band. Although the quantitative EEG can indicate drug-induced CNS changes, is not easy to conclude whether such changes are valid predictors of sedation or anxiolysis (Schultz et al., 1999).

Clinical trials

Clinical trials with kava preparations have focused on the use as treatment option for anxiety disorders, mainly generalised anxiety (GAD). Several other trials have assessed effects of isolated compounds, as kavain.

a. General anxiety, nervousness and restlessness

Since many years preparations from kava are discussed and used as treatment option for anxiety disorders, mainly generalised anxiety(GAD).
Definition:

Generalized anxiety disorder (GAD) is an anxiety disorder characterized by excessive, uncontrollable and often irrational worry, that is, apprehensive expectation about events or activities. The diagnostic criteria for GAD is defined either by the Diagnostic and Statistical Manual of Mental Disorders DSM-5 (2013) or by ICD-10 criteria (F 41.1).

Guideline concerning the clinical investigation of medicinal products indicated for generalised anxiety disorder exists (e.g. CPMP/EWP/4284/02). The efficacy is assessed by rating scales as primary endpoints. The Hamilton anxiety rating scale (HAMA) is a widely used, though not optimal scale. The total scale can be used as primary endpoint, whereas the HAM-A psychic anxiety factor may be useful as a secondary endpoint. Other scales could be used provided that they are appropriate and validated (e.g. GAD-7 scale). Improvement of symptomatology should be documented as a difference between baseline and post-treatment score, but should also be expressed as the proportion of responders and/or remission. Responders are defined as patients with a clinical relevant reduction from baseline on the primary outcome scale. Remission is defined as a condition where no or only few signs of illness remain. The cut-off on a validated rating scale has to be defined in the protocol and should be justified (for response and for remission). Secondary endpoints might be Global assessment (e.g. a score of 1 or 2 on the Clinical Global Impression Scale of Global Improvement). Other scales with a well-established efficiency, as Sheehan disability scale, may also be used as secondary endpoints. Other supportive efficacy criteria: Changes from baseline for the HAMA psychic and somatic anxiety factors; CGI- Severity of Illness; QoL - may be used when validated for the patient population.

To evaluate the efficacy at least 8-weeks are required for short term use, while 6-12 months are required for long term use.

**Placebo studies**

**Ethanolic extract**

Connor et al., 2002 assessed in a randomised, double-blinded, placebo trial the efficacy and safety of ethanolic extract (no further data) in treating generalized anxiety disorder (GAD). 38 adults (31 female, 7 male; aged 31-75 years, mean 52 years) meeting DSM-IV criteria for GAD and having HAMA score > 16 were randomly assigned, following a 1-week placebo run-in, to 4 weeks of treatment with kava ethanolic extract (n=19) corresponding to 2 x 70 mg of kavalactones daily in the first week and dose 2: 2 x 140 mg of kavalactones daily for the last 3 weeks or a matching placebo (n=19). Weekly efficacy assessments [Hamilton Anxiety Rating Scale (HAMA), Hospital Anxiety and Depression Scale (HADS), Self Assessment of Resilience and Anxiety (SARA)] and safety evaluations (side effects, withdrawal symptoms) were conducted. Improvements were observed with both treatments, with response rates (> 50% reduction in baseline HAMA score) of 35% and 50% respectively, but no differences were found in the primary outcomes. Post-hoc analyses revealed significant differences based on baseline anxiety severity, whereby kava was superior on the SARA in low anxiety and placebo was superior on the HADS and SARA in high anxiety.

Safety: both treatments were well tolerated (no evidence of withdrawal or sexual side effects). Three subjects treated with kava experienced slight elevations in ALT, compared with no subjects in the placebo group, but these changes were not clinically significant. Side effects reported in kava group: diarrhea (2 cases), dry mouth (2 cases), rash (2 cases), nausea (2 cases); in placebo group: headaches, heart pounding, swelling, trembling (2 cases or each side effect).

**Comments:** no differences between verum and placebo; The authors concluded that further studies are needed.
**Acetonic extract**

The efficacy and tolerability of Kava extract WS®1490 (DER 11–20 :1; extraction solvent: acetone 75% in water) were investigated by Gastpar et al. (2003) in a randomized, placebo-controlled, double-blind multicenter study in patients suffering from neurotic anxiety (DSM-III-R diagnoses 300.02, 300.22, 300.23, 300.29, or 309.24). 141 adults, male and female out-patients received 150 mg/day kava-extract (corresponding to 105 kavalactones; n=71) or placebo(n=70) for four weeks, followed by two weeks of observation without study-specific treatment. The primary outcome measure for treatment efficacy was the average total score of the Anxiety Status Inventory (ASI) at the end of randomized treatment (week 4). 14 (9 in the verum group and 5 in the placebo group) were withdrawn from the study, but in 6 of these patients premature termination was unrelated to the investigational treatment. Without baseline correction, the ASI total score means (with 95% confidence interval) at treatment end were 39.0 (36.6; 41.3) points for verum and 40.6 (38.3; 43.0) points for placebo. The U-test for the difference between the treatment groups was not significant (p > 0.05). But an exploratory analysis of variance across the differences between treatment end and baseline, with center as a second factor, showed superiority of the verum over placebo(p < 0.01, two-sided). 73% of the patients treated with verum exhibited ASI score decreases >5 points versus baseline, compared to 56% for placebo. Significant advantages for verum were also evident in a structured well-being self-rating scale (Bf-S) and the Clinical Global Impressions (CGI), while the Erlangen Anxiety, Tension and Aggression Scale (EAAS) and the Brief Test of Personality Structure (KEPS) showed only minor treatment group differences.

**Safety:** Neither physical examination nor vital signs assessment indicated any adverse effects. The same applied to the results of the safety laboratory examination (liver function tests in particular- GOT, GPT, γ-GT, alkaline phosphatase) where no systematic or individual changes towards abnormal values were observed.

**Points of criticism: mixed anxiety population correlated with the short duration of the trial and too short follow-up phase limit the conclusions that can be drawn from this report.**

In a randomized, placebo-controlled, double-blind outpatient trial the efficacy and safety of kava extract WS®1490* was investigated for 4 weeks in 50 patients (39 women and 11 men); aged 51–90 years (mean age 76 years) suffering from non-psychotic anxiety (Geier et al., 2004). During the treatment patients received 150 mg (3 x 50 mg) kava extract (standardized to 70 % of kavalactone; n=25) or placebo(n=25). Treatment period as followed by a two week safety observation period. Inclusion criteria were the presence of non-psychotic anxiety (according to the DSM-III-R criteria agoraphobia, specific phobia, GAD and adjustment disorder with anxiety), a HAMA total score of at least 18 and a minimum score of 12 in the multiple choice vocabulary test (MWT-B). Primary outcome criteria were the HAMA total score which was determined upon inclusion in the one-week run-in phase (without study medication), at the start of the treatment and after 2, 3 and 4 weeks of the treatment. Secondary efficacy variables were the HAMA subscales with the dimensions 'somatic' and 'psychic anxiety', the Erlanger anxiety, tension and aggression scale (EAAS) and CGI. For the primary outcome variable and the intention to treat analysis, a tendency of superiority over the course of treatment was observed with verum (p = 0.1). Due to the erroneous inclusion of 5 patients (with a total HAMA score of less than 18) and 3 very early dropouts in verum, a per protocol analysis was performed. In this analysis a statistically and clinical relevant advantage of 4.7 points in favor of the kava treatment was observed after 4 weeks (p = 0.03).
For the HAMA subscales “somatic anxiety” and psychic anxiety a statistically significant advantage of verum was also detectable (p = 0.03 and 0.04). For the further secondary outcome variables a trend in favor of the kava extract was observed, but none of them reached significance. But on item I (severity of illness) of the Clinical Global Impression (CGI) scale the number of patients graded as “at least markedly ill” was twice as high (p = 0.08, chi-square test) in the placebo group (12 out of 21 patients) compared to the verum group (6 out of 22 patients), at the end of the treatment. At the beginning of treatment in both groups 16 out of 25 patients had been rated “at least markedly ill”. No adverse events related to the study medication were observed and none of the patients showed withdrawal symptoms during follow up phase.

* the extract is not characterized, but is known that WS®1490 extract has a DER 11–20:1 and extraction solvent: acetone-water

<table>
<thead>
<tr>
<th></th>
<th>Intention-to-treat analysis</th>
<th>Per-protocol analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>WS 1490 (n = 25)</td>
<td>Placebo (n = 25)</td>
</tr>
<tr>
<td>Before treatment</td>
<td>25.6 (21.6; 29.5)</td>
<td>27.6 (23.8; 31.5)</td>
</tr>
<tr>
<td>After 2 weeks of treatment</td>
<td>18.8 (14.8; 22.8)</td>
<td>21.0 (17.3; 24.7)</td>
</tr>
<tr>
<td>After 4 weeks of treatment</td>
<td>14.8 (10.5; 19.1)</td>
<td>16.8 (13.3; 20.4)</td>
</tr>
</tbody>
</table>

* Two-tailed.
Mean of HAMA total score with 95% confidence interval for the intention-to-treat and the per-protocol analysis respectively.

Comments: the errors observed by the authors including a higher HAMA score of the placebo group at baseline, differences between groups in previous medication (the number of patients receiving centrally active substances before the start of the study was twice as high in the active treatment group), inclusion of patients with HAMA > 18 limit the conclusions that can be drawn from this report.

In a multicenter, randomized, placebo-controlled, double-center trial Lehrl (2002) investigated the efficacy and safety of kava special extract WS 1490 in 61 patients with sleep disturbances associated with anxiety and restlessness states of non-psychotic origin. The patients included were diagnosed with GAD, agoraphobia, social phobia or adaptation disorders (according to the DSM-III-R: 300.02, 300.03, 300.29, 309.24), with a total score on HAMA of not less than 15 points and at least 2 points on HAMA item “insomnia”. The patients received 200 mg of kava extract (corresponding to 140 mg of kava lactones), or placebo (n=23) once a day for 4 weeks. Main outcome measures were the SF-B, the HAMA scale, the Bf-S self-rating scale of well-being and the CGI scale. Double-blind treatment was followed by a 2 weeks of phase without study medication. The confirmatory analysis of the two primary efficacy variables, the differences of sleep questionnaire SF-B sub-scores ‘Quality of sleep’ and ‘Recoverability effect after sleep’ after 4 weeks of double-blind treatment compared to baseline, demonstrated statistically significant group differences in favor of verum group (p= 0.007 and p= 0.018, respectively). Superior effects of kava extract were also present in the HAMA psychic anxiety sub-score (P= 0.002). More pronounced effects with respect to Bf-S and CGI also indicated superior therapeutic efficacy of kava extract.
Comments: even that statistically significant group differences in favor of verum group were calculated for the sub-scores 'quality of sleep' and 'recuperative effect after sleep' the confidence intervals are overlapping, therefore only a minor plausibility for the determined significance can be found in the given information. This should be correlated with other weaknesses of the study, such as mixed anxiety population and the short duration of the trial.

In a randomised double-blind study (Bhate et al., 1989), 56 hospitalized patients (aged 25-81 years) undergoing surgery under epidural anaesthesia were premedicated at 9.00 pm on the evening before the operation and again 1 hour before operation with 300 mg kava extract (no further detail) corresponding to 60 mg kavalactones (n=28) or placebo (n=28). Assessments were made on sleep quality, psychological status, blood pressure and pulse rate, evaluation of the course of narcosis, postoperative blood pressure and pulse, and patients’ questioning (anxiety scale). By dividing the patients into four groups with a planned operation duration of a) less than 40 min, b) 40 – 80 min, c) 80 – 120 min, and d) more than 120 min, verum and placebo turned out to have nearly the same good results in the first group. In the second and third group, the kava extract proved to be of doubtless advantage compared to placebo. Anxiety was significantly reduced (p < 0.05) In the fourth group the results were nearly equally.

Comments: the results are of dubious clinical relevance due to the brief duration of treatment (2 doses) and the nature of the results (nonstandard scoring scale, relatively small differences between the treatment groups); the extract is not fully characterised (DER, extraction solvent)

Neuhaus et al.(2000) examined in a randomized, placebo controlled, doubleblind study the anxiolytic effect of an ethanolic dry extract (150 mg extract is standardized to 47.5 -52.5 mg kavalactones) in 20 women with acute anxiety concerning suspected breast cancer. The patients were treated eather with kava -kava extract with 3 x 50 mg/day, orally for 7 days or placebo. The outcomes investigated were: two self-rating scales (State trait anxiety scale and 60 item characteristic word list) and one observed-rated scale (State trait anxiety inventory). Tests were conducted before and after 3 and 7 days. A significant reduction of anxiety compared with placebo was seen after 7 days, based on combined scores from the rating scales mentioned above. In addition a significant increase was noted in alertness and a lessening of fatigue, introverted behavior and excitability as well a reduction in levels of depression under kava treatment over the observation period. In none of the cases examined did any undesirable side effect occur.

* Points of criticism: diagnosis is different from GAD, small groups correlated with the short duration of the trial and no follow-up phase limit the conclusions that can be drawn from this report; the extract is not fully characterised (DER, extraction solvent)
Placebo reference controlled studies

Connor et al. (2006) analyzed the efficacy and safety of kava ethanolic extract in GAD. Data were analyzed from three randomized, double-blind, placebo-controlled trials of kava, including one study with an active comparator (venlafaxine), in adult outpatients with DSM-IV GAD. The first trial was a 4-week evaluation of kava vs placebo in patients who fulfilled DSM-IV criteria for GAD, using a modified duration requirement of 1 month (Connor et al., 2002) and with a minimum baseline HAMA score of 16.

A second trial was conducted using similar entry criteria, including patients with milder anxiety symptoms (baseline HAM-A score of 12–20). The third study was a randomized trial of patients meeting DSM-IV criteria for GAD (including minimum symptom duration of 6 months) of moderate severity (minimum baseline HAM-A score of 18) who were randomized to 8 weeks of treatment with Kava, venlafaxine-XR, or placebo. The pooled sample (n=64) included the following number of participants: kava, n=28; placebo, n=30; and venlafaxine, n=6. Study medication used in the first two trials was identical and a corresponded product was used for the third study. The dose in each trial was initiated at 140 mg kavalactones (KAV) per day (70 mg kavalactones twice daily) for 1 week and then increased to 280 mg kavalactones per day (140 mg kavalactones twice daily). In the third trial, a double-dummy design was employed, with placebo (PBO) matched for kava and for venlafaxine-XR (VEN), with the dose of venlafaxine-XR started at 37.5 mg/day and titrated to a maximum daily dose of 225 mg. Clinical assessments were virtually identical in the three studies and included the HAM-A Scale, the Hospital Anxiety and Depression Scale (HADS) and the Sheehan Disability Inventory (SDI).

Safety assessments conducted in each trial included liver function tests, which were performed at screening and at the completion of treatment. Given the comparability of the study designs, the data comparing kava and placebo were then pooled for further efficacy and safety analyses. No significant differences were observed between the treatment groups in any of the trials. In the pooled analyses, no effects were found for kava, while a significant effect in favor of placebo was observed in participants with higher anxiety at baseline.

Individual studies: In study 1, a significant effect was observed in favor of placebo on the SDI (P<0.03). In study 2, a trend was found in favor of KAV on the HAM-A (P=0.05). No other differences were observed between the treatment groups on any of the other continuous outcome measures or in the rates of treatment response, which were as follows: KAV, 0–50%; PBO, 29–60%; and VEN, 50%.

Further, no treatment differences were noted in terms of remission rates, which were as follows: study 1, KAV 24% (n=4), PBO 22% (n=4); study 2, KAV 50% (n=3), PBO 29% (n=2); and study 3, KAV 0% (n=0), PBO 0% (n=0), and VEN 33% (n=2).

### Table 2: Symptom severity on outcome measures before and after treatment by study and treatment group (median Q1, Q3)

<table>
<thead>
<tr>
<th>Study</th>
<th>HAM-A</th>
<th>PBO</th>
<th>KAV</th>
<th>PBO</th>
<th>KAV</th>
<th>PBO</th>
<th>KAV</th>
<th>PBO</th>
<th>KAV</th>
<th>PBO</th>
</tr>
</thead>
<tbody>
<tr>
<td>Before</td>
<td>21 (18, 21)</td>
<td>18 (16, 21)</td>
<td>17 (16, 18)</td>
<td>14 (13, 20)</td>
<td>32 (24, 34)</td>
<td>24 (20, 28)</td>
<td>29 (28, 32)</td>
<td>20.5 (18, 22)</td>
<td>18 (16, 21)</td>
<td></td>
</tr>
<tr>
<td>After</td>
<td>13 (9, 21)</td>
<td>10 (8, 13)</td>
<td>7.5 (3, 12)</td>
<td>10 (4, 17)</td>
<td>20 (20, 26)</td>
<td>12 (10, 20)</td>
<td>16 (16, 22)</td>
<td>13.5 (10, 20.5)</td>
<td>10 (8, 14)</td>
<td></td>
</tr>
<tr>
<td>HADS</td>
<td>171 (17)</td>
<td>181 (18)</td>
<td>161 (14, 19)</td>
<td>15 (14, 20)</td>
<td>21 (18, 23)</td>
<td>14 (11, 16)</td>
<td>17.5 (16, 19)</td>
<td>17 (14, 21)</td>
<td>16 (12, 17)</td>
<td></td>
</tr>
<tr>
<td>SDI</td>
<td>17 (12, 19)</td>
<td>16 (12, 20)</td>
<td>18 (14, 19)</td>
<td>15 (14, 20)</td>
<td>21 (18, 23)</td>
<td>14 (11, 16)</td>
<td>17.5 (16, 19)</td>
<td>17 (14, 21)</td>
<td>16 (12, 17)</td>
<td></td>
</tr>
<tr>
<td>Before</td>
<td>10 (5, 13)</td>
<td>12 (9, 17)</td>
<td>5 (0, 12)</td>
<td>14 (5, 15)</td>
<td>8 (7, 18)</td>
<td>1 (1, 10)</td>
<td>10 (0, 12)</td>
<td>9 (5, 13)</td>
<td>12 (5, 16)</td>
<td></td>
</tr>
<tr>
<td>After</td>
<td>10 (4, 12)</td>
<td>8 (5, 13)</td>
<td>2 (0, 4)</td>
<td>7 (3, 15)</td>
<td>6 (3, 14)</td>
<td>2 (2, 2)</td>
<td>6 (2, 12)</td>
<td>5 (1, 13)</td>
<td>7 (2, 13)</td>
<td></td>
</tr>
</tbody>
</table>

Response rates:<br> n=6, 39%; n=9, 50%; n=3, 50%; n=5, 29%; n=6, 39%; n=3, 50%; n=6, 39%; n=3, 50%; n=6, 39%; n=3, 50%<br> n=6, 39%; n=3, 50%; n=5, 29%; n=6, 39%; n=3, 50%; n=6, 39%; n=3, 50%; n=6, 39%; n=3, 50%.<br>Response: ≥ 50% reduction in HAMA score from baseline.

Pooled sample: Significant effects in favor of placebo were found on the HAM-A (F = 4.45, d.f. 1, P<0.04) and the HADS (F = 4.15, d.f. 1, P<0.05). A significant effect was also observed for study on the HAM-A (F = 15.96, d.f. 2, P<0.0001), and this was explained by the authors by a lower HAM-A entry criterion in study 2. When the groups were compared by baseline anxiety level, a significant treatment by baseline anxiety level interaction was found on both the HADS and the SDI Scales. Tukey's tests
between means showed an effect in favor of placebo in high anxiety on both the HADS and the SDI Scales. Remission rates in the pooled samples were as follows: KAV, 25% (n= 7); PBO 20% (n= 6); and VEN 33% (n= 2) (NS).

<table>
<thead>
<tr>
<th></th>
<th>Kava</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n</td>
<td>Mean (SD)</td>
</tr>
<tr>
<td>HADS*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low anxiety</td>
<td>11</td>
<td>-4.9 (6.0)</td>
</tr>
<tr>
<td>High anxiety</td>
<td>15</td>
<td>0.8 (3.9)</td>
</tr>
<tr>
<td>SDI</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low anxiety</td>
<td>11</td>
<td>-4.6 (3.7)</td>
</tr>
<tr>
<td>High anxiety</td>
<td>15</td>
<td>0.1 (3.7)</td>
</tr>
</tbody>
</table>

| HADS, Hospital Anxiety and Depression Scale; SDI, Sheehan Disability Inventory; low anxiety: baseline HAM-A ≤ 19; high anxiety: baseline HAM-A > 19.  
*Tukey’s test: F=7.70, d.f. 1, 53, P<0.01.  
*Tukey’s test: F=13.20, d.f. 1, 53, P<0.001.

No evidence of hepatotoxicity was found with kava, and all of the treatments were well tolerated.

Authors concluded that findings from these three controlled trials do not support the use of kava in DSM-IV GAD.

Cropley et al. (2002) performed an open, randomised study comparing the effect of valerian root, kava extract and an untreated control group in a pressure situation (psychological stress induced under laboratory conditions in a group of healthy volunteers). 54 students completed the colour/interference test with increasing speed of presentation before and after one week intake of 600 mg of valerian root extract (n=18), or 120 mg of an kava extract LI150* (no further details) (n=18) or no medication. Blood pressure and heart rate were recorded before, during and after the test situation, subjective ratings of pressure before and during the test were documented on a 7-point scale. At the second test, there was a significant decrease in systolic blood pressure responsivity in both the kava and valerian groups relative to first test, but there were no significant reductions in diastolic blood pressure. Between first and second test, the heart rate reaction to mental stress was found to decline in the valerian group but not in the kava group. Individuals taking kava or valerian reported less pressure during the task at second test relative to first test. There were no significant differences in blood pressure, heart rate or subjective reports of in the controls. Behavioural performance on the colour/word task did not change between the groups over the two time points. The results suggest that kava and valerian may be beneficial to health by reducing physiological reactivity during stressful situations. These results lead to the assumption that the kava extract decreases subjective experience of stress (while cognitive performance is not reduced).

Comments: The significance of the trial is decreased by potential biases due to the lack of blinding and absence of a placebo-group.

* LI150 extract is an ethanolic extract but not further detail was provided (DER)

In a randomised clinical study, Mittmann (2000) compared the acute sedative and anxiolytic activity of a viscous ("spissum") kava extract (extraction solvent: ethanol-water; no further detail) with those of benzodiazepines as pre-medication in women (n= 53, average age 68.3 years), waiting to undergo vaginal hysterectomy under regional anaesthesia. After randomisation, pre-medication was performed as follows: on the evening before the operation both groups received 25 mg promethazin p.o., whereby group I (n=27) also received flunitrazepam 1-2 mg p.o., and group II (n=26) 2 capsules of kava extract (corresponding to 100 mg kavalactones). On the morning of the operation both groups
received 0.5-1 mg atropine i.m. (dose corrected to body weight). Group I also received 10 mg diazepam i.m., while group II received kava extract equivalent to 100 mg kavalactones p.o. Factors in the evaluation included extent of anxiety, physician and patient evaluations of medication induced sedation (3-step scale), blood pressure, pulse frequency and blood oxygen saturation values; these were evaluated before and after application, as well as during and after operation. Physician and patient assessment of the anxiety and the quality of medication induced sedation, together with blood pressure, pulse frequency and blood oxygen saturation values showed comparable efficacy between kava extract and benzodiazepines. Significantly higher systolic blood pressures (p=0.029) were recorded in the benzodiazepines group.

Safety: Adverse events of nausea and vomiting were at the same level (5 cases) in both groups but could not be attributed to the medication.

**Comments:** the clinical relevance is limited due to the brief duration of treatment (2 doses combined with other CNS medications such as promethazin), small groups and the nature of the results (non-standard scoring scale)

### Acetonic extract

Malsch & Kieser (2001) conducted a 5-week randomized, placebo-controlled, double-blind trial to investigate the efficacy of kava-kava acetonic extract on non-psychotic nervous anxiety, tension and restlessness states, following pretreatment with benzodiazepines. 40 Patients (25 male, 15 female) suffering from agoraphobia (n=2), simple or social phobia (n=14), GAD (n=12) or adaptation disturbances (n=1) according to the DSM-III-R had been included in this trial. Further inclusion criteria have been a maximum score of 14 in the HAMA scale and a minimum history of 14 days (mean duration 21 months) of uninterrupted treatment with benzodiazepines (lorazepam, bromazepam, alprazolam, or oxazepam) prior to the study inclusion. Study medication was either 50 mg of dried acetonic kava extract (corresponding to 35 mg of kavalactones; no further details) or placebo. During the first week the daily dose was increased from 50 mg (1 capsule) up to 300 mg (3x2 capsules). Simultaneously, the preexisting benzodiazepine treatment was tapered off at a steady rate over the first two weeks of double-blind treatment (at least 50 % reduction at day 7). These three weeks of initial treatment were followed by 3 weeks of anxiolytic treatment with the study medication alone. The treatment was followed by a three-week follow-up-phase, at the end of which the patients were reexamined. Primary outcome measures of the trial were the differences in the overall scores of the Hamilton Anxiety Scale (HAMA) and the "Befindlichkeits-Skala" (Bf-S — subjective well-being scale) and the incidence of benzodiazepine withdrawal symptoms during the double-blind treatment phase. The results of the primary outcome measures showed a clear statistical significant superiority of verum compared to placebo (HAMA: p=0.01; Bf-S: p=0.002) at the end of the study. In the kava-group the HAMA total score improved with a median of 7.5 points between baseline and treatment end, with a beneficial treatment effect already visible after one week. In contrast, no comparable improvement was found in the placebo-group, in which the median HAMA total score varied around baseline level (maximum improvement: 1 point). There were 60% responders(defined as a reduction of the HAMA total score by at least 50%) in the kava-group and 20% in the placebo group. Furthermore, secondary variables measured on the Erlangen Anxiety and Aggression Scale (EAAS) and Clinical Global Impressions Index (CGI) do support the results of the primary outcome measures. After 3 weeks, 14 patients whose HAMA scores had improved while taking kava extract in the 5-week study received placebo; 9 of these patients showed a recurrence of the basic symptoms of anxiety disorder.
Points of criticism: mixed anxiety population, with only mild severity status (HAMA scores between 10-14) correlated with the short duration of the trial and too short follow-up phase limits the conclusions that can be drawn from this report; the extract is not fully characterised (DER, extraction solvent).

In a randomised, placebo-controlled double-blind multicenter study 101 outpatients (average age: 54 years, 74 female, 27 male) suffering from anxiety of non-psychotic origin (DSM-III-R criteria: agoraphobia, specific phobia, generalized anxiety disorder, and adjustment disorder with anxiety) were treated daily for with either 3 x 100 mg of WS 1490 lipophilic extract of kava-kava (no further detail) containing 70 mg kavalactones (n=52) or placebo (n=49) (Volz et al., 1997). The trial duration was 25 weeks after a one-week single-blind placebo washout period. After a 24-week random treatment period, a one-week placebo washout was performed. The following ratings were performed at the beginning of the placebo washout period and at weeks 0, 12, and 24: HAMA scale (main outcome criterion), self-report symptom inventory 90 items - revised (SCL–90–R), CGI, Adjective Mood Scale (Bf-S), and registration of adverse events according to an open, non-leading questionnaire. Additional HAMA ratings and adverse event checks were performed at weeks 4, 8, 16, and 20. The HAMA total score showed a pronounced decrease in both groups. The verum group was superior on all assessment days during the treatment phase. The difference was statistically significant at week 8 (p = 0.02) and increased later in the treatment period (week 12: p = 0.002, weeks 16, 20, 24: p < 0.001). The HAMA sub-scores showed a statistically significant advantage for the verum starting at week 8 (p = 0.02). The GCI also showed a very clear result; the patients treated with verum had a statistically significant advantage over those taking placebo (p = 0.001 after 12 weeks). For the self-rating scales the results are very similar (p < 0.05); in the case of the Bf-S, the result was borderline significant at week 24 (p = 0.08).

<table>
<thead>
<tr>
<th>Week</th>
<th>HAMA Total Score</th>
<th>Placebo</th>
<th>p</th>
<th>SCL-90-R (CGI)</th>
<th>Placebo</th>
<th>p</th>
<th>BF-S Total Score</th>
<th>Placebo</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>30.7 (7.2)</td>
<td>31.4 (9.2)</td>
<td>.98</td>
<td>1.7 (0.6)</td>
<td>1.7 (0.6)</td>
<td>1.00</td>
<td>39.6 (11.0)</td>
<td>40.0 (12.5)</td>
<td>.46</td>
</tr>
<tr>
<td>4</td>
<td>23.3 (9.2)</td>
<td>24.2 (8.6)</td>
<td>.23</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>17.1 (9.1)</td>
<td>20.3 (7.6)</td>
<td>.02</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>13.4 (9.6)</td>
<td>18.0 (9.1)</td>
<td>.002</td>
<td>1.0 (0.6)</td>
<td>1.3 (0.6)</td>
<td>.01</td>
<td>20.5 (15.4)</td>
<td>29.2 (15.4)</td>
<td>.01</td>
</tr>
<tr>
<td>16</td>
<td>10.9 (9.1)</td>
<td>16.4 (9.1)</td>
<td>&lt;.001</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20</td>
<td>9.8 (9.8)</td>
<td>15.5 (9.1)</td>
<td>&lt;.001</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>24</td>
<td>9.7 (9.9)</td>
<td>15.2 (9.6)</td>
<td>&lt;.001</td>
<td>0.7 (0.6)</td>
<td>1.0 (0.6)</td>
<td>.04</td>
<td>16.3 (13.8)</td>
<td>27.5 (15.5)</td>
<td>.08</td>
</tr>
</tbody>
</table>
In a randomized, placebo-controlled, double-blind trial including 58 patients (43 female; 15 male) with anxiety syndrome of non psychotic origin (according to ICD 9) were treated for a period of 4 weeks either with 3 x 100 mg of an WS 1490 dry extract of kava-kava (no further detail), containing 70 mg kavalactones (n=29) or placebo (n=29). Patients included in the trial showed a minimum total score of 18 on the HAMA scale. Outcome measures were examined at the start of the trial (day 1), day 7, 14 and at the end of the study (day 28). The total score of HAMA served as the main outcome measure to prove the effects of the therapies. From the first week on the verum group (mean total score = 16.2/SD = 7.1) showed significantly better results in the reduction of HAMA total scores than the placebo group (mean total score = 21.8/SD = 7.8). The reduction of HAMA total score increased during the treatment up to the end of the trial in the verum-group (mean total score = 12.6/SD = 8.6) while only a slight reduction of HAMA total score was observed in the placebo-group (mean total score = 21/SD = 10.1). The superiority of the kava extract compared to placebo was statistically significant on all three measurement points (p <0.01). Similar results have been observed in the secondary outcome measures, as the subscales of the HAMA (somatic anxiety and psychological anxiety) and the Clinical Global Impression Index (CGI). At the end of the trial 6 Patients (10 %), 4 in the verum-group and 2 in the placebo-group, dropped out without further explanation. During the 4-weeks treatment, the patients had reported no adverse effects (Lehmann et al., 1989).

Reference-controlled studies

Ethanolic extract

Boerner et al. (2003) investigated the effect and safety of Kava-Kava LI 150 (standardised to a content of 30% kavalactones, DER: 13-20:1 extraction solvent: ethanol 96%) in GAD in an 8-week randomized, reference-controlled, double-blind, multi-centre clinical trial. 129 out-patients (107 females, 20 males; age:20-65 years) received either 400 mg Kava LI 150 extract, containing 120 mg kavalactones (n=43), 10 mg Buspirone (n=43) or 100mg Opipramol (n=43) daily for 8 weeks. At week 9, subjects were seen to check for symptoms of withdrawal or relapse. Primary outcome measures comprised the HAMA scale and the proportion of responders at week 8. Secondary measures were the Boerner Anxiety Scale (BOEAS), SAS, CGI, a self-rating scale for well-being (Bf-S), a sleep questionnaire (SF-B), a quality-of-life questionnaire (AL) and global judgments by investigator and patients. The average duration of existing illness was 40 months and 62% of the patients had not previously been treated. After 8 weeks, about 76.7% of patients in kava group, 76.2% in the opipramol group and 73.8% in the buspirone group were classified as responders (defined by a reduction in HAMA score of 50% or to less than 9 points). Drop-out rate in kava group was 5%, while in the comparators group not one patient withdrew; In 127 patients no significant differences could be observed between the three treatments, regarding all seven secondary parameters, including CGI.
Safety assessment: a total number of 57 emergent adverse events have been documented during 8 week treatment, with one serious event occurring in the kava group (panic attack). Regarding laboratory values, slight increases of transaminases to values above the upper limit of normal range was observed in 2 kava patients, three buspirone patients and two opipramol patients.

Table 3. Summary of efficacy measures – 95% confidence intervals of differences of means between treatment groups (ITT population).

<table>
<thead>
<tr>
<th>Measure* (Baseline)</th>
<th>Kava vs. Buspirone (n = 43)</th>
<th>Kava vs. Opipramol (n = 43)</th>
<th>Buspirone vs. Opipramol (n = 42)</th>
<th>p-value**</th>
</tr>
</thead>
<tbody>
<tr>
<td>HAMA (total score)</td>
<td>−3.99 2.43</td>
<td>−4.43 1.58</td>
<td>−3.91 2.62</td>
<td>0.49</td>
</tr>
<tr>
<td>BOEAS (total score)</td>
<td>−2.46 1.93</td>
<td>−1.83 1.82</td>
<td>−1.96 2.48</td>
<td>0.98</td>
</tr>
<tr>
<td>SAS (Index)</td>
<td>−7.61 2.70</td>
<td>−8.21 1.02</td>
<td>−6.39 4.11</td>
<td>0.29</td>
</tr>
<tr>
<td>BF-S (total score)</td>
<td>−7.37 6.85</td>
<td>−8.55 3.70</td>
<td>−8.94 4.61</td>
<td>0.71</td>
</tr>
<tr>
<td>AL (total score)</td>
<td>−12.5 12.3</td>
<td>−16.1 7.6</td>
<td>−17.8 9.6</td>
<td>0.83</td>
</tr>
<tr>
<td>SF-B (factor SQ)</td>
<td>−0.69 0.28</td>
<td>−0.64 0.27</td>
<td>−0.47 0.52</td>
<td>0.50</td>
</tr>
<tr>
<td>(factor GES)</td>
<td>−0.70 0.29</td>
<td>−0.56 0.34</td>
<td>−0.38 0.56</td>
<td>0.68</td>
</tr>
<tr>
<td>(factor PSYA)</td>
<td>−0.70 0.16</td>
<td>−0.54 0.24</td>
<td>−0.30 0.53</td>
<td>0.48</td>
</tr>
<tr>
<td>(factor PSYE)</td>
<td>−0.48 0.19</td>
<td>−0.28 0.36</td>
<td>−0.14 0.52</td>
<td>0.74</td>
</tr>
<tr>
<td>(factor PSS)</td>
<td>−0.32 0.18</td>
<td>−0.38 0.10</td>
<td>−0.31 0.17</td>
<td>0.43</td>
</tr>
</tbody>
</table>

(Week 8)

| CGI (severity)      | −0.45 0.65                  | −0.23 0.86                  | −0.34 0.77                      | 0.57      |
| CGI (improvement)   | −0.43 0.56                  | −0.14 0.80                  | −0.23 0.75                      | 0.34      |
| Global judgement of efficacy (investigator) | −0.42 0.39                | −0.12 0.62                  | −0.16 0.69                      | 0.26      |
| Global judgement of efficacy (patient)      | −0.52 0.31                  | −0.30 0.47                  | −0.23 0.61                      | 0.64      |
| Response yes/no (HAMA reduction >50%)        | –                         | –                           | –                               | 0.95      |
| Remission yes/no (HAMA <9)                    | –                         | –                           | –                               | 0.98      |

* HAMA – Hamilton Anxiety Scale; BOEAS – Boerner Anxiety Scale; SAS – Self-Rating Anxiety Scale; BF-S – Self-Rating Scale for Well-Being according to von Zerssen; SF-B – Self-Rating Sleep Questionnaire; CGI – Clinical Global Impressions
** P-values of Kruskal-Wallis-Test, except for “Response” (Chi-Square-Test)

Table 4. Frequencies of treatment emergent adverse events* during 8-week treatment phase by treatment group.

<table>
<thead>
<tr>
<th>No. of Adverse Events</th>
<th>Kava (n = 43)</th>
<th>Buspirone (n = 42)</th>
<th>Opipramol (n = 42)</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of Patients reporting Adverse Events (%)</td>
<td>27 (65%)</td>
<td>16 (64%)</td>
<td>14 (63%)</td>
</tr>
<tr>
<td>No. of Adverse Events rated to be “probably” related to Medication</td>
<td>11 (24%)</td>
<td>3 (14%)</td>
<td>1 (8%)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Nos. of specific Adverse Events</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common Cold, Pharyngitis, Bronchitis</td>
</tr>
<tr>
<td>Nausea/Emesis</td>
</tr>
<tr>
<td>Diarrhea</td>
</tr>
<tr>
<td>Other Gastro-intestinal disorders</td>
</tr>
<tr>
<td>Weight Changes</td>
</tr>
<tr>
<td>Skin Affections</td>
</tr>
<tr>
<td>Tachycardia</td>
</tr>
<tr>
<td>Sedation</td>
</tr>
<tr>
<td>Others</td>
</tr>
</tbody>
</table>

* Adverse Events that have not been pre-existing at screening or baseline visit

Comments: the dosing regimen of buspirone (10 mg) and opipramol (100 mg) used in the trial would be considered to be sub-therapeutic, given the therapeutic dosing ranges of 15–60 mg/day for buspirone and up to 200 mg/day for opipramol in GAD, therefore the clinical significance of the results reported in this trial is questionable. The comparators used are not the first-line agents in GAD treatment. Moreover, the lack of a placebo arm further limits the conclusions that can be drawn from this report.
Acetonic extract

In a reference-substance-controlled double-blind multicenter study over a period of 6 weeks the efficacy of the kava extract WS 1490 (each capsule contains 100 mg dry acetone-water extract standardized to 70 mg kavalactones; no further detail) on patients with conditions of anxiety, agitation, and tension of non-psychotic origin was compared to that of oxazepam and bromazepam 172 patients (18 – 65 years; both sexes) from 12 medical practices were assigned randomly to three groups. One group received kava extract (3 x 100 mg/daily, n = 57), and the other two groups received either oxazepam (3 x 5 mg/ daily, n = 59) or bromazepam (3 x 3 mg/daily, n = 56). The data was objectified by the HAMA scale and CGI. All three types of treatment led to a significant decrease in anxiety. Statistical comparison of the variables of the three groups respectively did not produce a relevant difference between the three types of treatment with respect to a decrease in anxiety and concomitant variables (comparison of HAMA total score bromazepam / WS 1490 after six weeks: p = 0.0925, oxazepam/WS 1490 after six weeks: p =0.6198). Bromazepam led to a slightly more pronounced decrease in anxiety, but only to a minor extent as compared to the other two groups (Woelk et al., 1993).

Comments: The statistical analysis focused on the degree of differences rather than the demonstration of equivalence; heterogeneous (mixed) anxiety patients included because inclusion criteria were not sufficiently rigorous; the lack of a placebo arm further limits the conclusions that can be drawn from this report; the extract is not fully characterised (DER)

Non-controlled studies

52 outpatients (15 male, 37 female; average age: 49 ± 15) suffering from anxiety of non-psychotic origin with (n=26) or without (n=26) concomitant depression, were included in an open, observational, multicentric study. Patients were treated with capsules of unit dose 100 mg dry ethanolic extract (DER 11.5-21.5:1; extraction solvent: ethanol 96%*), corresponding to 50 mg kavalactones. The dosage varied from 2 to 6 capsules (15 patients received one capsule twice a day; 28 patients were given one capsule three times a day; and 9 patients were asked to take two capsules three times a day) and the mean treatment duration was 51 days. Global improvement was rated on a five-point scale as “slightly worse”, “no change”, “slightly improved”, “much improved” and “very much improved”. Target symptoms of “anxiety”, “tension”, and “restlessness” were rated by physicians on a four-point scale: “not present”, “mild”, “moderate”, and “severe”. On a global five-point improvement scale, 42 patients (80.8 %) rated the treatment as “very good” or “good”. The target symptoms of anxiety, restlessness, and tension all showed a pronounced decrease from baseline. Before therapy, 22 patients (42.3 %) rated their anxiety as “severe”, 16 (30.8 %) as “moderate”, and 7 patients (13.5 %) as “mild”; in 7 patients (13.5 %), no anxiety was present at baseline. At study end, 6 patients (11.5 %) described “moderate” anxiety and 26 patients (50.0 %) “mild” anxiety symptoms. No patient had “severe” anxiety, and 20 patients (38.5 %) did not report any anxiety at all. Before therapy, tension was rated “severe” in 26 patients (50.0 %), “mild” in 2 patients (3.8 %), and non-existent in 6 patients (11.5 %). By the end of the study, no patients had “severe” tension; 8 patients (15.4 %) had “moderate” tension and 29 patients (55.8 %) “mild” tension. In 15 patients (28.9 %), tension was no longer present. Before being treated, 21 patients (40.4 %) had “severe” restlessness, 18 (34.6 %) “moderate”, and 8 patients (15.4 %) “mild” restlessness; in 5 patients (9.6 %), this symptom was not present. By the end of the study, restlessness was “severe” in no patient, “moderate” in 6 patients (11.6 %), “mild” in 28 patients (54.8 %), and non-existent in 18 patients (34.6 %) (Scherer et al., 1998).

* data taken using commercial name of the product used

Comments: The small number of patients and the open design of the study preclude any conclusion on the efficacy and safety of kava-kava extract
1673 patients (average age: 48.84 ± 14.77; 1168 female, 503 male) suffering from anxiety (n=1421) and/or nervousness and restlessness participated in a post-marketing surveillance study and were treated daily with 3 x 133 mg ethanolic kava extract KW1491 (corresponding to 120 mg kavalactones) for a minimum of 4 weeks (Spree et al., 1992). After an average of 15.5 days an intermediate assessment was made followed by the final assessment after an average of 34.5 days. Clear improvements could already be seen at the intermediate assessment (done based on a questionnaire). After the treatment all primary (anxiety, nervous tension, restlessness) and secondary (sleep impairment, exhaustion syndrome, climacteric complaints, muscle tension) symptoms were clearly improved or eliminated. In the category “nervous tension and restlessness” more than 60% of the patients were suffering from severe or very severe complaints. By the final assessment, only 5% of the patients had not improved to “good” or “very good”. Anxiety symptoms decreased in average intensity from 2.33 to 0.74 and nervous symptoms from 2.7 to 0.99. Concerning the anxiety states, 25% of the patients were free of complaints, and more than 50% suffered from only minor ailments. Full effectiveness was reached after an average of 10.98 days, in 38% of patients it was 5 days, in 22% 5–10 days. In 75% of the cases, the efficacy of the treatment with the kava extract was good or very good.

Comments: This post-marketing surveillance is insufficient to prove the efficacy of kava extract as anxiolytic drug.

In a very large, open, multicenter drug-monitoring trial, 4049 patients (average age: 49; 72% female, 28% male) suffering from conditions of nervous anxiety, stress, and restlessness were included (Siegers et al., 1992). The major cause (55% of the cases) of nervous anxiety, stress, and restlessness was “exhaustion syndrome”, followed by “anxious upset” (31%), “loss syndrome” (24%), “climacteric discomforts” (20%) and others (6%). The data of 3873 patients could be analysed. In 70% of the patients only one cause was held responsible for the symptoms, in 25% it was two causes, and in 5% it was more than two causes. They received 150 mg kava extract WS 1490 (containing 105 mg kavalactones) for 6 weeks. Assessments were made before the beginning of the treatment, twice during the trial, and at the end. Assessments were made according to the HAMA scale. By the end of treatment, based on the HAMA the total score of “psychic symptoms” had dropped from 2.54 to 0.79 and the total score for “vegetative symptoms” from 2.13 to 0.62. After the end of the study, symptoms were improved or even non-existent in more than 80% of the cases. The majority of patients (87%) judged their general quality of life improved after the end of the study. 9% felt unchanged, 1.4% evaluated their state of health as slightly worse, and 2.7% did not comment. In about 74% of the cases, physicians rated the efficacy of the kava extract as “good” or “very good”, and as “satisfying” in about 18%. Poor efficacy was seen in only 6% of the cases. 850 patients (192 men and 574 women) suffering from anxiety syndrome were treated daily with 3x100 mg kava extract WS1490 for 4 weeks in an open multicentric study. The instrument of analysis used was the modified HAMA (Neto, 1999). The HAMA overall score dropped from 30 to 9 (a reduction of 70%) after the treatment showing statistical significance (p<0.0001) and efficacy was considered excellent or good by 93.7% of physicians and 86.9% of patients. The tolerability was considered good and very good in 95.8% of patients. Side effects were observed in 16.7% patients, including somnolence (2.7%), nausea (1.8%), epigastralgia (1.1%).

b. Anxiety in the climacteric phase

Controlled placebo studies

There are some placebo-controlled trials and positive-controlled-studies but also open studies that investigated the effect of kava extracts in women with climacteric psychosomatic disturbances.
**Extracts not characterised**

In the first double-blind study, 40 women with climacteric syndrome (primary anxiety and vegetative dysregulation in peri- and post-menopausal phases) were treated with either a placebo (n=20) or 2 x 150 kava extract (corresponding to 2 x 30 mg kavalactones; no further detail) daily, for 12 weeks. At the end of 4 and 8 weeks, assessment using Kuppermann Index (severity of climacteric symptoms) and Anxiety Status Index (rating of anxiety disorders) showed significant improvements (p<0.001) in the verum group, in which 11 patients reduced their daily dose to 1 x 150 mg kava extract in the final weeks of the study (mainly from week 9). Due to a high drop-out rate during week 6-10, primary because of lack of efficacy (2 in the verum group and 14 in the placebo group), statistical comparisons were not reliable after 12 weeks. In the verum group 5 patients reported minor adverse effects such as lowering of vigilance of tiredness in the morning; 2 verum and 3 placebo patients reported gastrointestinal complaints (Warnecke *et al.*, 1990).

**Acetonic extract**

In the second randomized, placebo-controlled double-blind study, 40 women (45 – 60 years) with climacteric-related symptomatology (psychovegetative symptoms as anxiety, restlessness and sleep disorders and psychosomatic symptoms) and HAMA initial score >18 were treated with the kava extract WS 1490 (3 x 100 mg/day, resulting in a daily dosage of 210 mg of kavalactones; no further detail; n=20) or a placebo (n=20) preparation for a period of 8 weeks (Warnecke, 1991). The main outcome- the HAMA overall score – was assessed after 0, 1, 4 and 8 weeks. After 1 week of treatment the average HAMA score in the verum group had decreased by more than 50% (from 31.10 to 14.65) significantly more (p < 0.001) than in the placebo group (decrease from 30.15 to 27.50). The differences widened by the end of week 4 and week 8 (p<0.0005). Other parameters such as depressive status inventory (DSI), the CGI and the climacteric symptomatology (Kuppermann menopause index and Schneider scale) also demonstrated a high level of efficacy of the kava extract over the whole treatment period. The mean score on the DSI decreased significantly from 42.5 to 24.8 (P < 0.01), while the mean score on the Kuppermann Index also decreased significantly from 20.35 to 3.60 (P < 0.01).

Comments: the small number of patients and the lack of follow-up phase preclude any conclusion on the efficacy of kava-kava extract; in addition the extract is not fully characterized (DER, extraction solvent).

To evaluate the efficacy of kava extract (containing 55% of kavain; no further detail) in combination with hormone replacement therapy and to compare it with hormone replacement therapy alone in the treatment of menopausal anxiety, 40 women patients in physiological or surgical menopause with GAD in accordance with DSM-IV criteria (HAMA > 19) were assigned to one of four treatments for 6 months, in a randomized trial (De Leo *et al.*, 2000). Twenty-two of the 40 women were in physiological menopause and 18 in surgical menopause due to benign uterine pathology. The former were randomly assigned to one of the following protocols: HRT-K (n=13): 50 µg/day (17 β-estradiol) with progestogen and 100mg/day kava extract; HRT (n=9): 50 µg/day (17 β-estradiol) with progestogen and placebo. The patients in surgical menopause were assigned to one of the following protocols: ERT-K (n=11): 50 µg/day (17 β-estradiol) and 100 mg/day kava extract; ERT (n=7): 50 µg/day (17 β-estradiol) and placebo. HAMA score was evaluated before and after 3 and 6 months of therapy in all four groups. A significant reduction in HAMA score was observed in all four groups of women. The reduction was more significant in groups using combination therapy (HRT-K, 55.5%; ERT-K 53.3%) than in groups treated with hormones only (HRT 23.0%; ERT 25.8%). Furthermore, in both groups given combination treatment (HRT-K or ERT-K), reductions of HAMA subscores for both somatic anxiety and psychic anxiety were significantly greater(p<0.05) than corresponding groups treated with hormones only.
Comments: combined treatment with hormone replacement therapy is limiting the conclusion regarding kava its self efficacy; the extract is not full characterized.

Reference-controlled studies

Eighty perimenopausal women with climacteric symptoms were enrolled in a 3 months open study (Cagnacci et al., 2003). Women received 1 g/day of calcium and were randomized to receive for 3 months: (1) no other treatment (control; n=40); (2) Kava extract 100 mg/day (corresponding to 55% of kavain; no further detail; n=20); (3) Kava extract 200 mg/day (n=20). No placebo was available. Data on 68 patients (n=34; n=15 and n=19 respectively) were available for evaluation. Anxiety was evaluated by the State Trait Anxiety Inventory (STAI, 20 items), while depression was evaluated by the Zung’s scale (SDS) and climacteric symptoms by the Greene’s scale. Evaluations were performed at baseline and after 1 and 3 months. In the control group during the 3 months, anxiety, depression and climacteric symptoms tended to decline, but not significantly. Compared with the control group, scores for anxiety in both kava-groups declined significantly (p<0.009, two-factors ANOVA). Baseline values were similar to those of the control group (46.5 ± 1.5) but significantly declined (P<0.0001) after 1 and 3 months of treatment. The effect was similar for the 100 mg and the 200-mg dose. In the 100 mg group (n=15) the anxiety score decreased (p<0.025) from baseline values of 47.3±2.2, to 43.2±1.9 after 1 month and to 42.7±2.25 after 3 months of treatment. In the 200 mg group (n=19) the anxiety score decreased (p<0.0003) from baseline values of 46.6±2.1, to 43.1±1.8 after 1 month and to 41.3±1.6 after 3 months of treatment. Although scores for depression and climacteric symptoms declined more in kava-groups and were significant compared to baseline, the differences were not statistically significant compared with control group. Also the modifications of Greene’s subscales that were observed during Kava treatment were not significantly different from those observed in the control group. Side effects as nausea and gastric pain were observed in 1 subject of the control group and 6 subjects receiving kava extract(17%). Intensity of these symptoms was slight. Only in 2 cases, receiving Kava extract gastric pain induced the subjects to withdraw from the study. In all women with side effects, the biochemical evaluation did not show any alteration, including those parameters documenting liver toxicity.

Comments: lack of placebo group, combined treatment with calcium and lack of statistically significant differences compared with control make this trial unuseful.

Meta-analysis

Pittler et al. (2000, 2003 and later 2010) provided a systematic review and meta-analysis aimed at assessing the evidence for or against the efficacy of kava extract as a symptomatic treatment in for anxiety. Only double-blind randomized placebo-controlled trials of oral treatment for the treatment of anxiety, without restrictions referring the language of publication, were included in this meta-analysis. Trials not performed using kava mono-preparations were not included. Twelve double-blind RCTs
(n=700) met the inclusion criteria. Seven of the 12 trials (Lehrl 2004; Geier 2004; Connor 2002; Malsch 2001; Volz 1997; Lehmann et al., 1996; Warnecke 1991), involving a total of 380 participants, used the total score on the HAMA as their primary outcome measure, and provided data suitable for meta-analysis. The five studies not included in the meta-analysis reported statistically significant improvements for kava recipients, compared with placebo recipients, on outcomes (e.g. response rates, reduction in scores on various anxiety scales). These five studies were heterogeneous in that they involved different patient groups, such as women with anxiety associated with the perimenopausal period, individuals with preoperative anxiety, and outpatients with neurotic anxiety. Consequently, dosage regimens of kava varied widely (e.g. equivalent to kavalactones 60 mg in the evening and 1 hour preoperatively, to 140 mg kavalactones daily for four weeks).

The result suggests a significant effect towards a reduction of the HAMA total score in patients receiving kava extract compared with patients receiving placebo (weighted mean difference: 3.9, 95% confidence interval: 0.1 to 7.7; p = 0.05; n = 380). All except one of these trials included participants with nonpsychotic anxiety; one study involved women with anxiety associated with the climacteric (perimenopausal period). Removing this trial and the trial that did not assess the kava extract WS-1490 from the meta-analysis indicated a statistically significant reduction in anxiety scores for kava patients compared with placebo (weighted mean difference: 3.4; 95% CI, 0.5-6.4; p= 0.02).

Adverse events as reported in the reviewed trials were mild, transient and infrequent as stomach complaints, restlessness, drowsiness, tremor, headache and tiredness. These are reported by patients receiving kava extract in 5 of seven trials. In two of these 7 studies no adverse effects were observed. Authors’ conclusions were that compared with placebo, kava extract is an effective symptomatic treatment for anxiety although, at present, the size of the effect seems small. The effect lacks robustness and is based on a relatively small sample. The data available from the reviewed studies suggest that kava is relatively safe for short-term treatment (1 to 24 weeks), although more information is required. Rigorous trials with large sample sizes are needed to clarify the existing uncertainties. Also, long-term safety studies of kava are required.

**Analysis 1.1. Comparison 1 Kava versus placebo for anxiety, Outcome 1 Improvement (HAMA-score).**

### Table: Analysis 1.1

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Treatment</th>
<th>Mean(SD)</th>
<th>Control</th>
<th>Mean(SD)</th>
<th>Mean Difference</th>
<th>Weight</th>
<th>Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Connor 2002</td>
<td>17</td>
<td>5.7 (7.6)</td>
<td>18</td>
<td>8.5 (4.2)</td>
<td></td>
<td>15.5%</td>
<td></td>
</tr>
<tr>
<td>Geier 2004</td>
<td>25</td>
<td>12.7 (6.7)</td>
<td>25</td>
<td>13.3 (7.3)</td>
<td></td>
<td>15.8%</td>
<td></td>
</tr>
<tr>
<td>Kindler 1991</td>
<td>29</td>
<td>12.3 (8.7)</td>
<td>29</td>
<td>3.6 (8.9)</td>
<td></td>
<td>15.1%</td>
<td></td>
</tr>
<tr>
<td>Lehrl 2004</td>
<td>34</td>
<td>10.6 (7.3)</td>
<td>23</td>
<td>9.2 (10)</td>
<td></td>
<td>14.6%</td>
<td></td>
</tr>
<tr>
<td>Malsch 2001</td>
<td>20</td>
<td>3 (7.5)</td>
<td>20</td>
<td>0.6 (4.6)</td>
<td></td>
<td>15.9%</td>
<td></td>
</tr>
<tr>
<td>Volz 1997</td>
<td>52</td>
<td>21 (13)</td>
<td>48</td>
<td>16.2 (14.3)</td>
<td></td>
<td>13.8%</td>
<td></td>
</tr>
<tr>
<td>Warnecke 1991</td>
<td>20</td>
<td>25.6 (12.8)</td>
<td>20</td>
<td>7.65 (15.9)</td>
<td></td>
<td>9.3%</td>
<td></td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>197</td>
<td>183</td>
<td></td>
<td></td>
<td>100.0%</td>
<td>3.85</td>
<td>0.05, 7.66</td>
</tr>
</tbody>
</table>

Heterogeneity: Tau² = 19.89; Chi² = 27.47, df = 6 (p = 0.0001); I² = 78%

Test for overall effect: Z = 1.98 (p = 0.049)
Witte et al., 2005 conducted a meta-analysis to assess the efficacy of the acetonic Kava-Kava Extract WS 1490 (DER 11–20:1; extraction solvent: acetone 75% (w/w) in patients with non-psychotic anxiety disorders. Six placebo-controlled, randomized trials with the kava extract WS 1490 were identified (Geier, 2004; Kinzler et al., 1991*; Lehrl, 2004; Malsch, 2001; Volz, 1997; Warnecke, 1991). The endpoints were the change in HAMA during treatment (continuous and binary). No restrictions regarding the daily dose, duration of treatment or follow-up time were imposed. Authors concluded that WS1490 has an effective success rate of OR=3.3 (95% confidence interval of 2.09–5.22) in patients with non-psychotic anxiety disorders. The continuous outcome supports this result: mean improvement with WS 1490 by 5.94 (95% confidence interval −0.86 to 12.8) points on the HAMA scale better than placebo. Kava seems to be more effective in females and in younger patients.

* Kinzler et al. is a duplicate of Lehmann et al., 1996

<table>
<thead>
<tr>
<th>Table 1. Description of included studies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Author</td>
</tr>
<tr>
<td>-----------------------------------------</td>
</tr>
<tr>
<td>Geier and Konstantinowicz, 2004</td>
</tr>
<tr>
<td>Kinzler et al., 1991</td>
</tr>
<tr>
<td>Lehrl, 2004</td>
</tr>
<tr>
<td>Malsch and Kieser, 2001</td>
</tr>
<tr>
<td>Volz and Kieser, 1997</td>
</tr>
<tr>
<td>Warnecke, 1991</td>
</tr>
</tbody>
</table>

All studies are randomized, controlled, double-blind trials treating patients with non-psychotic anxiety disorders. Patients in Warnecke (1991) had anxiety disorders due to climacteric complaints which is also a non-psychotic genesis. SD, standard deviation.

<table>
<thead>
<tr>
<th>Table 2. Treatment effects observed in the included studies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Author</td>
</tr>
<tr>
<td>-----------------------------------------</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>-----------------------------------------</td>
</tr>
<tr>
<td>Geier and Konstantinowicz, 2004</td>
</tr>
<tr>
<td>Kinzler et al., 1991</td>
</tr>
<tr>
<td>Lehrl, 2004</td>
</tr>
<tr>
<td>Malsch and Kieser, 2001</td>
</tr>
<tr>
<td>Volz and Kieser, 1997</td>
</tr>
<tr>
<td>Warnecke, 1991</td>
</tr>
</tbody>
</table>

HAMA difference is mean improvement of the disease under WS1490 application minus mean improvement under placebo. Success was defined as an individual improvement of HAMA score during treatment by at least 50% compared with baseline. OR, odds ratio of WS1490 to placebo. Positive differences and OR > 1 favour WS1490.

Assessor comments: all trials included in this meta-analysis were already assessed separately. The weaknesses of the analysis are correlated with: small size groups, significantly different HAMA baseline scores between trials that indicates different severity status, mixed anxiety disease (e.g Warnecke et al. 1991 had anxiety disorders patients due to climacteric complaints) short term studies (only 2 trials investigated the effect more than 4 weeks), differences between trials regarding tested dose (from 150 mg to 300 mg/day), one trial with significant errors (Geier, 2004).
Isolated compounds

Several randomised, double-blind, controlled trials (Möller et al., 1992; Möller & Heuberger, 1989; Lehmann et al., 1989; Staedt et al., 1991; Lindenberg & Pitule-Schödel, 1990) involving patients with anxiety have compared the effects of the (+)-kavain administered at a dose of 200 mg three times daily for 3–4 weeks, with those of placebo or benzodiazepines, such as oxazepam. Generally, these studies have reported beneficial effects for synthetic kavain, but typically have involved only small numbers of patients. Therefore their relevance is limited and cannot be extrapolated to the natural L-kavain.

Table 5: Clinical studies on humans in GAD= generalized anxiety disorder; Hamilton Anxiety Scale (HAMA) Hospital Anxiety and Depression Scale (HADS), Self Assessment of Resilience and Anxiety (SARA); Anxiety Status Inventory (ASl); Sheehan Disability Inventory (SDI); Subjective well-being scale (Bf-S); the Clinical Global Impressions (CGI)

<table>
<thead>
<tr>
<th>Type of anxiety</th>
<th>Study</th>
<th>Test Product(s)</th>
<th>Number of subjects</th>
<th>Type of subjects</th>
<th>Outcomes</th>
<th>Statistical analysis</th>
<th>Clinical relevance</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>A. General anxiety, nervousness and restlessness</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>A.1. Ethanolic extract</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Connor et al., 2002</td>
<td>Randomised placebo double-blind study</td>
<td>Placebo Verum: 70 mg kavalactones in the first week and 140 mg kavalactones for the last 3 weeks Orally 2 times daily Duration: 4 weeks</td>
<td>38 patients (31-75 years) Verum (n=19) Placebo (n=19)</td>
<td>DSM-IV GAD (HAMA &gt; 16)</td>
<td>Principal outcome: efficacy Assessed by HAMA, HADS, SARA</td>
<td>Student’s t or Kruskal-Wallis tests</td>
<td>No difference between placebo and verum</td>
</tr>
<tr>
<td>Neuhaus et al., 2000</td>
<td>Randomised placebo-controlled, double-blind study</td>
<td>Placebo Verum: 150 mg kavalactones/day Orally Duration: 7 days</td>
<td>20 patients Placebo (n=10) Verum (n=10)</td>
<td>women with acute anxiety concerning suspected breast cancer</td>
<td>Principal outcomes: two self-rating scales - State trait anxiety scale and State trait anxiety inventory</td>
<td>Student’s t-test</td>
<td>Verum treatment was superior to placebo</td>
</tr>
<tr>
<td>Connor et al., 2006</td>
<td>Three randomised double-blind positive control studies</td>
<td>Verum: 140 mg kavalactones 1 week, then 280 mg kavalactones Control: 37.5 mg venlafaxine/day Placebo Orally Duration: 4 to 8 weeks</td>
<td>64 patients Verum (n=28) Control (n=6) Placebo (n=30)</td>
<td>Patient with GAD First trial: HAMA &gt; 16; Second trial: HAMA (12–20); Third trial: HAMA &gt; 18</td>
<td>Outcome measures: HAMA, HADS, SDI</td>
<td>Student’s t-test</td>
<td>No significant difference between the treatment groups in any of the trials</td>
</tr>
<tr>
<td>Mittmann, 2000</td>
<td>Randomised positive control study</td>
<td>Verum: 100 mg kavalactones + 25 mg prometazine; next day: another 100 mg kavalactones Control: 1-2 mg flunitrazepam + 25 mg prometazine; next day: 10 mg</td>
<td>53 patients (average age 68.3 years) Verum (n=27) Control (n=26)</td>
<td>Patients undergoing vaginal hysterectomy</td>
<td>Primary outcomes: sedation (3-step scale), blood pressure, pulse frequency and blood oxygen saturation values</td>
<td>Student’s t-test</td>
<td>Comparability of efficacy</td>
</tr>
<tr>
<td>Type</td>
<td>Study</td>
<td>Test Product(s)</td>
<td>Number of subjects</td>
<td>Type of subjects</td>
<td>Outcomes</td>
<td>Statistical analysis</td>
<td>Clinical relevance</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>--------------------------------------------</td>
<td>---------------------------------------------------------------------------------</td>
<td>--------------------</td>
<td>------------------</td>
<td>---------------------------------------</td>
<td>----------------------</td>
<td>-------------------</td>
</tr>
<tr>
<td>Boerner et al., 2003</td>
<td>Randomised, double-blind, reference-controlled multicenter study</td>
<td>Verum: 400 mg Kava LI 150 (containing 120 mg kavalactones, DER: 13-20:1 extraction solvent: ethanol 96%), Control 1: 10 mg buspirone Control 2: 100 mg opipramol</td>
<td>129 patients</td>
<td>Verum(n=43) Control 1(n=43) Control 2(n=43) Drop-out:</td>
<td>GAD</td>
<td>Primary outcome: HAMA score and % of responders. Secondary measures: Boerner Anxiety Scale, SAS, CGI, Bf-S</td>
<td>No differences between the groups</td>
</tr>
<tr>
<td>Scherer et al., 1998</td>
<td>Open, observational, multicentric study</td>
<td>200 mg to 600 mg dry ethanolic extract (DER 11.5-21.5:1; extraction solvent: ethanol 96%*), 100 mg extract corresponding to 50 mg kavalactones</td>
<td>52 outpatients (15 male, 37 female; average age: 49 ± 15)</td>
<td>Anxiety of non-psychotic origin with (n=26) or without (n=26) concomitant depression</td>
<td>None</td>
<td>Supportive</td>
<td></td>
</tr>
<tr>
<td>Spree et al., 1992</td>
<td>Post-marketing surveillance study</td>
<td>3 x 133 mg ethanolic kava extract (corresponding to 120 mg kavalactones)</td>
<td>1673 patients (average age: 48.84 ± 14.77 ; 1168 female, 503 male)</td>
<td>Anxiety and/or nervousness and restlessness</td>
<td>Questionnaire</td>
<td>None</td>
<td>Supportive</td>
</tr>
<tr>
<td>A.2. Acetonic extracts</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gastpar et al., 2003</td>
<td>Randomised, double-blind, placebo-controlled multicenter study</td>
<td>Placebo Verum : 150 mg kava-extract (DER 11-20:1, extraction solvent: acetone 75% v/v in water) corresponding to 105 kavalactones</td>
<td>141 patients</td>
<td>Verum(n=71) Placebo(n=70) Drop-out:</td>
<td>neurotic anxiety (DSM-III-R diagnoses 300.02, 300.22, 300.23, 300.29, or 309.24).</td>
<td>Student’s t-test</td>
<td>Verum treatment was superior to placebo</td>
</tr>
<tr>
<td>Geier et al., 2004</td>
<td>Randomised, double-blind, placebo-controlled study</td>
<td>Placebo Verum : 150 mg (3 x 50 mg) kava-extract (standardized to 70% kavalactones)</td>
<td>50 patients (51-90 years)</td>
<td>Verum(n=25) Placebo(n=25)</td>
<td>Suffering from non-psychotic anxiety (DSM-III-R criteria; HAMA ≥18)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Type</td>
<td>Study</td>
<td>Test Product(s)</td>
<td>Number of subjects</td>
<td>Type of subjects</td>
<td>Outcomes</td>
<td>Statistical analysis</td>
<td>Clinical relevance</td>
</tr>
<tr>
<td>------</td>
<td>-------</td>
<td>-----------------</td>
<td>--------------------</td>
<td>------------------</td>
<td>----------</td>
<td>---------------------</td>
<td>--------------------</td>
</tr>
<tr>
<td>Lehrl, 2004</td>
<td>Multicenter, randomised, double-blind, placebo-controlled study</td>
<td>Placebo Verum: 200 mg kava-extract (corresponding to 140 mg kavalectones) Orally Duration: 4 weeks</td>
<td>61 patients (51-90 years) Verum (n=38) Placebo(n=23)</td>
<td>Patients GAD, agoraphobia, social phobia or adaptation disorders (DSM-III-HAMA ≥15)</td>
<td>Main outcome measures were the SP-B, the HAMA scale, BF-S, CGI scale</td>
<td>Student’s t-test</td>
<td>Verum treatment was superior to placebo</td>
</tr>
<tr>
<td>Malsch &amp; Kieser (2001)</td>
<td>Randomised, double-blind, placebo-controlled study</td>
<td>Placebo Verum: 50 mg kava-extract (corresponding to 35 mg kavalectones) up to 300 mg extract Orally Duration: 5 weeks</td>
<td>40 Patients (25 male, 15 female)</td>
<td>Non-psychotic nervous anxiety, tension and restlessness states following pretreatment with benzodiazepines</td>
<td>Primary outcomes: HAMA, BF-S and the incidence of benzodiazepine withdrawal symptoms</td>
<td>Student’s t-test</td>
<td>Verum treatment was superior to placebo</td>
</tr>
<tr>
<td>Woelk et al., 1993</td>
<td>Multicenter, randomised, double-blind, reference placebo-controlled study</td>
<td>Verum: 3 x 100 mg kava-extract (corresponding to 70 mg kavalectones) up to 300 mg extract Control 1: 3 x 5 mg oxazepam Control 2: 3 x 3 mg bromazepam Orally Duration: 6 weeks</td>
<td>172 Patients (18-65 years) Verum (n=57) Control oxazepam(n=59) Control bromazepam(n=56)</td>
<td>Anxiety, agitation, and tension of non-psychotic origin</td>
<td>HAMA score, CGI</td>
<td>Student’s t-test</td>
<td>No differences between the groups</td>
</tr>
<tr>
<td>Siegers et al., 1992</td>
<td>Open, multicenter drug-monitoring trial</td>
<td>150 mg kava extract WS 1490 (containing 105 mg kavalectones) Orally Duration: 6 weeks</td>
<td>4049 patients (average age: 49; 72 % female, 28 % male)</td>
<td>Nervous anxiety, stress, and restlessness</td>
<td>Modified HAMA</td>
<td>None</td>
<td>Supportive</td>
</tr>
</tbody>
</table>

A.3. Other extracts (not defined)

<p>| Bhate et al., 1989 | Randomised, double-blind placebo-controlled study | Placebo Verum: 300 mg kava-extract (corresponding to 60 mg kavalectones) Orally | 56 patients (25-81 years) Verum (n=28) Placebo(n=28) | Patients undergoing surgery under epidural anaesthesia | The primary outcomes: sleep quality, psychologic al status, anxiety | None | Small differences |</p>
<table>
<thead>
<tr>
<th>Type Study</th>
<th>Test Product(s)</th>
<th>Number of subjects</th>
<th>Type of subjects</th>
<th>Outcomes</th>
<th>Statistical analysis</th>
<th>Clinical relevance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Volz et al., 1997</td>
<td>Randomised, placebo-controlled double blind multicenter study</td>
<td>Placebo Verum: 3 x 100 mg kava-extract (corresponding to 70 mg kavalactones) Orally Duration: 25 weeks</td>
<td>101 patients (27 male and 74 female; mean age: 54 years) Verum (n=52) Placebo (n=49)</td>
<td>Anxiety of non-psychotic origin</td>
<td>Primary outcome: HAMA score, CGI, BF-S</td>
<td>U-test Verum treatment was superior to placebo</td>
</tr>
<tr>
<td>Lehmann et al., 1996</td>
<td>Randomised, placebo-controlled double blind multicenter study</td>
<td>Placebo Verum: 100 mg kava-extract (corresponding to 70 mg kavalactones) Orally Duration: 4 weeks</td>
<td>58 patients (15 male and 43 female) Verum (n=29) Placebo (n=29)</td>
<td>Anxiety syndrome of non psychotic origin (HAMA &gt; 18)</td>
<td>Primary outcome: HAMA score, CGI</td>
<td>Student’s t-test Verum treatment was superior to placebo</td>
</tr>
<tr>
<td>B. Anxiety in the climacteric phase</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>B.1. Acetonic extracts</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Warnecke, 1991</td>
<td>Randomized, placebo-controlled double-blind study</td>
<td>Placebo Verum: 3 x 100 mg kava extract WS 1490 (daily dosage of 210 mg of kavalactones) Duration: 8 weeks</td>
<td>40 patients (45 – 60 years) Verum (n=20) Placebo(n=20).</td>
<td>Climacteric syndrome (HAMA &gt; 18)</td>
<td>HAMA score, depressive status inventory (DSI), CGI, Kupperman menopause index and Schneider scale</td>
<td>Student’s t-test Verum treatment was superior to placebo</td>
</tr>
<tr>
<td>De Leo, 2000</td>
<td>Randomized, placebo-controlled double-blind study</td>
<td>HRT-K: 50 µg/day 17 β-estradiol + progestogen + 100mg/day kava extract(containsing 55% of kavain); HRT: 50 µg/day 17 β-estradiol+ progestogen + placebo ERT-K: 50 µg/day 17 β-estradiol+ 100 mg/day kava extract; ERT: 50 µg/day 17 β-estradiol + placebo</td>
<td>40 women HRT-K(n=13) HRT (n=9) ERT-K(n=11) ERT (n=7)</td>
<td>Climacteric syndrome</td>
<td>Primary outcome: Kupperman Index and Anxiety Status Index</td>
<td>Student’s t-test Combined treatment superior to hormonal treatment</td>
</tr>
</tbody>
</table>
Type Study Test Product(s) Number of subjects Type of subjects Outcomes Statistical analysis Clinical relevance

<table>
<thead>
<tr>
<th>Type Study</th>
<th>Test Product(s)</th>
<th>Number of subjects</th>
<th>Type of subjects</th>
<th>Outcomes</th>
<th>Statistical analysis</th>
<th>Clinical relevance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cagnacci, 2003 Randomised positive control study</td>
<td>Control: 1 g/day of calcium Verum 1: 1 g/day of calcium + 100 mg kava extract/day (corresponding to 55% of kavain); Verum 2: 1 g/day of calcium + 200 mg kava extract/day</td>
<td>80 patients Control (n=40) Verum 1(n=20) Verum 2(n=20) Drop-out: 12</td>
<td>Climacteric syndrome</td>
<td>Anxiety was evaluated by the State Trait Anxiety Inventory (STAI, 20 items), while depression was evaluated by the Zung’s scale (SDS) and climacteric symptoms by the Greene’s scale.</td>
<td>Student’s t-test</td>
<td>No differences between the groups</td>
</tr>
</tbody>
</table>

* should be seen in correlation with the weaknesses of the trial (see descriptive part)

4.3. Clinical studies in special populations (e.g. elderly and children)

No data available.

4.4. Overall conclusions on clinical pharmacology and efficacy

There are several trials that evaluated the use of kava preparations as treatment option for anxiety disorders, as generalised anxiety or anxiety in the climacteric phase. However the majority are small with methodological weakness, such as: mixed anxiety population, short duration of the trials, short follow-up phase, no data regarding percentage of responders. There were many differences in the products studied (acetonic or ethanolic extracts, different DERs, sometimes synthetic compounds), study designs (mainly open studies) and methodology and the dosage administered that was reported either in milligrams of kavalactones or in milligrams of kavain. Taking into account all these differences comparison of the results between products is rather difficult and it is not possible to assess correctly the impact of kava preparations on those patients.

Some meta-analysis (Pittler et al., 2000, 2003 and 2010) that investigated the reliability and quality of some of the clinical trials did not differentiated the type of extract involved, therefore clinical improvements cannot be attributed confidently to a particular extract, while other meta-analysis (Witte et al., 2005) included short term studies with significantly different HAMA baseline scores between the trials, patients with mixed anxiety diseases, different doses tested. Therefore no clear conclusion on efficacy can be drawn and further studies are needed, especially on long-term efficacy and safety.

To conclude, the clinical data available for kava preparations as treatment option for anxiety disorders, are not considered sufficient for the support a well-established medicinal use according to Article 10a of Directive 2001/83/EC as amended.
5. Clinical Safety/Pharmacovigilance

5.1. Overview of toxicological/safety data from clinical trials in humans

Traditional use outside Europe

During its long-term traditional nonEU use kava has not shown any severe side effects that suggested any severe liver damage but there are some studies that suggest at least a minimal effect induced by kava aqueous preparations.

39 healthy aboriginal users of kava preparation (dried rhizome prepared as infusion in cold water) were compared with non-users by Matthew et al., 1988; 20 were classified as very heavy users (mean consumption, 440 g/week), 15 were heavy users of kava (310 g/week) and 4 were occasional users (100 g/week). Various adverse effects were observed at these high intakes, including the levels of gamma-glutamyl transferase which were increased greatly: 251 UI/l in very heavy users, 312 in heavy users and 77 in occasional users, compared with < 60 UI/l considered as normal values. Very heavy users of kava were 20% underweight. Albumin, plasma protein, urea and bilirubin levels were decreased in kava users, and high-density lipoprotein cholesterol levels were increased.

On the same community in a cross-sectional study with 98 participants, 36 non-users and 62 kava users (of which 23 had discontinued kava at least 1 year before the study) liver function tests were done. Continuing users had not used kava for 1 to 2 months (n = 10) or 1 to 2 weeks previously (n = 15) and some (n = 14) had used kava within the previous 24 hr. The average quantity of kava powder consumed was 118 g/week, and median duration of use was 12 years (range, 1-18 years). Almost one-half (48%) of the kava users showed GGT above a normal reference range (OR=2.6, 1.0–6.5, p = 0.034), with 37% having abnormally elevated alkaline phosphatase ALP (OR=3.4, 1.2–10.1, p = 0.017) but not with alanine aminotransferase or bilirubin, which were not elevated. There was no association between duration of kava use and abnormally elevated liver enzymes. However, quantity consumed per week was associated with an abnormally elevated ALP (p = 0.009). In those who were not heavy alcohol users, only those who used kava within the previous 24 hr showed GGT levels higher than non-users (p < 0.001), whereas higher ALP levels occurred only in those who last used kava 1 to 2 weeks (p = 0.015) and 24 hr previously (p = 0.005). The authors concluded that liver function changes in users of aqueous kava extracts at these moderate levels of consumption appear to be reversible and begin to return to baseline after 1 to 2 weeks abstinence from kava. No evidence for irreversible liver damage has been found (Clough, 2003).

Later, Brown et al. (2007) investigated the effects of regular use of kava beverage on the liver function tests of 31 healthy adult kava drinkers and compared against a control group of 31 healthy adult non-kava drinkers. The liver function profile included AST, ALT, ALP, GGT, and bilirubin (total and direct). Other tests included total protein, albumin, and screens for viral hepatitis and hemochromatosis when indicated. Chronic kava beverage consumption was associated with elevation of GGT in 65% of the kava drinkers versus 26% in the controls (p = 0.005). ALP was elevated in 23% of kava drinkers versus 3% in the controls (p = 0.053).

Kava users more frequently showed a characteristic kava-induced skin reaction, a scaly rash that is suggestive of ichthyosis – a condition called “kava dermopathy” (pellagroid dermopathy) that appears to heavy chronic dunkers and has been attributed to niacin deficiency. Although the skin becomes yellow, the description does not suggest an underlying hepatic condition, the rash is not itchy and the condition is ameliorated without treatment if heavy use of kava is reduced (Ruze, 1990)
Use in Europe

Clinical trials

Apart from the experience of the non EU-traditional use which is referring to aqueous infusions, several controlled and non-controlled trials can be referred to when evaluating the safety of kava extracts.

Old clinical trials of kava extracts generally have suffered from well-known shortcomings, such as small sample size, short periods of treatment (usually 4-8 weeks and up to 24 weeks), lack of information about type and dose of extract used, ill-defined patient population, lack of adverse event reporting, etc. Therefore WHO assessed in the document "Assessment of the risk of hepatotoxicity with kava products" only the new trials. The adverse effects found in these clinical trials are summarised as following

Table 6: Clinical safety data from clinical trials

<table>
<thead>
<tr>
<th>Type</th>
<th>Study</th>
<th>Test Product(s):</th>
<th>Number of subjects</th>
<th>Type of subjects</th>
<th>Adverse reactions</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>A. Ethanolic extracts</td>
<td>Boerner et al., 2003</td>
<td>verum: 400 mg kava standardized extract to 30% kavalactones /day Reference group: 10 mg/day buspiron 100 mg/day opipramol Orally Duration: 8 weeks + 1 week follow-up</td>
<td>129 patients (25-65 yrs) verum (n=43) reference groups: buspiron(n=43) Opipramol (n=43) 4 drop-out (verum) 1 drop-out (reference)</td>
<td>Patients with GAD</td>
<td>Verum: slight increases of transaminases above upper limit in 2 subjects (one had already displayed values slightly above normal at baseline). One subject suffered from panic attack requiring stationary treatment. No significant hepatotoxic reactions were reported in about 330 treatment weeks in this trial Reference group: Slight increases of transaminases above upper limit in 5 subjects (4</td>
<td>No difference was observed between placebo and verum groups.</td>
</tr>
<tr>
<td>Type of Study</td>
<td>Test Product(s):</td>
<td>Number of subjects</td>
<td>Type of subjects</td>
<td>Adverse reactions</td>
<td>Comments</td>
<td></td>
</tr>
<tr>
<td>---------------</td>
<td>-----------------</td>
<td>--------------------</td>
<td>-----------------</td>
<td>------------------</td>
<td>----------</td>
<td></td>
</tr>
<tr>
<td>Cropley et al., 2002</td>
<td>Randomized, controlled trial</td>
<td>verum: 120 mg/day Kava LI120 valerian group: 2 x 600 mg/day Valerian LI 156 placebo orally Duration: 1 week</td>
<td>54 volunteers (18-30 yrs) Verum (n=18) Valeriana (n=18) Placebo (n=18)</td>
<td>Healthy volunteers</td>
<td>Verum: none reported Control/Reference group: none reported Placebo Group: none reported</td>
<td></td>
</tr>
<tr>
<td>Connor et al., 2002</td>
<td>Randomized, double-blind, placebo-controlled</td>
<td>verum: Dose 1: 140 mg/day kavalactones Dose 2: 280 mg/day kavalactones placebo orally Duration: 1 week of dose 1 followed by 3 weeks of dose 2</td>
<td>38 patients (31-75 yrs) Verum (n=19) Placebo (n=19) 3 drop-out</td>
<td>Patients with DSM-IV GAD</td>
<td>Verum: diarrhea (2 cases), dry mouth (2 cases), rash (2 cases), nausea (2 cases); in placebo group: headaches, heart pounding, swelling, trembling (2 cases or each side effect)</td>
<td></td>
</tr>
<tr>
<td>Mittmann et al., 2000</td>
<td>Randomized, unblinded, diazepam controlled</td>
<td>Verum: 100 mg kavalactones + 25 mg promethazin evening before</td>
<td>53 patients Verum (n=26) Reference group (n=27)</td>
<td>Women with planned vaginal hysterectomy</td>
<td>Nausea and vomiting were at the same level (5 cases) in both groups but could not be attributed</td>
<td></td>
</tr>
</tbody>
</table>

*had already displayed values slightly above normal at baseline). Only one GGT increase was rated to be of clinical relevance (opipramol).*
<table>
<thead>
<tr>
<th>Type</th>
<th>Study</th>
<th>Test Product(s):</th>
<th>Number of subjects</th>
<th>Type of subjects</th>
<th>Adverse reactions</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>operation and 100 mg 60 min. before operation Reference group: 1-2 mg flunitrazepam +25 mg promethazine orally</td>
<td>20 patients</td>
<td>Women with anxiety concerning suspected breast cancer</td>
<td></td>
<td>No difference was observed between placebo and verum groups</td>
</tr>
<tr>
<td></td>
<td></td>
<td>verum: 450 mg kavalactones /day placebo orally Duration: 7 days</td>
<td>20 patients</td>
<td>Verum (n=10) Placebo (n=10)</td>
<td></td>
<td>None observed</td>
</tr>
<tr>
<td></td>
<td></td>
<td>verum: 300 mg kavalactones /day placebo orally Duration: 1 dose</td>
<td>20 patients</td>
<td>Verum (18-53 yrs) Placebo (n=10)</td>
<td>Healthy volunteers</td>
<td>No difference was observed between placebo and verum groups</td>
</tr>
<tr>
<td></td>
<td></td>
<td>verum: 150 WS 1490 acetonic extract mg/day placebo orally Duration: 4 weeks+ 2 weeks observation</td>
<td>141 patients</td>
<td>Verum (n=71) 9 drop-out Placebo (n=70) 5 drop-out</td>
<td>Patients with neurotic anxiety</td>
<td>Verum: Tiredness(one case) Placebo: sneezing attacks(1 case); developing a ganglion on left wrist(1 case)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>verum: 150 WS 1490 acetonic extract mg/day placebo</td>
<td>50 patients</td>
<td>Verum (51-90 yrs) Placebo (n=25)</td>
<td>Patients with nonpsychotic anxiety</td>
<td>Verum: none Placebo: nausea, retching, restlessness and</td>
</tr>
</tbody>
</table>

Assessment report on *Piper methysticum* G. Forst., rhizoma
EMA/HMPC/450589/2016
Page 75/85
<table>
<thead>
<tr>
<th>Type</th>
<th>Study</th>
<th>Test Product(s):</th>
<th>Number of subjects</th>
<th>Type of subjects</th>
<th>Adverse reactions</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>oraly</td>
<td>Duration: 4 weeks + 2 weeks observation</td>
<td>2 drop-out</td>
<td></td>
<td>sleeplessness</td>
<td>(1 case).</td>
</tr>
<tr>
<td></td>
<td>Lehrl , 2004</td>
<td>verum: 200 WS 1490 acetonic extract/day placebo orally</td>
<td>61 patients (24-72 yrs) Verum (n=34) Placebo (n=27) 4 drop-out</td>
<td></td>
<td>Patients with neurotic anxiety</td>
<td>verum: none placebo: gastrointestinal complaints and nausea (1 case)</td>
</tr>
<tr>
<td></td>
<td>Malsch et al., 2001</td>
<td>verum: 50 mg up to 750 mg extract/day gradually increased placebo orally Duration: 5 weeks + 3 week follow-up</td>
<td>40 patients (21-75 yrs) Verum (n=20) 3 drop-out Placebo (n=20) 1 drop-out</td>
<td></td>
<td>Patients with non-psychotic anxiety and pre-treatment with benzodiazepines.</td>
<td>Verum: none Symptoms due to withdrawal of benzodiazepine (5 cases) Placebo: none Symptoms due to withdrawal of benzodiazepine (10 cases)</td>
</tr>
<tr>
<td></td>
<td>De Leo et al., 2000</td>
<td>Verum: 100 mg extract/day placebo orally Duration: 6 months All received estradiol 50µg/day with or without progestogen</td>
<td>40 patients Verum(n=24 ) Placebo(n=16)</td>
<td></td>
<td>Women in physiological or surgical menopause</td>
<td>Verum: none Placebo: none</td>
</tr>
<tr>
<td></td>
<td>Cagnacci A et al., 2003</td>
<td>Group 1: 100 mg extract /day Group 2: 200 mg extract /day</td>
<td>80 patients (47-53 yrs) Group 1(n=20) Group 2(n=20)</td>
<td></td>
<td>Perimenopausal women.</td>
<td>Group 1 and 2: nausea and gastric pain (6 cases) Control: nausea and</td>
</tr>
</tbody>
</table>
### Table: Product(s) and Type of subjects

<table>
<thead>
<tr>
<th>Type</th>
<th>Study</th>
<th>Test Product(s):</th>
<th>Number of subjects</th>
<th>Type of subjects</th>
<th>Adverse reactions</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Control orally</td>
<td>Control (n=40)</td>
<td>gastric pain (1 case)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Duration: 3 months</td>
<td>All subjects received 1 g/ day of calcium during study</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

In all of these trials in general, kava extracts have been very well tolerated and no severe effects have been observed. Only rarely mild side effects or adverse reactions are reported in controlled clinical studies and non-controlled trials. Less than 2% of the patients complained about such adverse effects; the majority of adverse reactions were gastrointestinal complaints. WHO concluded that these trials are not designed or powered to pick-up adverse reactions, especially long-term adverse reactions.

Regarding serious liver toxicity the number of patients usually involved in Phase III clinical trials is typically too small to detect hepatic necrosis that occurs with an incidence of 1/10 000 and even too small to provide high assurance against risk with an incidence of 1/1000 or less.

The most drugs that cause hepatic necrosis also cause an asymptomatic, but significant (>5 fold), elevation of transaminases in a larger fraction of the population treated, which can be detected in typical Phase III trials. Therefore, any drug that is found to cause a significant incidence of elevated transaminases relative to control, must undergo additional investigations into the mechanisms involved. However that smaller elevations should not be seen as forerunners of more severe liver damage.

### 5.2. Patient exposure

Aside from its market presence and data from clinical studies in humans, kava is use as recreational beverage but can be found as dietary supplements.

In Arnhem Land, Australia, weekly per capita consumption was estimated as 145 g of powder for 1989–1990 and 368 g of powder for 1990–1991. In a detailed review of the literature on weekly consumption levels and possible lactone contents, the estimations encompassed a wide variation from 39 to 1840 g of kava powder consumed, and from 4.1 g to 188.6 g of lactones consumed per week (Clough et al., 2003).

Typical dosage of dried root or by decoction was reported to be 6–12 g per day (IARC, 2015).

### 5.3. Adverse events, serious adverse events and deaths

**Clinical trials** - see section 5.1.

**Pharmacovigilance database:**

In the VigILyze database of the World Health Organization’s Uppsala Monitoring Centre for the period up to May 2016, there were 94 spontaneous reports of suspected adverse drug reactions associated with the single-ingredient *Piper methysticum*. The adverse reactions declared with the highest incidence were: rash, pruritis, hepatitis. Regarding liver toxicity following adverse reactions were
reported: hepatic enzyme increased (8 cases), hepatitis (7), hepatic cirrhosis (3), jaundice (3). There are no detail regarding the type of extract used; only the daily dose (if was known) is reported.

Case reports:

No reports of hepatotoxicity associated with the use of kava extracts at therapeutic dose levels have been published until the late 1990s, when cases of severe liver damage linked to the use of kava, although rare, began to emerge and were increasingly reported in the literature and to regulatory authorised.

In 2007 WHO summarized all case reports up to 2002 worldwide:

**Germany**

Out of 105 spontaneous adverse reports on kava, 24 were associated with impaired liver function or symptoms that could be linked to liver toxicity (including cases of cirrhosis, cholestatic hepatitis, and other types of hepatotoxicity). Of the 24 cases, there was one fatality, three cases required liver transplant, and 18 cases were considered possibly or probably related to kava ingestion.

**Switzerland**

4 Swiss cases in which severe hepatic complications resulted from the use of an acetone extract of kava were reported. Of the 4 cases (2 severe hepatitis, 1 liver fibrosis, 1 severe liver injury), 3 were histologically confirmed, and one was a case of fulminant irreversible hepatitis requiring transplantation. In 3 of the cases, prothrombin time was increased. All 4 cases presented with jaundice.

**Australia**

On 15 August 2002 the Therapeutic Goods Administration (TGA) initiated a recall of all kava-containing products following the death of a woman associated with the use of kava-containing product.

**Canada**

On 26 August 2002 a summary of 11 case reports associated with kava was submitted to Health Product Safety Information Division (HPSID) of Health Canada. Four Canadian cases of liver toxicity associated with the use of kava-containing products were reported in response to a Public Advisory (issued 16 January 2002) in which health professionals were asked to report any cases of kava-related hepatotoxicity to HPSID. Two cases were considered serious.

**United Kingdom**

As of April 2002, the Medicines Control Agency (MCA) received 3 reports of liver toxicity suspected of being related to kava consumption.

**France**

In France, two non-serious liver case reports were reported, but both with questionable causality for kava.

**United States of America**

An update of the adverse reaction reports received by the FDA (4 March 2002) revealed a total of 47 adverse reaction reports received in association with kava, 20 of which were related to the liver.
In conclusion, up to July 2002, 68 cases of suspected hepatotoxicity associated with the use of kava extracts or isolated kavalactones have been reported worldwide, including cases of liver failure resulting in 6 liver transplants and 3 deaths.

For the comparisons between the different extracts- see Reviews of case reports

Cases reported after 2002

Several new case reports of liver toxicity have been published in the literature since 2002.

Brauer et al. (2003) reported an acute liver failure case that needed liver transplantation after administration of kava extract (240 mg daily) in association with other potential hepatotoxic drugs (oral contraceptives, rizatriptan and acetaminophen).

Two cases of acute liver injury have been associated with ingesting traditionally prepared kava extracts for 4-5 weeks. In the same study a survey on 27 heavy kava drinkers showed elevated gamma glutamyl transferase in 23/27 and minimally elevated transaminases in 8/27 (Russmann et al., 2003).

One case of icteric hepatitis in Spain was reported after two weeks of treatment with capsules containing 250 mg of an extract of kava-kava (no detail regarding the type of extract), 3 times daily (Bujanda et al., 2002).

In Australia a case of acute liver failure and death in a 56 year-old woman was associated with the use of a preparation containing 60 mg of kavalactones (no further detail), 50 mg of Passiflora incarnata and 100 mg of Scutellaria lateriflora (Gow et al., 2003).

Assessor comments: It is worth noting that the case reports of hepatotoxicity suspected to be associated with the use of Kava include many of the main forms of liver damage including necrosis, drug-induced hepatitis and cholestatic hepatitis. This could suggest that there is more than one constituent and/or mechanism involved.

Reviews of the case reports

Almost all known case reports were assessed by different researchers or expert working groups in order to find a relationship between kava exposure and hepatotoxicity (Schmidt, 2003, Stickel et al., 2003; Teschke et al., 2003; Gruenwald, 2004;; WHO, 2007; Teschke et al., 2009, Teschke et al., 2010). The majority of severe adverse effects associated particularly with liver toxicity are derived from the files of the BfArM in Germany.

Schmidt (2003) analyses 82 hepatotoxicity cases from different sources: German health authorities - BfArM): 38 reports (excluding double entries), Swissmedic: 5 reports (excluding those also listed in the German case reports), US FDA: 21 reports, UK-MHRA: 4 reports, Health Canada: 3 reports, France (AFSSAPS): 2 reports, Australia TGA: 1 report, EMEA: 1 report (excluding those already mentioned in other categories), medical literature: 5 reports (excluding those already mentioned in other categories), unconfirmed German newspaper stories: 2 reports). The author states that 20 cases are obviously not related to kava intake; in 21 case reports a potentially hepatotoxic concomitant treatment was identified. In seven cases there is considerable doubt concerning the causality of kava, whereas in 31 other cases the available data is too fragmentary for an assessment. That leaves only three cases where a likelihood of hepatotoxic effects by kava can be established, although in two of these three there were higher dosages and longer-term treatment than recommended. In only one of these case reports was kava taken according to the dosage recommendations of the German Commission E Monograph of no more than 120 mg kavalactones per day for three months or less. Therefore only one case remains. The authors also did a thorough analysis of the hepatotoxic potential of frequently used concomitant medications and a comparison of kava with other treatments for anxiety. They concluded that the hepatotoxic effects of kava intake cannot generally be ruled out but,
in comparison with pharmaceutical treatments for stress and anxiety disorders, and in relation to drug intake related hepatotoxicity in general, the risk of adverse liver effects seems to be very low.

A review of 36 cases of hepatitis in Germany concluded that kava was the certain or probable cause of the hepatitis in 24 of the cases, nine patients developed fulminant liver failure and eight of these patients required liver transplantation. Three patients died. In all other patients, a complete recovery was noticed after the withdrawal of kava. Hepatic necrosis or cholestatic hepatitis were noticed with both alcoholic and acetonc kava extract (Stickel et al., 2003). This review has been criticized and considered of little value because of reporting of wrong data, age of patients, gender, concomitant treatments and lack of liver test.

Another independent analysis of 19 known cases from Germany was published in the peer-reviewed literature in 2003 (Teschke et al., 2003). The authors conclude that only two cases were probable kava-associated hepatotoxicities. In addition, 80% of these patients took kava overdoses and or self medicated kava for longer than three months. Most patients were taking concomitant medications with known hepatotoxicity. The authors also analyse discrepancies in the evaluations of cases made by regulatory agencies in Germany (BfArM) and UK (MCA). The authors advise nevertheless, that physicians and patients should be alert to possible hepatotoxic side effects in the course of kava treatment, stop the treatment at first suspicion and begin a careful diagnostic work up ruling out all other causes.

WHO report (2007) assessed 93 case reports that involved different types of extracts. In only 54 of the cases (58%) the type of extract could be identified: ethanolic n=32; acetone n=14; water n= and synthetic n=4. The doses used, expressed as kavalactones were the following: in the acetone extract group the mean dose was 142.7 mg/day; range 70-245 mg/day; in the ethanolic extract group mean dose was 165.8 mg/day; range 30-840 mg/day. The doses for water extracts were very much higher and taking into account that kavalactones content was not known, these cases were excluded from the comparative analysis. 74 (80%) of the reports provided information on duration to onset of the event. The mean for these cases was 111 days, range 6-730 days. 80% fell within 135 days (4.5 months), while 90% fell within 195 days (6.5 months). The median time to onset was 90 days. Only 46 (62%) of known durations were 90 days or less. Hepatic events (as cholestatic and hepatocellular types of liver disorder) were described, but with many of the reports it was not possible to determine the initial type of injury. Necrosis was described in 16 (57%) of the 28 cases, hepatocellular injury in 8 (29%), cholestatic injury in 7 (25%) and in a further 8 (28%) cases the abnormalities were described as toxic in appearance or typical of drug induced or chemical damage. The presence or absence of concomitant therapy was also included. In 57 (61.3%) of the cases other concomited drugs used might have caused or contributed to hepatic abnormalities while 15 (16%) of the patients had either no other drug, or alcohol, or no other suspect therapy. Overall there were 14 liver transplants and seven deaths. Of the 93 reports, eight (8.6%) were coded as having a probable causality and 53 as possible. 28 were unassessable because of lack of data. Three comparisons were made between the different products: (a) acetonc versus ethanolic extracts, (b) acetonc versus synthetic extracts and (c) ethanolic versus synthetic extracts. Cases were included regardless of the relationship (causality) assessment. There was no statistically significant difference in the relative risk of hepatotoxicity between products prepared from acetonc and ethanolic extracts, but the hepatotoxicity with the product prepared from an acetonc extract occurred at approximately six times the rate of that for synthetic products while the hepatotoxicity with products prepared from ethanolic extracts occurred with a relative risk of approximately seven when compared with synthetic products. This difference is statistically significant. WHO concluded that a causal relationship between products derived from acetonc and ethanolic extracts and liver toxicity seems likely. Risk factors appear to be the use of organic extracts, the presence of chemicals other than kavalactones (e.g ochratoxins), concomitant therapy with potentially hepatotoxic drugs or other drugs with a potential for interaction with kava,
pre-existing liver disease, alcohol and genetic polymorphism of the cytochrome P450 system causing enzyme deficiency.

The problems linked to the quality of reports on hepatotoxicity have been considered by Teschke et al. in at least four reviews (Teschke et al., 2008, 2009a, 2009b, 2010).

Teschke et al. (2008) reassessed using the CIOMS scale the suspected 26 cases of hepatotoxicity induced by kava preparations. Causality was unassessable, unrelated, or excluded in 16 patients owing to lack of temporal association and causes independent of kava or co-medicated drugs. Low CIOMS scores additionally resulted in excluded or unlikely causality assessments (n=2), leaving a total of eight patients with various degrees of causality for kava ± comedicated drugs. The authors declared that only one out of these eight patients adhered to the regulatory recommendations regarding both daily dose (120mg kavalactones) and duration of therapy (3 months) and experienced toxic liver injury with a probable causality for kava (CIOMS score = 9). In six cases with kava overdose and/or increased duration of kava treatment causality for kava was possible (n=3) and for kava together with the comedicated drug(s) possible (n=2) or probable (n=1). The authors concluded that kava taken as recommended is associated with rare hepatotoxicity, whereas overdose, prolonged treatment, and co-medication may carry an increased risk.

Teschke et al. (2009a) reassessed the causality of hepatotoxicity by aqueous kava extracts and kava–herbs mixtures using the updated score of the quantitative CIOMS (Council for the International Organizations of Medical Sciences). Causality was established in five patients from New Caledonia, Australia, the United States and Germany for aqueous kava extracts and kava–herbs mixtures (CIOMS scores between 3 and 8). A comparison with 9 patients from Germany and Switzerland with established causality of hepatotoxicity by ethanolic and aceton kava extracts reveals that the clinical picture in all 14 patients is similar, independently whether aqueous, ethanolic and acetonic kava extracts or kava–herbs mixtures were used. The authors concluded that kava hepatotoxicity occurs also with traditional aqueous kava extracts of the South Pacific islands and thereby independently from ethanol or acetone as chemical solvents, suggesting that the toxicity is linked to the kava plant itself with a possibly low quality of the used kava cultivar or kava plant part rather than to chemical solvents.

The same authors (Teschke et al., 2009b) also analysed 20 cases of suspected kava extract hepatotoxicity reported by BfArM using the updated score of the quantitative CIOMS. The authors concluded that the regulatory information is scattered and selective, and items essential for causality assessment, such as exclusion of kavain-dependent causes, were not, or only marginally, considered by the regulator. Quantitative causality assessment for kava was possible (n=2; CIOMS scores=3), unlikely (n=12), or excluded (n=6), showing no concordance with the regulatory ad hoc causality evaluation. Later they also assessed causality in 26 patients from Germany and Switzerland, using two structured quantitative analytical methods: the system of Maria and Victorino (MV) and that of the CIOMS. In all 26 patients (that took either ethanolic or aceton extract), regulatory ad hoc evaluation had suggested a causal relationship between liver disease and kava use. Assessment with the MV scale resulted in no or low graded causality for kava in the 26 patients with liver disease. Causality was probable (n=1), possible (n=2), unlikely (n=7), and excluded (n=16). Causality for kava was more evident with the CIOMS scale: highly probable (n=1), probable (n=2), possible (n=6), unlikely (n=2) and excluded (n=15). The authors concluded that the results of both quantitative causality assessments are not supportive for most of the regulatory ad hoc causality assessments of the 26 patients. Grades of causality for suspected hepatotoxicity by kava were much lower when evaluated by structured quantitative causality assessment scales than by regulatory ad hoc judgements (Teschke et al., 2010).

**Assessor comments:** Only MV were provided; CIOMS scores are missing.
**Market overview**

Adverse events were also mentioned from Member States even for products, not authorized anymore.

Chech Republic reported the following adverse reactions:

**Kava-kava extractum siccum, extraction solvent acetone 75% (m/m):** allergic skin reactions such as redness, swelling, pruritus (rare); gastrointestinal disorders (very rare); during long-term treatment, yellowish colouration of the skin and skin adnexa (nails, hair) may occur. In only one case the liver damage occurred after the use of the product, which was reversible and completely resolved after discontinuing the treatment.

**Kava-kava extractum siccum, extraction solvent ethanol 96% (V/V):** allergic skin reactions (rare); general allergic reactions, dyspepsia (very rare). In long term treatment, yellow colouration of skin and skin adnexa may occur.

Taking into account the case reports of hepatotoxicity Federal Institute for Drugs and Medical devices (BfArM) implemented the German graduated plan ("Stufenplan") since August 2015, which includes the following recommendation:

- medical prescription only for preparations containing kava-kava
- clear indications: mild to moderate severe generalized anxiety disorders; depression is not an indication
- maximum daily dose corresponding to 120 mg of kavalactones
- package size limited to 30 daily doses
- usual duration of therapy: 1 month, maximum 2 months
- determination of liver parameters (GTP and gamma-GT) before the treatment and once a week thereafter
- avoidance of concomitant medication with potentially hepatotoxic medications, especially beta-blockers, antidepressants and anti-migraine preparations. Caution in the consumption of alcohol.

**Literature**

ESCOP 2003: extrapyramidal side effects were reported on four patients (mechanism unknown); hypersensitivity reactions resulting in generalized rash and severe itching was reported in one-case after 3 weeks of treatment with a daily dose of 120 mg kava extract.

Gruenwald et al., 2004: rare cases of allergic reactions and gastrointestinal complaints; slight morning tiredness can appear at the beginning of the therapy; dyskinesia and choreoathetosis of limbs, trunk, neck and facial musculature have been reported; endocrine effect (weight loss), musculoskeletal effects (minor inhibition of movement and impaired motor reflexes).

On the basis of the available data the frequency is not assessable. So the frequency is not known.

**5.4. Laboratory findings**

No data available.
5.5. Safety in special populations and situations

5.5.1. Use in children and adolescents

No data available.

5.5.2. Contraindications

Kava preparations are contraindicated in patients with endogenous depression because it increases the danger of suicide. It is also contraindicated during pregnancy and lactation (Gruenwald et al., 2004).

5.5.3. Special warnings and precautions for use

Unusual fatigue, weakness or loss of appetite and unintended weight loss, yellow discolouration of the conjunctiva or of the skin, dark urine or colourless stool can be signs of damage to the liver.

Concomitant use with beta-blockers, antidepressants and anti-migraine preparation should be avoided (Gruenwald et al., 2004)

5.5.4. Drug interactions and other forms of interaction

There is limited clinical evidence regarding interactions with other drugs even that theoretically, based on preclinical studies, kava preparations may interact with CNS depressants or psychoactive agents. The clinical evidence of drug interactions was reviewed by Anke et al. (2004) that found only 3 clinical case-reports and 3 clinical trials, and concluded that the evidence for true interactions is poor. Following interactions were summarized by Anke et al.: coma followed by interaction with alprazolam (one case-report; no data regarding kava dose); reduced effectiveness of levodopa (one case-report; 300 mg kava extract/day, 10 days) and rhabdomyolysis after association with caffeine (one case-report; 100 mg kava preparation as single dose).

Kava aqueous extract (1g/kg) potentiated sedation, intoxication and impairment of cognition/co-ordination when combined with alcohol (Anke et al. 2004; Gruenwald et al., 2004).

5.5.5. Fertility, pregnancy and lactation

No data available, therefore ESCOP monograph (2003) considered that in accordance with general medical practice, the product should not be used during pregnancy or lactation, while WHO monograph contraindicated the use during pregnancy (WHO, 2004).

5.5.6. Overdose

The traditional ceremonial drinking of kava beverage in South Pacific can be considered as an overdosage. Various effects were noticed in heavy kava drinkers, including pellagroid dermatopathy, loss of body weight, up to 20% (ESCP, 2003) or saccade abnormalities and cognitive impairment Kava intoxication is characterized by specific abnormalities of movement coordination and visual attention but normal performance of complex cognitive functions (Cairney, 2002).

Other effects reported by isolated cases are: (1) visual effects such as reduced near point of accommodation, increased pupil diameter and disturbed oculomotor balance were noted in a male subject (with no previous experience of kava-kava) who ingested 600 ml of kava-kava beverage in 15 minutes (Garner & Klinger, 1985); (2) rhabdomyolysis associated with ingestion of large amount of kava in a male subject of 34-years old (Bodkin, 2012); (3) an acute neurological syndrome involving...
generalized choreoathetosis was reported three times in the same patient as symptom of acute intoxication from excessive drinking of kava beverage (ESCOP, 2003). There are no reported cases of overdosage with kava extracts.

5.5.7. Effects on ability to drive or operate machinery or impairment of mental ability

According to WHO monograph (2004) that took into account Commission E monograph (Blumenthal et al., 1990) when administered within the recommended dosage range, motor reflexes and the ability to drive or operate heavy machinery may be adversely affected by kava preparations. According to ESCOP monograph (2003) kava did not impair the ability to drive or to operate machines.

In a randomized, placebo-controlled, double-blind study of 22 adults aged between 18 and 65 years were tested with a driving simulator after being randomly administered a dose of kava dry aqueous extract (corresponding to 180 mg of kavalactones), oxazepam (30 mg), or placebo one week apart in a crossover design trial. No impairing effects on driving outcomes were found after kava administration compared to placebo. Results on specific driving outcome domains revealed that the oxazepam condition had significantly slower braking reaction time compared to the placebo condition \( p = 0.002 \) and the kava condition \( p = 0.003 \). The kava condition had significantly fewer lapses of concentration compared to the oxazepam condition \( p = 0.033 \). No significant differences were found between conditions for steering deviation, speed deviation, and number of crashes. Results were not modified by driving experience. On the Bond-Lader visual analogue sub-scale of alertness, a significant Treatment × Time interaction \( p = 0.032 \) was found, with a significant reduction over time for oxazepam decreasing alertness \( p < 0.001 \), whereas no significant reduction was found in the kava or placebo conditions (Sarris et al., 2012).

5.5.8. Safety in other special situations

No data available.

5.6. Overall conclusions on clinical safety

Unfortunately just a few clinical trials included the assessment of liver function and the only effect observed was the raised liver enzyme levels, which cannot be considered as an evidence of hepatotoxicity. These trials generally have suffered from different shortcomings, such as small sample size, short periods of treatment (usually 4-8 weeks up to 24 weeks), lack of information about type and dose of extract used, so were not designed or powered to pick-up adverse reactions, such as rare hepatic reactions.

Some signals regarding suspected adverse reactions associated with kava use are included in the VigiLyze database. Liver toxicity (such as hepatic enzyme increased, hepatitis, hepatic cirrhosis, jaundice) is reported but there some uncertainties correlated with these cases such as no detail regarding the type of extract and the single dose used.

The strongest signal of herbal induced liver injury (HILI) is correlated with single case reports. Up to July 2002 68 cases of suspected hepatotoxicity associated with the use of kava extracts or isolated kavalactones have been reported worldwide, including cases of liver failure resulting in 6 liver transplants and 3 deaths. After 2002 only four new case reports have been published, but the type of extract involved is unknown. The small number of new case reports could be correlated with the measurements took by different EU-Member states, such as Czech Republic, France, Spain, UK, Hungary, Germany and Portugal that revoked the authorisations for kava products.
There is limited clinical evidence regarding interactions with other drugs even that theoretically, based on preclinical studies, kava preparations may interact with CNS depressants or psychoactive agents.

Kava preparations are contraindicated in patients with endogenous depression because it increases the danger of suicide. It is also contraindicated during pregnancy and lactation.

6. Overall conclusions (benefit-risk assessment)

Even that the medicinal use of *Piper metysticum* rhizoma is documented in several medicinal handbooks, the medicinal products are withdrawn from the EU market since 2002 based on safety concern.

Repeated dose studies and carcinogenicity studies provided sufficient evidence in experimental animals for the carcinogenicity of one kava preparation. In mice, the preparation caused a significant increase in the incidence of hepatoblastoma in males and hepatocellular adenoma or carcinoma (combined) and hepatocellular carcinoma in females at doses of 0.25 and 0.5 mg/kg. In male rats the same extract at doses of at 0.5 and 1.0 mg/kg caused a significant increase in the incidence of testis interstitial cell adenoma. This preparation is included by NTP in group 2B, meaning sufficient evidence in experimental animals and possible carcinogenic to humans and this constitute a strong cause for safety concern.

The clinical trials available for *Piper methysticum* rhizoma preparations as treatment option for anxiety disorders, as generalised anxiety or anxiety in the climacteric phase have methodological weakness, such as: mixed anxiety population, short duration of the trials, short follow-up phase, no data regarding percentage of responders. There are many differences in the products studied (acetonic or ethanolic extracts, different DERs, sometimes synthetic compounds), studies design and the dosage administered that was reported either in milligrams of kavalactones or in milligrams of kavain.

The strongest signal of kava induced liver injury in humans is correlated with the spontaneously reported cases. There are cases of suspected hepatotoxicity associated with the use of kava preparations or isolated kavalactones, including cases of liver failure resulting in liver transplants and deaths. These cases led to the withdrawal of the marketed products in Member States due to safety concerns.

The HMPC/MLWP concluded that, based in the available data, benefit-risk balance of the oral use of *Piper methysticum* rhizome for the treatment of anxiety disorders is unfavourable and that the following requirement for the establishment of a European Union herbal monograph on traditional or well-established herbal medicinal products containing *Piper methysticum* rhizoma is not fulfilled

- the requirement laid down in Article 16a(1)(e) of Directive 2001/83/EC that the data on the traditional use of the medicinal product are sufficient; in particular the product proves not to be harmful in the specified conditions of use and the pharmacological effects or efficacy of the medicinal product are plausible on the basis of long-standing use and experience.

- the requirement laid down in Article 10a of Directive 2001/83/EC that the active substance has a recognised efficacy and an acceptable level of safety and that the period of well-established medicinal use has elapsed.

In conclusion, based on the above-mentioned information, the HMPC concluded that a European Union herbal monograph on *Piper methysticum* rhizoma cannot be established.

**Annex**

**List of references**